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ABSTRACT
In the past ten years. a tremendous amount of work has demonstrated that enhanced cell
proliferation caused by activation of oncogenes or inactivation of tumor suppressor genes is one of
the major causes of human cancer. However, recently, mounring evidence strongly suggest !hat
decreased cell death by apoptosis via inactivation of pro-apoptotic genes or activation of anti-
apoptolic genes may also play an important role in carcinogenesis. Inactivation of!he pro-apoptoric
gene pH by mutations or DNA tumor ...;ruses and overexpression ofanti-apoPlotic gene bd-2 have
been found in the majority of human cancers.
In an attempt to identify !he transcription factors regulating JC virus expression, our lab
isolated a protein called KI, which has an amino acids sequence identical to !hat of BAG-I. BAG-I
is a protein originally isolated from mouse embryonic cells as a Bcl-2 interacting protein. To
understand thc role of BAG-l in human cancer, I isolated a 1.3 kb full length human BAG-I cDNA
by screening a human cervical cell cDNA library using mouse BAG-I cDNA as a probe. The amino
acid sequence of human BAG-I cDNA is identical to a honnone receptor-binding protein, RAP46,
and has 75% identity and 84% homology with that of mouse BAG~1. BAG-I RNA was expressed
in a variety ofhuman tissues and at higher levels in the heart and pancreas. Characterization of BAG-
I protein ill vitro and in vivo found that human BAG-I protein is expressed as four isofonns, p50,
p~6, p33, and p29, by alternative translation initiation of the start cedons through a leaky
mechanism. Different BAG·I isofonns have distinct subcellular localization.
Like mouse BAG-I, overexpression ofhuman BAG-I can inhibit apoptosis induced by various
apoptotic stimuli such as UV irradiation, heat shock, staurosporine, cisplatin and doxorubicin. The
C-terminal BAG-l sequence is responsible for its anti-apoptotic activity. However, BAG-I sensitizes
4-HPR-induced apoptosis by activation ofcasp~-3 through the BAG-! central region. This result
iii
suggests that BAG-! can be a pro- or anti-apoptotic protein, depending on the apoptotic inducer.
Since BeI-2 has been shown to be overexpressed in most human cancers, I examined whether
the expression of BeI-2~interactingprotein. BAG-I, was also enhanced during tumorigenesis. [n this
study, enhanced expression of BAG-I protein was detected in breast and cervical cancer cell lines
and tissues. The increased BAG-I protein in cancer cell lines was due to enhanced transcription
rather than genomic rearrangement of the BAG-I gene. Correlated with that ofBcI~2 and Bel-XL'
the levels of BAG-l proteins incrcased progressively after immortalization and tnmsformation
during multistagc carcinogenesis ofcervical cells. The increased BAG-I protcin was correlaled with
progressively increased resistance to apoptosis induced by staurosporine. Moreover, the level of
BAG-l protein correlated with that of other BAG~I-binding proteins such as BcI-2 and Bel-XL only
in human breast and cervical cell lines but not tissues.
To understand the molecular mechanism of overexpression of BAG-! in human cancers. I
eloned a 0.9 kb BAG-I 5'-flanking region from genomic DNA. Deletion analysis of this sequence
localized the region of maximal BAG-I promoter activity from nucleotide positions -353 to -54,
upstrcam of the first stan codon CTG. Sequence analysis of the BAG-I promoter region showed the
absence of a TATA box but identified a CCAAT box. several GC boxes, a CpG island and several
transcription factor binding sites, which may be important in thc regulation of BAG-I transcription.
Most importantly, functional characterization ofthe BAG-I promoter in vivo demonstrated that gain-
of-function p53 mutanl5 derived from human tumors upregulated the transcription of BAG-I RNA
and the expression of a reporter gene from the BAG-I promoter. These data indicated that
o\"crcxpression of BAG-! in some tumors may be duc to upregulation of thc human BAG-!
promotcr by mutant p53.
In summary. human BAG-! cDNA and promotcr/enhanccr wcrc eloned and characterized in
iv
this study. Fl;U1her analysis of BAG-I RNA and prolein demonstr.l.led that enhanced expression of
BAG-l may play an imponant role in carcinogenesis.
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SECTION I CHAPTER I
GENERAL INTRODUCTION: APOPTOSIS AND CANCER
1.1 Delinition ofapoPlosis
The phenomenon ofapoptosis, also called programmed cell death. was defined by Kerr et al.
in 1972. It is a process in which cells commit suicide under nonnal (embryogenesis, development,
immune response, differentiation. aging, tissue atrophy, etc.) or stress [ultraviolet (UV) irradiation,
gro\\th factor deprivation. etc.] conditions. Apoptosis is an important fonn of cell death occurring
in thc human body. Distinct from the two other major types ofcell death, senescence: and necrosis,
apoptosis has Wlique morphological and molecular charncteristics, which are summarized in Table
1.1.
Apoptotic bodies are efficiently phagocytosed by neighbouring cells or macrophages and
usually do not elicit an innammatory immune response ill vivo as occurs when cells undergo
necrosis. Therefore. apoptosis is a bener strategy to eliminate unnecessary, dying or hannful cells
during normal developmeDl or under stress conditions without damaging adjacent tissues.
Senescence also causes little tissue damage, but is less well regulated. possibly representing a
housekeeping fonn of cell death, as occurs during nonnal epithelial differentiation (Simon and
Gordon. 1995).
1.2 Role of cell prOliferation venus apoptosis in carcinogenesis
It has been known for a long time that cell proliferation and cell death (apoptosis, senescence.
and necrosis) are required to be balanced for tissue survival in a process called homeostasis. 10 the
past ten years, a tremendous amount of work has been published on the role ofdysregulated cell
proliferation in the development ofhllman cancers (for review, see Clunnan and Roberts, 1998;
Fearon. 1998; Park. 1998). It was found that cell proliferation can be enhanced due to activation of
some oncogenes such as c·myc and H·ras. or inactivation of rumor suppressor genes such as p53 and
Table 1.1 Changes occurring during apoptosis
A. Morpbological cbanlcs
Cell shrinkage
Cell membrane blebbing
Cytoplasm. nuclear and chromosome condensation
Nuclear fragmentation
Fonnation of apoptotic bodies
B. Biochemical and molec:ular changfl
Increased apoptosis inducing proteins to inhibiting proteins ratio
Mitochondrial changes
Decrease of mitochondrial membrane potential
Release ofdeath factors, such as cytochrome c and apoptosis.inducing factor (AIF)
Fonnation of reactive oxygen species (ROS)
Loss of asymmetry in plasma membrane phospholiplids such as phosphatidyl serine
Activation of caspases
Cleavage of key cellular proteins
DNA fragmentation into 50·300 kilobase pair (kb) large and/or intemucleosomal DNA
fragments
(ncrease of plasma membrane pcnneability for vital dye
Rb. Increased proliferation without a compensatory increase in cell death can cause the accumulalion
of celts and. finally, lead to cancer through a multistage carcinogenesis mechanism. Recemly.
mounting evidence suggesl that decreased cell death, especially by apoptosis. may also plays an
important role in muhistage carcinogenesis. Cell death can be repressed due to downregulalion of
cellular genes that induce it or upregulation of cellular genes that inhibit it. Decreased apoptosis
without a similar change in cell proliferation can similarly cause cell accumulation and finally cancer
(Fig.Ll). Although the molecular mechanism for dysregulation of cell proliferalion in the
development of human cancer has been extensively studied. the role ofapoptosis in human cancer
remains relatiVely unexplored.
1.3 Signallr3llsduciioD palbways or apoplosis
Although apoptosis can be induced by a variety of apoptotic stimuli, ils regulators,
executioners. and substrates in the signal transdUClion pathway often overlap and are summarized
in Fig.I.:!. Apoptosis stimuli generally originale eXlemalIy 10 lhe cells. Some such as the cytotoxic
cytokines. lumor necrosis factor-a (TNF-a). Fas ligand (Fast). and TRAIt can bind to their
receptors on the plasma membrane, causing dimerization of their receptors and thereby activation
of an initiator caspase such as caspase-8 through interaction of the receptors with death adaptor
proteins such as Fas-associaled death domain (FADD) or TNF-reccplor I·associaled death domain
(TRADD) (Nunez ef aI., 1998; Baker and Reddy, 1998). On the other hand, canccr
chemotherapeutic drugs. such as cisplatin, can reduce the mitochondrial membrane potential (~'¥)
and cause release of cytochrome c from mitochondria. This activates Apaf-I (apoptotic proteinase
activating faclor-I). which activates initiator caspase caspase-9 (Li el ai., 1997; Zou et al.• t 997).
Fig.l.I The effect of relative rates ofcell proliferation and cell dealh on rumorigenesis (adapted from
Thompson, 1995). Unchanged rates of cell proliferation and cell death are indicated by lhe same
thickness of arrows. Increased rate ofcell proliferation and decreased rate ofcell death are indicated
by thicker and thinner arrows, respectively.
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Fig. 1.2 Signal transduction pathways ofapoptosis (adapted from Reed. 1998b). Apoptosis stimuli
activate downstream apoptosis executioners, which can subsequently cause apoptosis by cleaving
DNA and key cellular protein substrates (Sec text for details).
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The activated initiator caspase (e.g., caspase-8,.9 or -10) will subsequently activate an effector
caspase (e.g., caspase.3) by proteolytic cleavage of their procaspases (Thombeny and Lazebnik,
1998). The decrease of mitochondrial membrane potential can also cause the release of effector
caspases, such as caspase-3, and lranslocation of apoptosis-inducing factor (AIF) from the
mitochondria 10 the nuclear membrane and DNA fragmentation (Susin et ai., 1999). In a partially
overlapping pathway, the pro-apoptotic &1-2 family member protein Bid is cleaved by Fas-activated
caspase-8 and tnmslocated from the cytosol to the mitochondrial membrane, and induces the release
of cytochrome c, which in tum activates Apaf-l, which binds and activates the most upstream
caspasc, caspase-9 (Li et al., 1998; Luo et ai., 1998).
Acti\'ated cffector caspases can cleave imponam protein substrates such as PARP, lamin and
actin, and anti-apoptotic proteins such as Bcl·2 and Bcl-X l (Cryns and Yuan, 1998) or activate
caspase-activated DNase (CAD) by cleaving/releasing inhibitor ofCAD (ICAD) from CAD. The
activmed CAD can then be tnmslocated to the nucleus and causes DNA fragmenlation (Enari et af.,
1998; Sakahira el ai., 1998). Cleavage ofproleins and DNA will finally cause apoplosis, which has
the unique morphological characteristics described in Table 1.1 and Fig. 1.2.
1.4 Genes regulallDI _poplosis aad Ibelr role in caacer
As described in Section 1.2, reduced cell death may cause the accwnulalion ofcells and finally
lead to human cancer. Therefore, reduced apoptosis may play an important role in carcinogenesis.
The significance of apoptosis in the process ofoncogenesis is evidenced by at leaslthree important
observations. The first is that most cancer chemotherapeutic drugs acl to induce apoptosis (Martin
and Green, 1995). The second is that the frequency ofapoptolic cells in a tumor negatively correlates
closely with outcomc. That is, tumors with low apoptotic indices tend 10 be more aggressive than
those displaying higher incidence of apoptosis. Therefore, apoptosis is almost certainly an imponant
factor controlling tumor growth (Arends et al., 1994). The third observation is that a number of
oncogenes and tumor suppressor genes have been found to regulate the process of apoptosis (Manin
and Green, 1995; Bissonnette et al., 1994; Hollinan and Liehermarm, 1998; Kharbandaet al., 1998;
Amundson el al., 1998). Therefore, studying the molecular mechanism of apoptosis will be useful
for understanding and guiding the prevention ofoncogenesis and design ofcancer therapy.
Apoptosis can be promoted by proteins. such as Bak, Bax, Bik and Bid, or inhibited by
proteins, such as Bel·2 and Bel-XL' through, for example, modulation of mitochondrial membrane
function (Green and Reed, 1998; Reed, 1998). Apoptosis can also be inhibited through inactivation
of either initiator caspases by FLICE-inhibitory proteins (FLIPS) or effector caspases by survivin,
c-Llj>-I, and c-JAP-2 (Fig. 1.2; Thome et aI., 1997; Cryns and Yuan, 1998; LaCasse el al., 1998).
Since such proteins have essential roles in regulating apoptosis, their mechanisms of action and
expression levels in human normal and cancer cell lines and tissues have been studied, as follows:
1.4.1 bcl·Z family
1.4.1.1 Pro-apoptolic genu
To dale. about 12 hwnan BcI-2 family members (Bad, Bak, Bax, BeI-Xs, Bid, Bik, BimlBod,
Blk. Bok, HrklDp5, Nip3 and Nix) have been identified that can enhance apoptosis (for review, see
Chao and Karsmeyer, 1998; Zamzami et ai" 1998; Reed, 1998a). Of these, however, only Bak and
Ba.x have been reported to be associated with carcinogenesis.
l)ba.r:
Bax is a protein that can enhance apoptosis by binding to and inhibiting the anti.apoptotic
function of Bel-2 (Oltvai et 01., 1993). Bax expression is induced following a variety of DNA-
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damaging treatments (Miyash.ila et al., 1994a, b; Zhan et al., 1994). It has recenl1y been shown that
the bax gene expression is induced by p53, which can bind to a p53-response element in the bax
promoter and transaetivate its transcription (Miyash.ita et af., 1995). The following evidence suggest
that Sax may be involved in human cancer: 1) reduced levels ofbox RNA and protein have been
reponed in breast carcinomas and were com:lated with poor responses to combination chemotherapy
and shoner overall survival (Bargou et af., 1995, 1996; Krajewski et al., 1995); 2) mutations ofbax
have been found in a variety of human cancers including lymphomas, leukemias, and colorec:tal,
endometrial. gastric, ovarian and stomach cancers (Rarnpino et af., 1997; Brirnmell et aI., 1998;
Colella, 1998; Ouyang el aI., 1998); and 3) overexpression of Sax was found to suppress
tumorigenesIs ill vivQ (Yin et aI., 1997).
2)bak
bakis a pro-apoptotic gene that was originally identified by vinue of its homology to bel-2 and
the ability of its protein (0 interact and Inhibit the anti-apoptotic activity ofadcnovirus (Ad) EIB
19K protein (Chittenden et of., 1995; Farrow et 01., 1995; Kiefer et 01., 1995). Reduced expression
of bak was found in breast, colon and skin cancers (Krajeska et al., 1996; Tomkova et aI., 1997;
Zapata el 01., 1998). In addition, overexpression of bak significantly inhibited ,.as-induced
lumorigenicity (Rosen et 01., 1998), indicating that bak may act as a tumor suppressor gene in some
1.4.1.2 Anli-apoplolic lenes
To date, five human anti-apoptotic bel-2 family members, bcl-2, bel-XL' mel-I, bcl-w, and bj1.
I, have been identified (\Iaux et al., 1988; Boise et 01., 1993; Choi et al., 1995 Gibson et aI., 1996;
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Lomo ef 01.. 1996). However, only bcl-2. bel-Xl and bfl·1 have been shown to be involved in human
l)bcl-2
The bcl-2 gene was identified in 1984 while studying the t(14; 18) chromosome translocations
that occur frequenlly in B cell leukemia and non-Hodgkin's follicular lymphoma (Yunis el al., 1982;
Tsujimoto ef al., 1984). The gene is located at chromosome 18q21, but the t(14; 18) translocation
ju.xtaposes it with the immunoglobulin heavy chain (IgH) locus on chromosome 14. This bcl-2IIgH
rusion gene expresses high levels or bel-2 (Tsujimoto ef al., 1984; Tsujimoto et al., 1985).
Therefore, bcl-2 was originally regarded as an oncogene that contributed to the oncogenesis orB·
cells. However, a later study demonstrated that bcl-2 functions differently from conventional
oncogenes. since it neither promoted cell growth nordirecliy led to cellular transformation (Reed,
1994). Instead, overexpression of BcI·2 contributed to oncogenesis by increasing cell survival
through suppressing apoptosis. resulting in increased numbers or cells, which accumulated further
oncogenic mutations (Fig. 1.1). For example, 15% of transgenic mice overexpressing BcI·2
developed aggressive B-cell lymphomas. Approximately 50% of lymphomas expressed elevated
levels orc-Myc, indicating that BcI·2 overexpression leads 10 impaired apoptosis and thus increased
mutations in genes. such as c-myc, controllingcellularprolireration (Yaux ef al., 1988). Later studies
rurthcr demonstrated that overexpression of bel-2, may be involved in the deveiopmenl of other
human cancers. An enhanced level of Bcl·2 was round in a variety of human cancers, including
neuroblastoma. and breast, cervical, colorectal, head and neck, lung, skin and prostate cancers
(McDonnell el 01., 1992; Halder el of., 1994; lkegaki ef al., 1994; Liang el 01., 1995; Sinicrope er
al., 1995; Delehedde er al., 1999; Pena et af., 1999). Increased bel-2 expression in human cancers
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is due panly to the loss of its repression by p53 tumor suppressor after frequently occurring
mutations ofp53 (Harder et af., 1994; Miyashita et af., 19943, b).
2)bcl-XL
bel-XL is a bcf-2 family member Ihat has anti-apoptotic activity. It is Ihe long splice variant of
the bel-X gene (Boise et af., 1993). Like BcI-2, Bel-XL can inhibit apoptosis induced by many
different apoptotic stimuli (Boise et al., 1993; Chao and Korsmeyer, 1998; Reed, 1998a). In addition.
BcI-XL can also inhibit some apoptosis palhways Ihat ttansfcction with bcl·2 does not affC(:t
(Gottschalk et al., 1994). Overexpression of Bel-XL has been found in lymphomas, and bladder,
coloreclal, head and neck, pancreatic, and stomach cancers ( Kondo et al., 1996b; Krajewska et af.,
1996; Xerri Ct al., 19%; Hirose et af., 1997; Kirsh et al., 1998; Miyamoto etal., 1999; Penaet al.,
1999).
3) bjI-1
bfl-I is a bcl-2 family member and the human homolog ofmousc anti.apoptotic Af gene. Btl-I
efficiently suppresses apoptosis induced by the p53 tumor suppressor protein and cooperates with
the dominant Ad E1A oncoprotein in the transfonnation of primary epithelial cells in vitro
(O'Sa-Eipper et al., 1996). Unlike other BeI-2 family proteins, expression ofBfl-l can enhance cell
proliferation (O'Sa.Eipper et al., 1996). In addition, enhanced expression ofbfl-I was observed in
lymphomas, and breast, colon, stomach and ovarian cancers (Choi et al., 1995; Park ct al., 1997).
1.4.2 Deatb and dec:oy receptors
1.4.2.1 Deatb receptoR
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Death receptors are TNFR superfamily members, which are defined by their similar, cysteine-
rich extracellular domains and homologous cytoplasmic death domain (Nagata, 1997). Death
receptors can mediate apoptosis induced by death ligands (TNF-a, FasL, and TRAIL) by activating
caspases through death domains-death adaptors (for review sec Ashkenazi and Dixit, 1998; Baker
and Reddy. [998). Until now, about seven types of death receptors, FaslCD95/Apol, TNFR-I,
TNFR-II, DRJ/Apo3, DR4, DR5IApo2!KJLLERfTRAlL·R2, and DR6, have becn identified
(Ashkenazi and Dixit, 1998; Baker and Reddy, 1998).
Fas-mediated apoptosis plays an important role in lymphocyte homeostasis and killing of virus-
infected or cancer cells (Varadhachary and Salgame, 1998). Therefore, inactivation ofjas may cause
enhanced [ymphoproliferation and accumulation ofcancer cells. Consistently, mutations ofjas gene
were found in leukemia and lymphoma (Beltinger er a/., 1998; Gronbaek el aI., 1998; Lamy er al.,
1998; Maeda et al., 1999). Furthennore. reduced expression ofjas was also reported in colon cancer
(Butlcr et al., 1998), indicating that downregulalion of jas by either mutation or decreased
expression may be responsible for the development of human cancers. Except in one case in which
loss-of-function truncation mutation ofa TRAIL death receptor gene, DR5fK1LLER, was detected
in a head and neck primary canccr(Pai et aI., 1998), no mutations of other death receptors have been
found in human cancers.
1.4.2.2 Decoy recepCon
Decoy receptors, such as DcRI. DcR2 and OcRJ, are those which are structurally similar to
death receptors, but lack an intracellular domain. are therefore incapable of transducing death
receptor-like signals, and compete with death receptors for binding to the same ligands (Sheridan
elal., 1997; Pini etal., 1998; Ashkenazi and Dixit, 1998). Recently, it was found that OcRJ decoy
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receptor for FasL was amplified in about halfof35 primary lung and colon tumors, indicating that
tumors may block FasL-depmdent immunocytotoxic attack by expressing a decoy receptor (Pini et
01.. 1998).
1...&.3 labibilon of apoplosis protrial (lAPs)
The lAP family members can suppress apoptosis by direct inhibition ofcaspase activity (Fig.
1.2; for review, see LaCasse et al., 1998; Deveraux and Reed, 1999). They are char.acterized by an
approximately 70 amino acids domain termed the baculovirallAP repeat and a RING zinc finger.
To date, six lAP members have been identified in humans: c·IAPI, c·1AP2, htLP, NAIP, XlAP, and
survivin (Deveraux and Reed, 1999). Increasing reports indicate that lAPs may playa role in
oncogenesis. The strongest evidence implicating lAP in cancer came from survlvin studies. Survivin
has been found to be expressed in a high proportion of the most common human cancers. such as
breast. lung. colon and prostate cancers, but not in normal. terminally differentiated adult tissues
(Ambrosini el 01.,1997; Adida etal., 1998; Lu etal., 1998; Kawasaki elal.• 1998).
I.S Cellular oacogeaa aad lbeir roles ia apoptO$is
Genes whose products have the ability to ttansfonn eukaryotic cells are caJled oncogenes. Most
oncogenes arc derived from nonnal genes. or proto-oncogencs, that encode proteins involved in
essential cellular fwlctions related to control ofcell proliferation and differentiation., such as growth
factors (e.g., epithelia growth factor (EOF), platelet-derived growth factor (PooF). and fibroblast
growth factor (FGF), growth factor receptors [e.g., PDGF rcceptor (PDGFR) and EGF receptor
(EGFR lJ, signal transducet"$ (e.g.• H·Ras), transcription factors (e.g., c·Myc, c-Fos and c-Jun) and
cell cycle regulators (e.g., E2F). However, once activated by either overexpression or mutations,
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oncogenes can increase cell proliferation, resUlting in accumulation of cells and leading Ultimately
to cancer. In addition, oncogenes have been shown to be involved in tumorigenicity and metastasis
(Vogelstein and Kinzler, 1993).
The conclusion that oncogenes are involved in apoptosis originated from studies of anti-
apoptotic bcl-2 oncogene involved in B-cell follicular lymphoma as described in Section I.J.I.2.
Later studies demonstrated that many activated oncogenes, including c-abl, AP-I (c-fos/c-jlln), c-
myc, H-ras, and mdm2, can not only transfonn cells by increasing cell proliferation, but also have
the ability to modulate apoptosis. Oncogenes can either enhance or inhibit apoptosis, depending on
the specific gene, celltype5 or growth conditions, such as the level of growth factors (Colotta et al.,
1991; Schreiber et af., 1995; Verheij et al., 1996; Yuan et al., 1997).
1.5.1 c-abl
The mammalian c-abl proto-oncogene was identified as the cellular homolog of the
transfonning v-ubf oncogene of the Abelson murine leukemia virus (Gorf et al., 1980). It encodes
a nonreceptor tyrosine kinase that is ubiquitously expressed in a variety of human tissues (Ben-
Neriah CI al., 1986). c-Abl can not only phosphorylate proteins, but also transactivate some cellular
genes by binding to an EP element found in the promoter/enhancer regions of certain cellular and
viral genes (Dikstein CI al., 1992, 1996).
Previous reports indicated that the c-abl gene on chromosome 9 can be translocated to the bel'
gene locus on chromosome 22, forming the Philadelphia chromosome (Kelliher et al., 1990). This
translocation produces a chimeric bcr-ab/ gene, the protein product of which exhibits an
uncontrolled tyrosine kinase activity, which is thought to lead to uncontrolled cell growth and
chronic myeloid leukemia (CML). Later, it was found that the resistance ofa CML cell line (K562)
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to several apoptotic stimuli, including cytotoxic drugs and serum withdrawal, can be overcome by
downrcgulating expression of c-ah! mRNA (McGahon er al., 1994). Furthermore, tr'ansfection of
K562 cells with v-abl restores their resistance to the same apoptotic stimuli, indicating that the c-ahl
gene has an anti-apoptotic function that may be responsible for the development ofeML (McGahon
et uf., 1994). However, several other studies demonstrated that c-Abl can provide pro-apoptotic
function in cells deficient in p53 (Yuan et af., 1997). In addition. c-Abl can bind to and enhance the
pro-apoptotic activity ofp73 (Kharbanda el al., 1998). Therefore, depending on the cellular content,
c-abl plays distinct roles in apoptosis.
1.5.2 c-foslc.-jutl
AP I is a trnnscription factor fonned by dimerization ofc-Fos and c-Jun proto-oncoproteins and
can activate a variety of cellular genes associated with cell proliferation (Curran and Franza, 1988).
III I,jtro, the expression ofc-[os and c-jun mRt"llA and proteins is rapidly and transiently induced after
stimulation ofquiescent cells by growth factor (Sassone-Corsi and Venna, 1987). Therefore, c-fos
and C-jlll/ are immediate early genes responsible for proliferation in response to growth factor. In
lAo. amplification ofbaln genes nas been found in osteosarcomas (Park,1998).
AP-I was observed to increase apoplosis induced by withdrawal of cell survival factors. For
example, c-[os and C-jUII expression was rapidly induced after growth factor withdrawal from IL-6-
and !L-2-dependent murine lymphoid cells. Blocking the expression of either c-Ios or c-jun with
antisense oligonucleotides increased lymphoid cell survival following growth factor deprivation
(Colotta et af., 1992). In addition, AP-I can enhance apoptosis induced by stress (e.g., TNF-o, x-
rays, UV light and heat shock) (Verheij et 01.,1996). However, in some cases, AP-I can act as an
anti-apoptotic protein. For example, it was shown that loss of AP-I function can increase apoptosis
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induced by short-wavelength UV lighl in c-los null mouse JT3 fibroblasts (Schreiberet af., 1995).
Therefore, AP-I appears to function as a positive and negative regulator of apoptosis, depending on
the cell types or growth conditions.
1.5.3 c·nr)'c
c·myc is a proto-oncogene thai has been shown to playa pivotal role in cell proliferalion and
prevention of differentiation in response 10 mitogenic stimuli (Evan and Linlewood, 1993; Ryan and
Birnie. 1997). Overexpression of c-myc can promole cell proliferation by aClivating one or more
cellular genes associated with Ihe cell cycle such as cyclin A, cyclin E, and cdc25A (Dang et al.,
1999). Therefore, dysregulation ofc-myc may cause uncolltrolled cell growth and finally cancer.
Increased expression or amplificalion of c·myc has been consistently found in a variety of human
cancers including lymphomas, and breast, cervical, colon, esophageal, lung and ovarian cancers
(Park. 1998).
Recenl studies indicate that deregulated expression of c-myc not only promotes proliferation,
but also can either induce or sensitize cells to apoptosis (Evan et al., 1992; Shi et af., 1992). c.Myc
promotes cell proliferation in the presence of growth factors, whereas it promotes apoptosis in Iheir
absence (Evan et al., 1992; Shi et al., 1992). Therefore, c-Myc expression affords a proliferative
advantage and also makes cells particularly susceptible to apoptosis under growth faclor Iimitalion
conditions.
In cooperation with c.Myc, mulalion of other oncogenes or overexpression of anti-apoptotic
genes can cause either escape from growth factor dependency or inhibilion of apoptosis, leading to
tumor growth. For example, Bel·2 can inhibit c·Myc-induced apoptosis in some cell systems
(Packham and Cleveland, 1995; Thompson, 1998), while having no effect on Ihe proliferative
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function of c-Myc (Fanidi et aJ., 1992: Packham and Cleveland, 1995). !II vitro co-ttansfection
studies showed that c-myc and bci-2 can cooperate to ach.ieve immortalization of several cell types
(Bissonnette et at., 1992; Fanidi et ai., 1992). Furthermore, ill vivo studies demonstrated that c-myc
and bcl-2 double transgenic mice develop tumors much more rapidly than c~myc transgenic mice
(Strasser et aJ., 1990). This interaction between c-myc and bcl-2 provides an explanation for the
cooperation of c-myc and bd-2 in cell transformation (Vaux et ai., 1988; Bissonette et ai., 1992).
Thus, c·myc and bcl-2 synergizc during multistage tumorigenesis.
1.5.4 mdm2
Mdm2 is a proto-oncoprotein originally cloned by vinue of its interacting with pS3 (Oliner et
al.. 1992). While its mRNA expression can be induced by pS3, Mdm1 can bind to and inhibit the
function of wild-type p53 protein (Momand et al., 1992). Overexpression of Mdm-2 can transform
murine fibroblasts (Momand and Zambeni, 1997). Furthermore, amplification oroverexpression of
the mdm·2 gene has been detected in various human tumors, including leukemias, neuroblastomas,
soft tissue tumors. and breast, ce""'ical, lung and ovarian cancers (Momand and Zambetti, 1997).
Recently. it was sh.own that Mdm-2 is involved inapoptosis by abrogationofpS3 pro-apoptotic
activity. Overcxpression of mdm-2 can inhibit apoPlosis induced by a variety of apoptotic stimuli
(Kondo el aJ., 1995; Chen et aJ., 1996; Haupt et aJ., 1996). These results suggest that inhibition of
cell death by Mdm-2 through. inactivation ofp53 may play an imponant role in oncogenesis.
1.5.5 r45
The c-ras proto-oncogene product is a GTPase that mediates signal ttansduction from growth
hormones to cellular proteins associated with proliferation. Upon mutation at amino acid positions
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I:? or 61. c·Ras can be activated and continuously activate its target proteins. This leads 10
uncontrolled cell proliferalion and cancer. Consequently. mUlation of ras is responsible for its
oncogenic activity. In fact. about 30010 of human cancers were found to contain activation mutations
in a ras (N-. K.i and H-ras) gene (Park. 1998).
ras has been found 10 be involved in the regulalion of apoptosis. Overexpression of ras gene
can not only increase mitotic indices but additionally cause apoptosis (Wyllie et 01., 1987).
Ne\"enheless. mutation-activated ras can inhibit apoptosis (Fenlon et al.• 1998). Tumor cells
expressing activated Ras exhibit greatly enhanced mitotic indices while retaining lower apoptotic
indices than parental cells (Wyllie el al.• 1987). Consequently. activated ras may be involved in
oncogenesis. not only by enhancing proliferalion. but also by inhibiting apoptosis. The mechanism
for the inhibition of apoplosis by oncogenic ras is still unclear. However, it was found thai
oncogenic ras can inhibit/as-induced apoptosis by inhibition ofFas (CD95) expression (Fenton et
01..1998).
1.6 ViTal oncogenes and tbeir- role in apoplosis
Apoptosis is implicated in the elimination of viral-infected cells whose survival might be
hannful to the organism. ApoPlosis can be triggered by cytotoxic T lymphocytes or tumor necrosis
factor. which induce cndonucleases that can target replicating viral nucleic acids and prevent virus
production at early stages of viral infection. To proliferate in host cells, many viruses have acquired
genes encoding proteins that effectively suppress or delay apoptosis long enough for the production
ofsufficienl numbers of progeny" On the other hand, a growing list ofvirnses are now known to
induce apoptosis actively allate stages of infection (Table 1.2).
In general. viruses regulate apoptosis by the following mechanisms:
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1) InaclivaliooJdegndatioD orp53
The best characterized viruses that inhibit apoptosis by inactivating p53 are tumor viruses, such
as Ad, hepatitis B virus (HBY), human papillomavirus (HPV), and simian virus 40 (SV40). DNA
tumor virus oncoproteins, such as Ad EIB (19 and 55 kDa), HBVpX, HPV E6 and SV4Q largeT
antigen, can bind p53 and inactivatc p53-dependent apoptosis (White el al., 1991; Rao et aJ., 1992;
Shcn el al., 1994; Symonds et al., 1994; Wang et al., 1995; Tsang et al., 1995; Thomas el al., 1996).
However, inhibition ofp53-indueed apoptosis by these viruses involves distinct events. FOf" example,
E6 protein of high risk HPVs can abolish p53-induced apoptosis through ubiquitin-mediated p53
degradation (Thomas el al., 1996). However, SV40 large T antigen prevents p53-induced apoptosis
by interacting with the p53 DNA binding domain and blocking p53-mediated transactivation
activity (Bargonetti el al., 1992; Symond el al., 1994; also see section 1.7.1).
2) Inactivalion of RB
Some viral oncoproteins, such as Ad EIA and high.risk HPVs E7, can induce apoptosis by
binding and blocking the anli-apoptotic activity of RB (see section 1.7.3). In addition. these
oncoproteins can also induce pS3 accumulation and p53-dcpendent apoptosis (Dcbbas and White,
1993; Jones et aI., 1997).
3) TranscripitioDal regulatioo o(apoplosJs.associated gcon
Some retrovirus oncoprotcins. such as human immunodeficiency virus (HIV) Tat and human
T-cell leukemia virus type I (HTlV-I) Tax can induce apoptosis by do....nrcgulation of anti-
apoptotic Bcl·2 (Yamada el al., 1994; Sastry et al., 1996; for detailed function of Bcl·2, see Section
1.4.1.2). In addition, HIY·I Tat can activate Fasl, causing Fas.depcndem apoptosis (Mitra et aJ.,
1996). On the other hand, Epstein Barr virus (EBV) lMP I inhibits apoptosis through induction of
anti-apoptotic Bcl-2 (Henderson et al., 1991).
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T:lhle 1.2 Vir:.1 gl,.'1IC products rcg\llalil1~ ilpoplosis
EfTeclon
llllOPtosis Mechanism ReferencesViruses Product
Ad EIA
EIBI9kDu
EIB55kDll
Oaculovirus pll
lAP
Cowpox virus CmlA
EBV LMPI
BHRFI
HSV y134.5
HBV pX
IIIV·1 Tot
+ Inactivalion ofRO DchhllS and White, 1993
Inactivatiol1ofp53 While 1'1 ttl., 1991;
5I1el1l:llIl., 1994
Inactivation ofr53 Roo C/ IIf., 1992
Caspaseinhibitor Clem 1:1111., 1991
Caspasc inhibitor Crook e/ II!., 1993
Caspase inhibitor Gagliardini e/ til., 1994
Induction ofBcI-2 Henderson 1~/1I1., 199\
BcI·2 homology Henderson CIIII., 1993
Restore cellular Chou and Roizl1lan, 1992
protcinsynthesis
Inactivationofp53 Wange/llf., 1995
Downrcgulalion of Sastry CI aI., 1996
Bcl·2, uprcgulalion Mitrll c/ 11/. (1996)
of BilK, FasL, activation Barti': mul Emen11l1ll (1999)
ofcaspasc
HPV E6 Dercgulation ofp53 Tsang Clld., 11)1)5;
TholllllS CIIi/., 1996
E7 + Inactivation of RB Jones CI (II.• 1997
HTLV·! Tax + Downregulationof Yamuda el III.• 1994
Bcl·2
CMV lEI and IE2 Inactivation ofpSJ Zhu elill., 1995
SV40 Large T antigen Inactivattoll ofpS3 Symonds CI Ill., 1994
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4) Regulation ofcaspasc activity
Baculovirus p35 and IAP and Cowpox virus CrmA can inhibit apoptosis by inhibiting caspase
activiation (Clem et 01., 1991; Crook et al., 1993; Gagliardini et al., 1994). While wild-type p35 can
inhibit host cell apoptosis during infection, p35 mutant viruses result in extensive induction of
apoptosis and a reduction in infectivity both in vitro and in vivo (Clem et 01., 1991; Clem and
Miller. 1993). Baculovirus lAP was the first rAP found to inhibit caspases. Several mammalian and
Drosophila homologs have been isolated and have similar function (for detail, see Section 1.4.3).
Cowpox virus CrmA is another caspase inhibitor. It can inhibit apoptosis caused by cytotoxic T cdls
(Tewari etol., 1995) and FasL(Tewari and Dixit, 1995). Moreover, HJV-I has been shown 10 induce
apoptosis by activating caspase-8 (Bartz and Emerman, 1999)
1.7 Tumor suppressor genes aad tbeir roles in apoptosis
Tumor suppressor genes are genes whose mutation, deletion or inactivation is associated with
the developmenl of malignancy. Tumor suppressor genes have at least one of the following
characteristics: I) loss-of-function mutations accompanied by loss ofhcterozygosity in tumors; 2)
mutations in inherited syndromes that predispose to cancer; 3) somatic mutations in spontaneous
tumors; 4) inhibition of transformed cell growth in vitro; and 5) knockout mutation transgenic mice
showing a predisposition to cancer rnat mirrors a human cancer syndrome.
1.7.1 p5J andp73
pS3 is a nuclear DNA-binding phosphoprotein that is a transcriptional activator ofspecific target
genes, and can exert transcriptional repression, probably by interaction with transcription factors or
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genern.l uanscriptional machinery proteins such as TATA-binding protein (for review, sec Levine,
1997). pH has been regarded as a tumor suppressor gene for the following reasons: I)pH mutations
are found in 50-55% ofhuman cancers (Hollstein et 01., 1994); 2) transfection ofpjj into carcinoma
cells represses t\1tnO(" growth and arT'C5lS cells in the GI phase (Levine, 1991); and 3) pS3 knockout
mice exhibit a predisposition to various cancers (OonehoweI" et aI., 1992). The p53 protein is
nonnally present at very low levels. but is up-regulated rapidly by DNA damage. viral infection or
olher factors. causing a G 1- or G2-specific cell-cycle atTeSt. allowing subsequent DNA repair (for
reviews. see Levine. 1991; Zambetti and Levine, 1993; Levine. 1997). Therefore, loss ofp53 cell
cycle checkpoint and subsequent loss of genomic stabililY in hwnan cells has been regarded as the
most importanl cause of human cancer.
Recent experiments suggested that pS3 can suppress tumor growth and progression by induction
of apoptosis (Symonds et aI., 1994; Gonlieb and Oren. 1996). Apoptosis induced by agents such as
irr:Jdiation. oncogene activation and cytokine deprivation is pS3-dependent (for review. see
Amundson et 01.,1998). Ectopic expression ofwiki-typepH can induce apoptosis in various cell
lines. On the other hand. inactivation ofpjJ by either mutations or DNA twnor virus oncoproteins
(see Section 1.6.1) can cause resiswx:e to apoplosis induced by different apoptosis stimuli (Yonish-
Rouach, 1991. 1993; Ryan et al.. 1993; Lowe.. 1995; White, 1996; Levine. 1997; Amundson elol.•
1998; Bales and Vousden, 1999).
Se\'eral studies indicate that scquence-speeilic transactivation is a required function for p53-
mediated apoptosis in some experimental systems (Anardi et 01., 1996; Sabbatini el 01., 1995). An
increasing number of p53-responsive genes are associated with apoplotic pathways (Table 1.3).
bax is a pro-apoptotic gene that is up-regulated by pH in many systems undergoing pH-
dependent apoptosis (Selvakumarnn et al., 1994; Miyashita et 01., 1994; Zhan et aI., 1994). ApH-
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Table 1.3 Apoplosis-regulaling genes tranS3Clivaled or repressed by wild-type p53
Gene
Pro-apoplOtic
hax
c-fos
DRS
fa,
IGF-BP3
PAG608
Allti-apoptotic
hd-l
IGF·IR
MAP4
eH effect
transactivation
transaclivalion
transaclivation
transaclivation
transactivation
ttansactivation
repression
repression
repression
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Reference
Miyashita et 01. (1995)
Elkeles el 01. (1999)
WU et 01. (1997)
Owen-Schaub el 01.( 1995)
Buckbindcr et 01. (1995)
Isracli et01. (1997)
Miyashilaet 01. (1995)
Prisco et of. (1997)
Murphy et 01. (1996)
response element has been identified in the bax promoter that mediates p53-induced transaetivation
(Miyashitaelal..l995).
c-fos is a proto-oncogene that can induce apoptosis in a nwnberof conditions (Section 1.5.2).
Using lhe suppression subtractive hybridization differential screening technique, c-fos was identified
as a target for transcriptional activation by p53 in cells undergoing p53·mediated apoptosis (Elkeles
et al., 1999). Overexpression of wild-type p53 can induce c-fo:r mRNA and protein both in vitro and
ill \';\·0. Interestingly, the basal c1°S promoter is not regulated by p53. Rather, p53 binds a distinct
region within the first C10$ intron and trartsaetivates c1°S promoter (Elkeles et al., 1999). Therefore,
activation ofc-fos by p53 may be partially responsible for pH-induced apoptosis.
DR5/KlLLER is a member of the TNFR family that is also induced by p53 (Wu et al., 1997) or
p53-independent genotoxic stress (Sheikh el al., 1998). lnteraction of DRS with its ligand, TRAIL,
can activate the cytoplasmic death domain of DRS, which in tum induces apoptosis through
activation of the caspase cascade (Ashkenazi and Dixit, 1998).
jas is another mediator of apoptosis that can be upregulated by p53 in several cell types (Owen-
Schaub et al.. 1995). Binding of Fasl to Fas can induce apoptosis by caspase recruitment and
activation (for review, see Ashkenazi and Dixit, 1998), Therefore, p53 can induce apoptosis by
enhandng signal transduction through the FasUFas and caspase pathway.
bd-2 (Miyashita cl at., 1994, 1995),IGF-IR (Prisco et al., 1997), and MAP4 (Murphy et al.,
1996) are three anti-apoptotic proteins whose expression has been shown to be inhibited by pS3,
suggesting another mechanism by which pS3 promotes apoptosis. This explains why, while
transactivation of some apoptosis-inducing genes can lead to apoptosis, p53 mutants lacking the
wild-type sequence-specific transactivation function have also been shown to induce apoptosis in
a cell type-specific manner (Haupt el al., I99Sb; Haupt and Oren, 1996).
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p73 was originally identified as a candidate tumor suppressor gene in neuroblastomas. It encodes
a protein with considerable homology with p53 tumor suppressor and transactivates genes containing
p53-rcsponsive elements, such. as WAFI (Kaghad et 01., 1997). Nevenheless, p73 is different from
p53 in several aspects. For example, p73 is not induced by DNA damage and its protein is not
targeted for inactivation by viral oncoproteins, such as $V40 T antigen, adenovirus EIB and HPV
E6 (Kaghad, [997; Marin e/ 01.,1998). In addition, unlike pH, p73 mutations are rare in human
cancers (Mai et 01" 1998; Sunahara elol., 1998: Han et 01., 1999; Tsao eloJ., 1999). However, like
p53, overexprcssion ofp73 inp53-null human cancer cells or in baby hamster kidney cells induced
apoptosis (Jost et 01., 1997). The molecular mech.anism for the pro-apoptotic function ofp73 remains
to be elucidated.
1.7.2 WAFlICipl/Sd;1/pll
WAFI is a gene that is directly transactivated by wild-type p53 (EI-Deiry et 01., 1993). It encodes
a 21 kDa protein that functions as a cyclin-dependent kinase (cdk) inhibitor, and has been shown 10
block predominantly the GI-$ phase cell cycle transition (Sherr and Roberts, 1995). Like p53,
overexpression of WAFt can suppress tumor growth (EI-Deiry et 01., 1993), demonstrating that it
is a tumor suppressor gene.
Although WAF1 plays an important role in p53-inJuced Gl arrest, its role in p53-induccd
apoptosis remains controversial. WAFI has been shown to either promote (EI-Deiry et 01., 1994;
Kondo et al., 1996a) or inhibit (Gorospe et 01.,1997) p53-induced apoptosis, depending on the
apoptotic stimuli or cell lines used. For example, in one study, it was shown that WAFI was
activated during p53-dependent cisplatin-induced apoptosis of U87-MG glioma cells, and
ovcrcxpression of WAFt caused apoptosis (Kondo et aI., 1996a). However, in another study.
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overexprcssion of WAFt protected human melanoma cells againstp5J-mediated apoptosis (Gorospe
etal.,1997).
1.7.3 RB
RB is a gene that is inactivated by deletion or mutation in many different human cancer cell lines,
including retinoblastoma. small-eelliung cancer, bladder cancer and osteosarcoma lines (for reviews,
see lee. 1991; Hamel etal., 1993). Transfecling wild-type RB cDNA into tumor cell lines lacking
functional RB can revcrse the transfonned phenotype (Huang et al.. 1988; Xu et aI., 1991; Antelman
et al., 1995), indicating that RB can act as a twnor suppressor. RB has the ability to suppress cell
proliferation after its cell cycle-dependent phosphorylation. In GO, RB is hypophosphorylated and
can bind to transcription factors such as E2F and inhibit transcriptional activation ofcellular genes,
such as c·myc andJos, by E2F. In proliferating cells, RB was phosphorylated in late GI by cdk.
Phosphorylation of RB releases E2F, which ean induce entry into S phase by induction ofcellular
genes associated with DNA replication or eel! proliferation, such as c-myc, cdc2, DNA polymerase-
a. thymidine kinase. and dihydrofolate reductase.
Apart from the role ofRB in tumorigenesis and cell proliferation, several studies demonstrated
an additional function for RB: regulating apoptosis. RB deficient mice have been shown to exhibit
extensive apoptosis in their lens and nervous system (Clarke et al., 1992; Morgenbesscret al., 1994;
Macleod et al., 1996). On the other hand. overexpression of RB can inhibit apoptosis induced by
ceramide. IFN-y, ilTadialion. and p53 (Haupt et al., 1995; McConkey et al., 1996; Ishii et aI., 1997).
Furthennore, RB is cleaved and inactivated by caspase-3 during aPOPlosis induced by TNF-a and
Fas, suggesting that RB degradation contributes to the activation of apoptosis. RB may inhibit
apoptosis by inhibiting the pro-apoptotie function ofp53 through interaction with Mdm2 (Hsieh et
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al., 1999).
1.7.4 pl6 aodp/9A.RF
Several experimental resulls indicate that pl6 is a tumor suppressor and involved in cancer
development: I) pl6 deletions or mutations have been found in a variety of human cancers; in
addition. inactivation ofp16 expression by hypennethylation of its promoter has also been found in
colon, non-small cell lung and head and neck cancers, and high.grade gliom~ 2) pl6 gennline
mutations have been found in melanoma-prone kindreds; 3) overexpression ofpl6 inhibits tumor
growth; and 4) pl6-null mice develop cancer and are susceptible to DNA-damage reagents (for
review, see Kamb, 1998). Overexpression ofpl6 can induce apoptosis in various cell systems
(Urashima et aI., 1997; Frizelle et al., 1998; Schreiber et al., 1999). It is postulated that pl6 induces
apop!osis by inhibiting the function ofanri-apoptolic RB (Frizelle el al., 1998).
pl9ARFis a tumor suppressor gene transcribed by alternative splicing from genomic sequence
shared with thepl6lrallscript but encoding a different open reading frame (Haber, 1997). Like pl6,
p 19ARF exens its tumor suppressor function by inducing G I arrest. However, unlike p16, P19ARF
cannot inhibit cdk activity. Instead, it blocks inftibilion ofp53 by Mdm2 (pomerantz et aI., 1998).
Consistent with the link between pl9ARF and p53, pl9ARF can induce apoprosis through a p53-
dependent pathway (Radfar el al., 1998).
1.8 Functions of BAG-I
BAG-I is regarded to be a multifunctional protein that regulates several cellular processes,
including apoptosis, signal transduction, hormone response, growth arrest, and protein folding (Fig.
1.3).
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1.8.1 Anti-apoplosis
BAG-I was a novel protein first cloned from mouse cells by screening proteins interacting with
the aflli-apoptotic protein, BcI-2. (Takayama et al.• 1995). Cotransfection with mouse BAG-I
(mBAG-I) was shown to increase BcI-2-mediated protection from apoptosis triggered by se\'eral
stimuli, including staurosporine. anti-Fas antibody and cytolytic T cells (Takayama el al., 1995). In
addition, overexpression of BAG-I alone in mouse 3D fibroblasts and lymphocyte cells can prolong
cell survival following apoptotic stimulus treaunent orcytolOne withdrawal (Takayama et at., 1995;
Clevenger et 01.,1997). Recently, mouse BAG-I was shown to bind the plasma membrane-
associated receptors for hepatocyte growth factor (HGF) and PDGF and enhance their inhibition of
apoptosis (Bardelli et aI., 1996).
1.8.2 Signal Iransduelion p.tbw.ys
BAG-I was reported to interact with serine/threonine-specific protein kinase, Raf-I, in vitro and
(II \'i\'o and increase its kinase activity through a Ras-independent mechanism (Wang el al.• 1996).
Raf-l is a mitogen-activated protein (MAP) kinase kinase (MAPKK) that plays a central role in the
Ras signal transduction pathway in response to receptor lyTosine kinases, such as EGF receptor
(Park, 1998). Therefore. BAG-1 may playa role in signal transduction by phosphorylating and
activating Raf-1.
1.8.3 Regulation ofbormone receptor fUDction
Recently, human BAG-I was shown to be idenlical to a protein. RAP46. which binds to many
members of the nuclear steroid honnone family receptors including estrogen receptor (ER),
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Fig. 1.3. Interaction and modulation ofcellulM proteins by BAG~ I (see text for delails).
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glucocorticoid receptor (GR), progesterone receptor (PR), androgen receptor (AR), myroid receplor
(TR). and retinoic acid receptor (RAR) (Zeiner and Gehring, 1995; Liu et al.. 1998; Yang el a/.,
1998). Binding of BAG·1 prolein to AR can enhance the ability of AR 10 lransactivate reporter gene
plasmids containing an androgen response element (ARE) (Froesch el aI., 1998). On me other hand,
binding of BAG· I 10 GR and RAR can inhibil their ability to transactivate other genes and induce
apoptosis (Liu er 'II., 1998; Kullmann el al., 1998). Thus, elevated BAG-I level in cancer cells (sec
Section 4) potentially contnbules to their resistance to androgen, glucocorticoid and retinoid response
by inhibiting the function of their receptors.
1.8.4 Inhibition or growth 8rreSl
BAG·! also has been shown 10 bind to p53-downstTeam human homologs or Drosophila seven
in absenlia (sina) proteins that are called SINA-homologous (Siab) proteins. In cotransfection
experiments, wild-type BAG-I but not a C-Ierminal deletion mutant of BAG· I, can abolish Siab-
induced growlh arrest in 293 and GM701 cells (Malsuzaw3 er aI., 1998). In addilion, BAG-I can
prevent growth arrest following UV-irradiation·induced gcnoloxic injury without interfering with
accumulation ofp53 protcin or activation of WAFI, suggesling thai BAG-I can suppress cell.cycle
arrest by inhibiting p53-downstTeam Siab funclion (Malsuzawa et aI., 1998).
L8,S Chaperone coracln..
BAG-I was found to bind Ihe ATPase domain ofHsp70IHsc70 both i" vilro and i" vivo through
Ihe BAG-I C-Ierminal domain (Takayama er al., 1997; Zeiner and Gehring, 1995; Hohfeld and
Jcntsch, (997). Furthermore, BAG·1 can bind other proteins such as c·Jun through Hsp70 (Zeiner and
Gehring, 1995), indicating that BAG-I may acl as an Hsp70 chaperone cofactor to regulalc Ihe
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function ofother proteins. Binding of BAG-I to Hsp7OJHse70 can either inhibit HsplHse7Q-mediated
ill vitro refolding ofan unfolded protein substrate (Takayama el al., 1997; Zeiner and Gehring. 1995)
or cooperate with Hsp40 to stimulate the steady-state ATP hydrolysis activity ofHsc70. These results
indicate that the observed anti-apoptotic function of BAG-I may be exened through modulation of
Hsc70 chaperone activity.
1.9 Purpose of tbis study
To isolate the factors regulating the expression of lC virus OCV), a protein called Kl, which can
bind to the NF I-binding site in the lCV enhancer and transactivate its promoter, was isolated from
mouse P19 embryonal carcinoma cell eDNA library (Kumar et al., unpublished data). A homology
search in Genbank found that the amino acid sequcnce of KI was identical to that of mouse BAG· I,
an anti-apoptotic protein (Takayama et aI., 1995). Since dystegulation of BcI-2 was found to be
involved in carcinogenesis (Tsujimoto and Croce., 1986; Hollstein et al., 1991: McDonnell el al.,
1992: Halderetal., 1994; Ikegakietal., 1994; Reed, 1994; Liang et al., 1995; Sinicropeetal., 1995),
my hypothesis was that BAG-I, a BcI-2-interacting protein, also plays a role in human cance~.
Because human BAG-I was not cloned when I staned my PttD program several years ago, in
order to study the role of BAG-I in human cancer, the first purpose of my study was to clone and
analyze the human homOlog of mouse BAG· I eDNA. Second, since mouse BAG-I was originally
identified as an anti-apoptotic protein (Takayama et al., 1995), I tried to examine whether human
BAG-I plays similar role in apoptosis. Third, I had previously developed an ill vitro cell model of
multistep cervical oncogenesis (Yang et al., 1996). To examine whether BAG-l and other apoptosis-
regulating protcins are involved in the different stages ofcervical carcillOgenesis. I assayed expression
of pro· and anti.apoptotic proteins and its correlation with the sensitivity ofdifTerent cervical cells
34
to apoptosis. Fourth. it had been found that enhanced expression of anti.apoptoric genes, such as bd-
l. is involved in human cancers (Tsujimoto and Croce., 1986; Hollstein et aI., 1991; McDolUleli et
at., 1992; Halder et aI., 1994; lkegaki et 01., 1994; Reed, 1994; Liang et 01., 1995; Sinicrope et 01.,
1995). To study the possible role of BAG-I in human cancer, BAG·l RNA and protein levels were
examined in cclilines and lissuesoftwo common cancers in women, breast and cervical cancer. Fifth,
many apoptosis-regulating genes are transcriptionally transaclivated or repressed by key molecules
for regulating apoptosis and oncogenesis, such as p53 (Selvakumaran et 01., 1994; Miyashita et 01.,
1994; Zhan el 01., 1994; Miyashita et al., 1995). Therefore, the last purpose of my study was to clone
the BAG·l promoter and test whether it can be regulaled by other transcription faclors.
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SECTION 2
CLONING AND ANALYSIS OF HUMAN BAG-I
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CHAPTER 2
HUMAN BAG-I eDNA CLONING, SEQUENCE ANALYSIS
AND RNA EXPRESSION
:U INTRODUCTION
At the beginning of my studies, a mouse BAG-I eDNA was cloned in OUT lab. Preliminary data
indicated thaI BAG-l plays an imponant role in the transcription ofJC virus. a human DNA tumor
virus (Kumar, unpublished data). To study the rolc of human BAG-I in apoptosis and
carcinogenesis. I isolated a human BAG·] eDNA clone by screening a human cervical cell eDNA
library using mouse BAG-I eDNA as a probe. The sequence ofBAG· I eDNA was analyzed. Tissue-
specific expression of BAG-l RNA was also examined.
2.2 MATERIALS Ai"110 METHODS
2.2.1 Construction or human cervical cell eDNA library
The i. phage ZAP-eDNA s)1lthesis kit (Stralagene) was used for constructing an HEN-16-2
HPVl6-immortalized human cervical cdl eDNA library. The procedure is illustrated in Fig. 2.1 and
described as follows:
1) ExtraclioD orpol~'(Ar mRNA
Total R,'JA was cxtraeled from HEN·16-2 cultured to 70"/c,confluence using lhe CsCl gradient
centrifugation method (Sambrook et aI., 1989). Poly(Af mRNA was extracted by passing tolal RNA
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Fig. 2.1 Flow l;han ofl;DNA library conSlnlction. See the text for description.
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twice through oligo(dT)-cellulose columns, washing the columns with high salt buffer (10 mM
Tris~HCI, I mM EOTA,O.5 M NaCI) and low salt buffer (10 mMTris·HCl, I mM EOTA.O.I M
NaCI). and eluting poly(Af mRNA from the columns with 65 °c elution butTer (10 mM Tris~HCl,
pH 8.0, I mM EOTA) included in lhemRNA purification kit (phannacia). The purity and integrity
of the poly(A)' mRNA was examined by electrophoresis on agarose gels.
2) First strand cDNA Sf.tbesis
About 5 IJ&of poly (Af RNA were incubated at 37°C for I h in a premixed solution conlaining
1>< first strand buffer, 10 mM OTT, 0.6 mM first strand methyl~nucleotidemixture, 56 ngl~1 of
linker.primer. 0.8 U/~I of RNase Block., and I U M-MuLV reverse uanscriptase. As a control,S !-lCi
00-C1Pj-dATP (Amersham) were mixed with 1/10 volume of the above reaction solution and
incubated in the same conditions. The nonradioactive first stand reaction mixture was placed on ice
after incubation until it was used for second strand synthesis. The radiolabelled reaction mixture was
used for gel electrophorctic analysis of first strand synthesis products on a I% alkaline agarose gel.
3) Second strand cDNA syatbesis
The nonradioactive first strand reaction mixure was incubated in 1>< second strand butTer, 4 roM
OTT. 0.15 roM second strand nucleotide mixture. 20 !-lCi n-[ Jlpj-dATP, 4.5 U RNase H, and 100
U DNA polymerase at 16"C for 2.5 h. The DNA was phenoVchloroform-extracted, precipitated and
resuspended in sterile water. Then, 3 IJ.I were analyzed for second strand synthesis by gel
electrophoresis on a I% alkaline agarose gel.
4) Preparation of cDNAs and lbeir ligation lnlo veclor
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To blunt-end me cDNA tennini, the second strand reaction mixture was incubated in Ix
Buffer#3 (supplied in the Stratagene kit), 125 ~M dNTP mix and 2.5 U KIenow fragment of DNA
polymerase I at 37·C for 30 min. The blunt-ended cDNA was ligated with XhoVEcoRJ adaptor by
incubation in ligation buffer(lx Buffer #3. 0.28 ~gI~1 XhoVEcoRi adaptor, I mM y-ATP, and 4 U
T4 DNA ligase) at 8·C overnight. The ligase was heat-inactivated and the EcoRJ ends on the cDNA
were phosphorylated by incubating in kinase buffer (Ix Buffer#3, 2 mM y-ATP and 10 U T4
polynucleotide kinase) at 37 "C for 30 min. Xhol digestion was men perfonned by incubation of the
kinase reaction mix wim 120 U Xhol in I x Xhol buffer.
For size fractionation of cONA, it was first loaded on a Sephacryl S-400 spin column and the
first fraction was collected by centrifuging me column in a tube at 400x g for 2 min. 1be second and
third fraction were collected by loading 60 I.d of Ix STE buffer on the column and centrifuging, as
for fraction I. The size ofcONA in each fraction was examined by electrophoresis of 1/10 of the
fractions on a 5% nondenalUring acrylamide gel. The cDNA was quantified by comparing me
nuorescence intensity of I ~l ofeach fraction with those of ONA standards on an ethidium bromide-
containing plate irradiated by short wavelength UV light.
To ligate the cDNA into Uni-ZAP XR). phage vcctor arms, approximately 100 ng ofcDNA were
incubated overnight at 12·C in ligation mixture (Ix ButTer/H. I mMy-ATP, I ).ls!).ll Uni-ZAP XR
vector. and 2 U T4 DNA ligase).
5) PackagiDg recomblDant eDNA Into pbage
GIGAPACK II packaging exttaet (Stratagene) was used to package recombinant cDNA-vector
amlS. In bric( I ).ll of ligated eDNA-vector arms mixed with Freeze-Thaw extract (Stratagene) was
placed on ice, 15).l1 of Sonic extract (Stratagene) was added, the mixture was incubated at room
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Icmpcrnture for 2 h. 500 lotI ofSM buffet" and 20 III of chlorofonn were then added into the tube and
the supernatant containing the packaged cDNA was collected.
6) Plating and titratiDI tbe rccombi.aot eDNA libra')'
One lotI of the final packaged reaction product was first mixed with 200 lotI of XLI-Blue MRF'
cells (0060(1=0.5). After incubation at 37°C for 15 min, 3 ml of top agal'", 15111 ofO.5M IPTG and
50 III of X-gal (250 mglml) were added and the mixture was plated immediately 0010 the NZY
plates. which were further incubated at 37°C for 6-8 h. Blue plaques were considered to be
background, while white plaques were considered as recombinant plaques. The number of white
plaques was used to calculate the titer ofcDNA library.
7) Amplification ortbe eDNA library
Aliquots of packaged mixture or library suspension containing approximately 50.000 phage
fonning unit (Pfu) were mixed with 600 III of host bacteria at OD6lIO ... 0.5 in Falcon 2059 tubes
(Fisher). After incubation of the tubes for 15 min at 37°C, 6.5 ml of melted top agar (cooled to
approximately 48 ·C before use) was added into the tubes. The mixture was immediately spread
evenly 0010 150-mm plates containing bottom agar. The plates were then incubated at 37 °C for 6·8
h to achieve plaques in the 1-2 mm range, overlaid with 10 ml SM buffer(IOO mM NaCl, 20 mM
MgSO., 50 mM Tris-HCI, pH 8.0, and 0.01 % gelatin), and incubated at 4·C overnight. The phage.
containing SM buffer was removed from the plates, collected. titrated, as above, and stored at 0.3%
chlorofonn at 4 ·C.
2.2,2 Screening tbe eDNA library'
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To screen the cDNA library, mixtures ofabaut 5>< 10' pfu phages. 600 ~I of XLI-blue cells
(OD~ = 0.5) and 6.5 ml of top agarose were overlaid on 150-nun NZY plates. The plates were
incubated at37 "C for 8 h and chilled for 2 h at 4 "c. The plaques were then panially transferred for
1 min to nitrocellulose membranes, denatured in 1.5 M NaCI and 0.5 M NaOH for 2 min, neutralized
in 1.5 M NaCI and 0.5 M Tris-HCI (pH 8.0) for 5 min. and rinsed in 0.2 M Tris-HCI, pH 7.5, and
1>< sse for 30 sec. The membranes were then baked at 80 "c for 2 h. prehybridized at 60'C in
QuickHyb hybridization buffer (Amersham) forO.s hr, and hybridized QuickHyb buffer containing
l:P_labelled mouse BAG-I cONA probes (2 >< 1Ci' cpmlml hybridization buffer) at6CfC for 2 h. The
membranes were washed twice with 2>< SSC and 0.1 % sodium dodecyl sulfate (50S) at room
temperature for 15 min and twice with 0.1>< SSC and 0.1 % SOS at 60 "c for 10 min. Then, the
membranes were scaled in clean plastic bags and exposed to Kodak XAR film overnight at -80 "C.
Putative positive clones were identified on the films and aligned with the plates. One cm diameter
disks of bacteria and phage lysates surrounding the positive clones were scraped off the plates with
tooth picks and transferred to tubes containing 1 ml SM buffer and 20 ~l of chloroform. To titrate
phages. 5 I..LI of vonexed mixtures were spread on 100 rom NZY plates. The procedure used for the
first screening was repealed until all plaled plaques were aligned with positive signals for each
clone.
2.2.3 Rel.'o\·er~· of recombiD8at eDNA pbagemlds
The eDNA insens in the final positive clones were then excised from the Urn-ZAP XR phage
vector using the ExAssistiSOLR system (Slr.ltagene). In brief, single plaques from agar plates were
transferred 10 sterile microfuge rubes containing 500 ~I ofSM buffer and 20 ~1 ofchloroform. Tubes
were incubaled at 4 "c overnight, and mixtures of 100 ~I phages, 200 I..LI of XLI-Blue bacteria
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(00,,00= 1.0) and I ","I of ExAssist filamentous helper phage were incubated at 37 "C for IS min.
Three ml of2>< YT media were then added and the mixtures were incubated in 50 ml conical tubes
al 37°C for 2.5 h with shaking. The tubes were heated at 70°C for 20 min and centrifuged for 15
min at 4,OOOx g. One ~I of supernatants containing me packaged phagemids were men incubated
with 200 III ofSOLR bacteria at 37 "C for IS min and plated on LB-ampicillin (SO Ilgfml) plates.
The plates were incubated at 37°C overnight and me colonies containing me pBluescript double-
stranded eDNA phagemid were scraped &om me plates with tooth picks and grown in lB-ampicilin
(50 ","glml) medium at 37 °e overnight. The phagemids were purified from the bacteria using a
plasmid purification kit (Qiagen).
2.2.4 Testing eDNA dODes
To lest positive eDNA clones, dot and Northern blot analysis were perfonned. For dot blot
analysis, approximately 100 ng of phagemid DNA were applied to nitrocellulose membrane. The
membranes were baked at 80°C for I hr, prehybridized. and hybridized with l2P_labeJled mouse
BAG- I probe (2 x 106 cpmlml hybridization buffer) using the same conditions as for cDNA library
screening. For Nonhern blot analysis. approximately 20 Ilg total RNA were size-fractionated in
denaturing 1% agarose gels and transferred to Hybond nitrocellulose membrane (Amersham). The
blots were hybridized in QuickHyb hybridization buffer containing l2P-labelled putative human
BAG-l eDNA probes (2 x 106 epmlml hybridization buffer) at 65 "C for I h. The blots were then
washed twice with 2" sse and 0.1% SOS at room temperature for IS min and twice with O.lx sse
and 0.1 % 50S at 60 °e for 10 min. Then. the membranes were exposed to Kodak XAR film
overnight. For the expression of Il-aetin internal control RNA, membranes were subsequently
stripped. reprobed with J2P_labelied Il-actin eDNA (5 x 10' cpmlml hybridization buffer), washed
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and exposed to film. as described above.
2.2.5 Sequencing and ~ue.«a.alysis or cDNA clones
The positive cONAs confirmed by dot and Nonhero blot analysis were sequenced from both S'-
and 3'-ends using a Scquenase Version 2.0 kit (USB). Sequence homology sean::hes were perfonned
\\lilh the BLAST program (NCBl) through internet (hllp:/Iwww.ncbi-nih.gov). An analysis for (1.
helical structure was performed using a protein secondary structure analysis program provided by
Saylor Coliege 0 f Medicine (http://doLimgen.bem.tmc.edu:9331/seq.searchlslruc.predic.html).
2.3 RESULTS
2.3,1 (DNA library cODstnetlon
The firsl and second strand eDNA was synthesized and ranged from O.S kb to 8 kb (Fig. 2.2),
which includes bands with the sizes of almost all the mRNA species expressed in eukaryotie cells.
While the primary eDNA had a tOlal titer of 4 x 106 pfu, the amplified eDNA library had a titer of
5)( 10,opfulmL The insensizcsof20 plaques examined by PCR in the eDNA library ranged from
0.5 kb to 3.5 kb.
2.3.2 Screening and testiDg BAG-I eDNA c10Des
Aftcrprimary screening of 5 x IDS pfu, 22 positive phage clones were identified, recovered and
subjected to further screening. After three rounds of screening, seven positive clones were identified
and isolated. An example of a screening result is shown in Fig. 2.3. In general. after the third
screening, all plaques were separated from each othet'" and hybridized strongly with the mouse BAG-
4'
Fig. 2.2 Alkaline agarose gel analysis of first and SC{;ond strand eDNA synthesis. Five J11 of
reaction mixture from radiolabclled eDNA synthesis were size-fractionated on I% alkaline agarose
gels, which were subsequently vacuum dried at 80 ·C, before exposure to X-ray film at -80 e
overnight. Molecular weights in kb are shown on the left.
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Fig. 2.3 eDNA library screening. 5 " 10' pfu phages were plaled, incubated at 37 OC for 6-8 h, and
transferred to nitrocellulose membrane. The membranes were hybridized with JlP.labelled mouse
BAG·\ eDNA probe in QuiekHyb hybridizalion buffer at 60 OC for 2 h and washed before exposure
10 X-ray film at.sO "C o\-·emight. The plItati\'c positive clones and their surrounding plaques were
taken from Ihe plates and subjected to similar second and third screening.
48
eo
•"'c
" •e~
"E
M
'I... .•
• eo •
4.- • \ .••
• .1.1.: _.. •
en •• • r . ....... :
.E.. •••c.. • A • •!l .. , .::..... •
b •••~•• • _ ••• ,
.;. ... ,,:.
i'l _.: ..010 \
•
Fig. 2.4 Dot blot analysis ofB5-2 eDNA and Northern blot analysis ofBAG-' RNA. A. Dol blot
analysis of homology of B5-2 to mouse 8AG-I eDNA. 100 ng ofHPV 16 and 85·2 plasmid DNA
were spotted on nitrocellulose membrane, whieh was subsequently dried. hybridized with 31p_
labelled mouse BAG-I eDNA probe and washed before exposure to X-ray film at -80 °C overnight
B. Northern bioI analysis of8AG-l RNA. 20 J.lgoftotal RNA from mouse (P19),and hwnan(HEN,
HEN-16-2 and HeLa) eells were size-fractionated on a 1% formaldehyde agarose gel, lransferred to
Hybond nylon membrane, and hybridized with llP_labclled 85-2 eDNA probe in QuickHyb
hybridizalion buffer 31 60 °C overnight. The membrane was exposed to X-ray film at ·80 ·C
overnight. Actin was used as internal conlrol. Size marker are shown on the left and BAG-I RNA
is indicated on the righl.
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1 eDNA probe.
Eaeh positive clone was then tested for homology with mouse BAG-I. Fig. 2.4 shows results of
dot and Nonhem blot analysis for the longest (1.3 kb)eDNA clone, B5-2. Mouse BAG-I eDNA
probes hybridized strongly with B5-2 eDNA, but not with the negative control HPVl6 DNA (Panel
A). When B5-2 eDNA was used as a probe, a single 1.35 kb transeript was detected in the RNA
from all four cell types, mouse PI9 embryonic carcinoma cells. HEN human endocervical primary
cells. HEN-16·2 HPVI6-immorta!ized human endocervical cells and HeLa human cervical
carcinoma cells (Panel B). The same results were obtained when mouse radiolabelled BAG-I cDNA
was used to probe the same blot after il was stripped, indicating that the 85-2 eDNA cloned is the
human BAG-I eDNA in full-length.
2.3.3 Sequences and fUDctioul dom.iDs of BAG-I eDNA
Sequencing of85-2 eDNA showed that it has a sequence of 1,3 12 bp containing an open reading
frame (from the first ATG stan to nucleotide position 1098 TGA stop codons) encoding a protein
of 274 amino acids (Fig. 2.5). Human BAG-I mRNA was also found to be translated from an
upstream CTG stan codon, resulting in a full-length 345 amino acid BAG-I called p50 (see Chapter
3 for details). (n addition. a polyadenylation signal. AATGAA, was also identified 44 nucleotides
upstream ofa poly(A) tail (Fig. 2.5). A search for sequences homologous to B5-2 human BAG-I
eDNA in the GenBank and EMBL databases revealed 100"10 identity to RAP46, a gene encoding a
honnone receptor-binding protein that was isolated from a human livercDNA library (Zeiner and
Gehring. 1995). Comparison of amino acid sequences of human and mouse BAG-! revealed 75%
identity and 84% similarity. While the sequences ofC-tenninal amino acids were nearly identical
in human and mouse BAG-I eDNA. those ofN-terminai were found to be less conserved (fig. 2.6).
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Fig. 2.5 Nucleotide and amino acid sequences of human BAG-I. The positions of the 1.3 kb cDNA
nucleotide sequence and the deduced 345 amino acid sequence are shown on the left. ATG (M) or
erG (l) translation start codons and termination codon (-) are in boldface. The polyadylation site
signal sequence (AATGAA) is boldfaced and underlined.
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1 TCG
4 GGCGGGGTTGTGAGACGCCGCGCTCAGCTICCATCGCTGGGCGGTCAACAAGTGCGGGC
63 CTG GCT CAG CGC GGG GGG GCG CGG AGA CCG CGA GGC GAC CGG GAG
1 L A Q R G GAR R P R G 0 R E
108 CGG CTG GGT TCC CGG CTG CGC GCC CTT CGG CCA GGC CGG GAG CCG
16 R L G 5 R L R A L R P G REP
153 eGC CAG TCG GAG CCC CCG GCC CAG CGT GGT CCG CCT CCC TCT CGG
31 R Q 5 E P P A Q R G P P P 5 R
198 CGT CCA CCT GCC CGG AGT ACT GeC AGC GOG CAT GAC CGA CCC ACC
46 R P PAR 5 T A 5 G H 0 R P T
243 AGG GGC GCC GCC GCC GGC GCT CGC AGG CCG CGG ATG AAG AAG AM
61 R G A A A GAR R P R M KKK
288 ACC CGG CGC CGC TCG Ace CGG AGe GAG GAG TIG ACC CGG AGC GAG
76 T R R R 5 T R SEE L T R 5 E
333 GAG TTG ACC CTG AGT GAG GAA GCG Ace TGG AGT GAA GAG GCG ACC
91 E L T L SEE A T W SEE A T
378 CAG AGT GAG GAG GCG ACC CAG GGC GAA GAG ATO AAT CGG AGC CAG
106 Q 5 E EAT 0 GEE M N R 5 Q
.. 2 3 GAG GTG Ace CGG GAC GAG GAG TCG ACC CGG AGe GAG GAG GTG ACC
121 E V T ROE EST R SEE V T
468 AGG GAG GM ATG GCG GCA GCT GGG CTC ACC GTG ACT GTC ACC CAC
136 R E E M A A A G LTV T V T H
513 AGC AAT GAG AAG CAC GAC CTT CAT GTT ACC TCC CAG CAG GGC AGC
151 S N E K H 0 L H V T S Q Q G S
558 AGT GAA CCA GTT GTC CAA GAC CTG GCC CAG GTT GTT GAA GAG GTC
166 S E P V v Q 0 L A Q v VEE V
603 ATA GGG GTT CCA CAG TCT TTT CAG AM CTe ATA TTT AAG GGA AAA
181 I G V P Q S F Q K L I F K G K
6'18 TCT CTG AAG GM ATG GAA ACA CCG ITG TCA GCA CTT GGA ATA CAA
196 S L K E MET P L SAL G I Q
693 GAT GGT TGC CGG GTC ATG ITA ATT GGG AM MG MC AGT CCA CAG
211 D G C R V M L I G K K N S P Q
738 GM GAG GTT GM CTA MG MG TTG AAA CAT TIG GAG AAG TCT GTG
226 E EVE L K K L K H L E K 5 V
783 GAG MG ATA GCT GAC CAG CTG GAA GAG TTG MT AAA GAG CTT ACT
241 E K I A D Q LEE L N K E L T
828 C-GA ATC CAG CAG GGT TTI CTG CCC AAG GAT TIG eM GCT GAA GCT
256 G I Q Q G F L P K 0 L Q A E A
873 CTC TGC AAA CTT GAT AGG AGA GTA AM GCC ACA ATA GAG CAG TTT
271 L C K L D R R V KAT I E Q F
918 ATG MG ATC TIG GAG GAG ATT GAC ACA CTG ATC CTG CCA GAA AAT
286 M K I LEE I D T L I L PEN
963 TIC AAA GAC AGT AGA TIG AAA AGG AM GGC TIG GTA AAA AAG GTT
301 F K D S R L K R K G L V K K V
1008 CAG GCA TTC CTA GCC GAG TGT CAC ACA GTG GAG CAG MC ATC TGC
316 Q A F L A E C D T V E Q N I C
1053 CAG GAG ACT GAG CGG CTG CAG TCT ACA AAC TIT GCC CTG GCC GAG
331 Q E T E R L Q S T N F A L A E
1098 T:AGGTGTAGCAGAAAAAGGCTGTGCTGCCCTGAAGAATGGCGCCACAGCTCTGCCGTC
1157 TCTGGAGCGGAATTTACCTGTTTCTTCAGOGCTGCTGGGGGCAACTGGCCATTTGCCAA
1216 TTTTCCTACTCTCACACTGGTTCTCAA'IGAAAAATAGTGTCTTTGTGATTTT(':;AGTAM
1275 GCTCCTATCTGTTTTCTIl.Il.AAAIl.AA AUAAAAAAAAA.
fig. 2.6 Comparison ofamino acid ~uences of human (h) and mouse (m) BAG-I. Identities are
indicated by vertical lines and similarities by two dots. The amino acids M or l encoding the
potential in-frame translation initiation start codons are in boldface. The potential NLS is boxed.
Numbers on the left indicate amino acid positions.
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hBAG-l ~AQKGGA~Rf R'fORERLGSR LRALRPGREP R9SoPPAQRG PPPSRRPPAR 50
mBAG-l I.lG~SllHp ~/;b~~pHp~ W~H~W ~QUSR1E~b LH~Q~SS~~ 50
hBAG-l LSEE--ATWS EEATQSEEAT QGEEHNRSQE VTROEESTRS EE-VTREEMA 140
mBAG-l HKNVTgQV ~gtKI~W 6TH~~VAE~ ~tQT~NMA~~ HJb-r~~~E 150
hBAG-l AAGtTyTYT7 ~NTKHPtHYT SmSmW 9PI19;'yEF I<WQSf9~t 190
mBAG-l T~R ~Vlt+H S~E~yb LVT PQQG~sHtt QblJ.Qiv~t;" TGV~LP~QK 200
:~~=~umnm uttntd!b ~mnu: !::I~Um m!:U:I~ ~:~
::~~~Umbtm mnm~ aruma nmmn mmun ~~~
::~=~ncr~tm mmm~ mmmr IJcrmm ~mmm ~~~
hBAG-l fALA~ 345
mBAG-l LiU/: 351
Fig. 2.1 Functional domains in h.uman BAG-I isoronns. The amino acid positions oreach domain
are shown either above or below the boxes. Different domains are indicated by distinct colors. The
dark yellow color box represents overlapping; region or a-helix and BAG- t domains.
57
p50
_I
f;;j\$,P,I'1.''1il I I I
70 76 163 199 241 345
p46
-, I("!i'~..,} -.·,9,:;lJiId I I I I
72 345
p33
I rAg" :t!16·"',t.";'f! I I I I
116 345
p29
L
139 345
• NLS oTRSEE repealS DUbiquitin homology o a-helix • BAG-I domain
Since four isoforms ofhuman BAG·) protein, namely p50, p46, p33 and p29. were produced by
altcrnative translation initiation (see Chapter 3). the functional domains of cach isofonn were
idcntified and are shown in Fig. 2.7. p50 isofonn, the full-length BAG-) protein, was found to have
five functional domains including a nuclear localization signal (NLS; PRMKKKT), )0 copies of
TRSEE (TItr-Arg-Ser-Glu-Glu) consensus homology repeats. a ubiquitin homology domain, an a-
helix. and a BAG-I domain. p46 contained all the other domains except five of eight NLS amino
acids. No NLS and only fourTRSEE consensus repeats were found in p33, whereas neilher NSL nor
TRSEE consensus repeats were contained in p29.
2.3.4 Tissue-specifk expression or bumaa BAG-l
The expression ofhuman BAG-I RNA in nonnaltissues was examined using a Multiple Tissue
Northern Blot (MTN, Clontech) containing 2 J.lg per lane ofpoly(Af RNA from different human
tissuc. BAG-l Rt'lA was found 10 be expressed in all thc human tissues: heart, brain. placenta, lung,
Iivcr. skeletal muscle. kidney. and pancreas (Fig. 2.8). Relatively higher level of BAG-I RNA was
dctected in heart and pancreas tissues.
2.4 DISCUSSION
Using mBAG·1 cDNA probe, the human homolog of mouse BAG-I cDNA has been
succcssfully isolated from a human cervical cell cDNA library. Surprisingly, human BAG-I has
100% homology with a honnone receptor-binding protein. RAP46 (Zeiner and Gehring, 1995).
RAP46 was isolated by protein-protein inleraction screening of a human liver cDNA expression
library with the glucocorticoid receptor. In addition 10 interacting with the glucocorticoid receptor.
RAP46 also interacted with other human honnone receptors. including the estrogen. progesterone
and thyroid receptors (Zeiner and Gehring, 1995). Therefore. BAG-I is a hormone receptor-binding
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fig. 2.8 Expression of human BAG·I RNA in different nonnal human tissues. An MTN blot
containing 21-1g11ane ofpoly(Ar RNA was hybridized with l!P·labelied human BAG·[ cDNA
probe. Conditions and labels are as described for Fig. 2.4 B.
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protein. Furthermore. human and mouse BAG-I cDNA share 75% identity and 84% homology and
are almost identical at their C-tennini. Interestingly, both human and mouse BAG-I mRNA were
shown to be expressed as a single 1.35 kb rranscript in mouse and human nonnaltissues (Fig. 2.8;
Zeiner and Gehring, 1995), suggesting that BAG-I is a ubiquitously expressed gene possibly
involved in a common event in different cell types.
Sequence analysis idenlified an NLS (pRMKKKT) in BAG-! similar to that identified in
SV40 largeT antigen (PKKKRKV) (Dingwall and laskey, 1991). The NLS in human BAG-I and
mousc BAG-I (pRVKKKV) were found to be conserved. However, the NLS was found to be full-
length only in human p50, partially present in p46, and not in p33 and p29 isofonns, suggesting that
different BAG-! isoforms may localize in different subcellular compartments. In addition. II copies
of consensus TRSEE pentameric motifs were identified in pSO and p46. Only four repeats were
found in p33, whereas none were found in p29. The biological significance of these repeats remains
unknO\~u. Furthermore, a 37 amino acid sequence that has high homology with ubiquitin or
uhiquitin-like proteins was also found in BAG-I protein. Ubiquitin is a small 76 amino acid protein
that is well conserved through evolution and can cause the degradation of target proteins also
containing ubiquitin homology by covalent formation between its conserved lysine at position 48
and the C-terminal glycine carboxyl group of the target proteins (for review, see Hershko and
Ciechanover, 1992). Therefore, this domain may be responsible for BAG-I protein degradation.
Furthermore. sequence analysis also identified an a.-helix-like sequence from amino acid position
225 to 261. a-helix domains have been shown to be involved in protein-protein interactions
{Muchmore et al .. 1996). Therefore, an a-helical suucture may be important for the interaction of
BAG-J with other proteins. Finally. the BAG-I domain is a sequence that is well conserved between
human and mouse BAG-I (Fig. 2.6). This domain is important for some functions of BAG-I , as it
will be described in Chapter 4.4.
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CHAPTER]
HUMAJ."I BAG-IIRAP46 PROTEIN IS GENERATED AS FOUR ISOfORMS
BY ALTERNATIVE TRAi"lSLATION INITIATION
3.1 INTRODUCTION
To elucidate the role of BAG· 1 in human cells. I isolated the hwnan homolog of mBAG-1
by screening a HPVI6-immortalized human cervical cell eDNA library with mBAG-! eDNA as a
probe (see Chapter 2). Recently, hBAG-! was also been independently cloned by others (Zeiner and
Gehring. 1995; Takayama el aJ.. 1996). Although the hBAG-! eDNAs isolated by us and the other
IWO groups have almost identical amino acid sequence. different molecular sizes of its protein
products were noted. hBAG·! or RAP46 was identified by Zeiner and Gehring (1995) as a prolein
wilh a molecular weight of46 kDa. whereas it was detected by Takayama el aJ. (J 996) as a protein
with molecular weight of 34 kDa.. In this study. three protein isoforms ofhBAG-1 were observed
ill \'itro that had molecular weights of 46 (p46), 33 (P33) and 29 kDa (P29). I e.'tamined the cDNA
sequence ofhBAG-1 and found three potential translation start codon ATGs (AVGs) at nucleotide
position number (nt) 276 (AUG I). 411 (AUG2) and 477 (AUG3). respectively. It is possible that the
distinct protein products ofhBAG·1 identified by different groups may resulted from translation
iniliation from different start codon AUGs. To test my hypothesis. I conducted site-direc:ted
mutagenesis of hBAG-1 cDNA and analyzed its protein products in vitro. My results provided
convincing evidence that p46. p33 and p29 are translated by alternative translation initiation from
slaneodons AUGI, AUG2 and AUG3. respectively. rn addition. an extra isoform ofhBAG-1 with
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a molecular weight of 50 kDa (p50) was also observed ill vitro and in vivo by us and recently by
Packham et al. (1997). p50 was found 10 be translated from CUG upstream of AUG I (Packham et
al.. 1997). The molecular mechanism of alternative translation iniliation of hBAG-1 mRNA. and
subcellular localization palterns of these four hBAG-1 isofonns were further invesligated in this
study.
3.2 MATERIALS A.~DMETHODS
3.2.1 Cell culture aDd IraDsCection
HeLa and C33A cervical carcinoma cells (ATCC) used in this study were cultured in
Dulbeco's modified Eagle's medium (DMEM) containing 10% fetal calfserum (FCS).
For cervical carcinoma C33A cell (an hBAG-1 negative cell line) u-ansfections. wild type or
mutated fonns of hBAG-1 cDNA were cloned into an eukaryotic expression vector PCRJ.I
(Invitrogen). Approximately 24 h prior 10 transfection. C33A were seeded at a density of5 x 10' cells
per IO-cm culture dish. Plasmid DNAs were stably transfecled into C33A cells by calcium chloride
or LipofcctAMINE (GffiCO-BRL) followed by selection in mediwn containing 0.8 mglml G418
(GIBCO-BRL). The resulting transfectants were maintained as cell lines and harvested for protein
subcellular fractionation or Weslern bioI analysis.
3.2.2 Generation or aali-bBAG-1 mouse monodoul ..llbody (mAb)
The coding region of hBAG-1 eDNA was cloned in-frame into pGEX-4T-3 veclor
(Phannacia). The resulting plasmid was then transfecled into BL21 bacleria and the GST-hBAG-1
fusion protein was induced with 0.1 mM isopropyl P-D-Ihiogalactoside a13(fC for 5 h. hBAG-1
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protein was purified by binding GST-hBAG-l on glutathione-Sepharose-4B beads (Pharmaeia) and
cleavage with thrombin. The mAb was generated by immunization of mice with purified hBAG·l.
After extensive screening, one clone named CC9E8, which recognized all the four isofonns of
hBAG-t and gave the best activily, was selected to produce anti·hBAG-l mAb used for Western blot
analysis.
3,2.3 Weslern bioI anah'sis
Western blot analysis was perfonned as described (Yang el aI., 1997). In brief, proteins were
extracted from 107 cells by lysis in I ml ice-cold extraclion buffer [50 mM Tris-HCI, pH 8.0, 150
mM NaCl. 0.02% sodium azide, 1% NP-40, 0.1 % SOS, 0.5% sodium deoxycholate] for 30 min and
centrifuged at 14,000 x g at 4 UC for 10 min. A DC Protein Assay kit (Bio.Rad, Hercules, CA) was
used to quantify the protein. Ten jJ.g proteins were fraclionated by 10"10 SDS-polyacrylamide gel
electrophoresis. according to standard prolocols. Siained protein markers (Amersham, Arlington
Heights. [L) were included in each gel as molecular weight slandards. The proteins were
subsequently transferred to Hybond enhanced chemiluminescence (ECl) nilroCellulose membrane
(Amcrsham) under semi-dry conditions. Immunodeleclion was perfonned by incubation with
antibodies 10 apoptosis-associated genes and then with HRP-eonjugated anti-lgO at I :1,500 dilution.
Aftcrdetection of signals ....ith the ECl system (Amersham), the blolS were stripped and rehybridized
with monoclonal anti-aclin antibody and HRP-eonjugated anti-JgG, and the signals were detected
with the same system. The inlensily of the signals was quanlified by measuring the densily of each
band with an Eagle Sighllmage Capture and Analysis system (Stratagene, la Jolla, CA). CC9E8
anti-hBAG-1 mAb and goat anti-mouse HRP-conjugated IgG were used as the firsl and the
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secondary antibodies. respectively. For testing the specificity of anti-hBAG-I mAb. the purified
hBAG-l protein was added to the hybridization reaction in Io-fold excess. The bands eliminated by
the addition ofhBAG-I protein were regarded as genuine bands.
3.2.4 In \'itro mulagenesb
Mutation ofhBAG-1 ATG start codon into TIG was carried out by oligonucleotide-directed
mutagenesis with QuikChange Site-Directed Mutagenesis kit (Strn.tagene). Deletion ofhBAG-l and
optimization of sequence surrounding hBAG-1 start codon into the Kozak setjuence
(GCCACCATGG) were carried out by PCR. All mutations were confinned by sequencing with
Sequenase Version 2.0 kit (USB).
3.2.5 In vitro transcription/traaslatina
Wild type and mutated hBAG-I cDNA were transcribed and translated in vitro in the
presence of (llS]-methionine (Amersham) using a coupled transcription/translation system (TNT;
Promega), as described by the supplier.lnbrief, I J.lg ofhBAG-1 cDNA plasmids containing wild-
type and mutated p46 were in vitro-transcribed/translated in the presence of [33SI_methionine. The
[33SJ-labelled protein products were separated by 10% 50S-PAGE and subsequently detected by
fluorography. Reticulocyte lysate and luciferase were used as negative and positive controls for
the reaction. respectively.
3.2.6 Indirect immunonunrescence analysis
For analysis ofhBAG-l subcellular localization, Hela cells grown on multiwell slides in
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monolayer culture were fixed in ice-cold 500/0 methanoll50% acetone for 30 min, air-drled and stored
at room temperature until use. The fixed cells were consecutively immersed 3 times in 100% ethanol,
3 limes in 70% ethanol, once in HP, and 3 times in I X PBS. The slides were incubated in 20"/0 goat
serum for I h, with mouse anti-hBAG·1 antibody in PBS at I :200 dilution for I h. and with FITC-
conjugated anti-mouse IgG diluted 1:40 in 20% goat serum for I h. Staining was visualized by
mounting in 30"/0 glycerol and examining under a Leitz Laborlux S Fluorescence Microscope
(Germany) in the dark. For nuclear staining, the slides were hydrated as above and then stained with
3 ~glmI4, 6-diamidino-2.phenylindole (DAPI) for 5 min. For control, anti-hBAG-I antibody was
omitted in the hybridization buffer.
3.2.7 Subcellular- proteill fractionation
About 10' HeLa cells were washed twice with PBS, lysed in 500 ~l hypotonic lysis buffer
(10 mM Hepes, pH 7.4, 38 mM NaC!, 25 ~glml phenylmethylsulfonyl fluoride and I ~glml
aprotininj. homogenized in a Dounce homogenizer and centrifuged at 900 x g to pellet the nuclei.
The postnuclear supernatant was then centrifuged at 130,000 x g at4 °c to pellet the membranes.
Both the nuclear and membrane pellets were resuspended in 500 ~llysis buffer (50 ffi.l\1 Tris-HCI,
pH 8.0, 150 mM NaC!, 0.02% sodium azide, 1% NP-40, 0.1% SOS, 0.5% sodium deoxycholate).
The cytosolic supernatant was adjusted to 150 mM NaCl, 1% NP-40 and 0.1% SOS. The relative
levels ofhBAG-1. BcI·2, Lamin B and J3-tubulin in the nuclear, eytosolic and membrane fractions
were analyzed by Western blot using 10 ~g protein for each fraction.
3.3 RESULTS
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3.3.1 hBAG-1 proleiD was expressed as (our lsO(Orms by alleraative luaslalioa iailialioa
To characterize hBAG-1 protein. I constructed the recombinant plasmid p46 by cloning the
hBAG-I coding region (nt 274-\113), which covering the region between the first start codon ATG I
and stop codon TGA. into a PCRJ.I vector. In Vitro-transcription/translation of p46 cDNA resulted
in t'.\'o major bands of 46 kDa (p46) and 3J kDa (P33). and one minor band of29 kDa. (P29) (Fig.
3.1 B). No translation products were found when rabbit reticulocyte lysate was used as a negative
control. A 6\ kDa luciferase protein was detected as a positive control for the reaction.
Although the amino acid sequences ofhBAG·1 and RAP46 are identical. diffcrent size of
protein products was found by us and two other groups (Zeiner and Gehring. 1995; Takayama et al.,
1996). RAP46 mRNA was translated in vitro into a46 kDa protein, whereas hBAG-I isolated by
Takayamaet al. (1996) was detected as a protein with molecular weight of34 kDa. Since there are
three AUG start codons in nBAG-1 mRNA at nt 276, 411 and 477 (Fig. 3.2), the distinct protein
products ofhBAG-I, p46, p33 and p29, respectively, may have resulted from alternative translation
initiation from each of these start codons (Fig. 3.2). To test this hypothesis. a series of cDNA
constructs containing a single base mutation ofeach of the three ATOs in p46 cDNA were generated
by silc-directed mutagenesis (Fig. 3.IA)./n vitro traIlscriptionitranslationofthese mutated constructs
indicated that p46. p33 and p29 were produced by alternative use of start codon AUGI. AUG2 or
AUG3 in hBAG-J mRNA. respectively. Mutation of any one of these ATGs into TIGs would
abolish its function as a translation initiation site and the production ofthe respective protein product.
Mutation of ATG I into TIG (dATG I) resulted in the loss of the p46 isofonn and the generation of
only p33 and p29; mutation ofthe second ATG (dATG2) led to the loss ofp33 and the production
of p46 and p29; whereas mutation of the third ATG (dATG3) caused the loss of p29 and the
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Fig. 3.1 Expression oftlBAG-l p46. p33 and p29 isofomtS from three altemative translational
Start sites. (A) Schematic representation of site-specific mutagenesis. The p46 eDNA. its mutated
consuucts and their expected molecular weights in kDa are shown. The mutated ATG start codons
were boxed TTGs. The nt for each ATG start codon and the TGA stop codon is indicated below
each construct. (B) In vitro transcription/translation of wild type and mutated hBAG-1. cDNAs
containing wild type and. mutated p46 were in Vitro-transcribed/translated in the presence of [335]_
methionine. The [JS5]-labelled protein products were separated by 10% SDS-PAGE and
sUbsequently detected by f1uorography. Reticulocyte lysate and luciferase were used as negative
and positive controls, respectively, for the reaction. Molecular weights in kDa are shown on the
lefl. The positions of p46, p33 and p29 were indicated on the right.
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Fig. 3.2 Translation of hBAG-1 mRNA may be initiated from ODe upstream CTG and three
potential sian codon ATGs. Nucleotide sequence of 5'-end hBAG-1 cDNA is shown. The CTG
Sian codon at nt 63 and three pOlenliai stan. cooon ATGs at nt 276. 422 and 477, are boxed and
in bold face. The respective protein prooucts, pSO, p46. p33 or p29, which were translated from
each stan codon. is indicated.
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~ TCGGGCGGOGTTGTGAGACGCCGCGCTCAGCTTCCATCGCTGGGCGGTCAACAAGTGCGG
IPSO
6 ~ GC~CTCAGCGCGGGGGGGCGCGGAGACCGCGAGGCGACCOOGAGCGGCTGGGTTCCC
12 ~ GGCTGCGCGCCCTICGGCCAGGCCGGGAGCCGCGCCAGTCGGAGCCCCCGGCCCAGCGTG
180 GTCCGCCTCCCTCTCGGCGTCCACCTGCCCGGAGTACTGCCAGCGGGCATGACCGACCCA
-C P46
24 J.. CCAGGGGCGCCGCCGCCGGCGCTCGCAGGCCGC~GAAGAAAACCCGGCGCCGCT
3O~ CGACCCGGAGCGAGGAGTTGACCCGGAGCGAGGAGTTGACCCTGAGTGAGGAAGCGACCT
--.r::: P33
3 61 GGAGTGAAGAGGCGACCCAGAGTGAGGAGGCGACCCAGGGCGAAGA~TCGGAGCC
-.r: ,2'
421 AGGAGGTGACCCGGGACGAGGAGTCGACCCGGAGCGAGGAGGTGACCAGGGA~
4. 81 CGGCAGCTGGGCTCACCGTGACTGTCACCCACAGCAATGAG. • 1312
generation ofp46 and p33 (fig. 3.1 B). Interestingly, when the second ATG was mutated (.6ATG2),
the expression ofp29 increased significantly.
To confirm our in ~'itro transcription/translation results in vivo, we produced anti-hBAG-1
mAb by immunizing of mice with purified p46 protein and examined the expression of hBAG-I
protein in human cervical carcinoma HeLa cells by Western blot. Consistently, p46, p33 and p29
were detected in the cells. Howe·...er, an exira SO kDa band, which migrated slower than p46 and was
eliminated by competition of anti·hBAG-I mAb with I()..fold excess purified hBAG·1 (data not
shown), was also detected by Western blots (fig. 3.3B). This protein is either a modified form of
hBAG-l protein or a protein translated from upstream translation stan codon. Recently, hBAG-l was
found 10 be translated from a CVG upstream of AUG I. However, only two hBAG·1 protein products
with molecular weight of SO and 36 kDa were observed both ill vitro and in vivo (Packham er 01.,
1997). Since the cDNA used previously for in vitrQ transcription/translation by us and others did not
contain the upstream CTG (Zeiner and Gehring, 1995; Takayama et aI., 1996), the absence of pSO
in ill \'itro transcription/translation products may have been due 10 the absence oftranslation initiation
from this upstream CTG. To test this possibility, 1 used the cDNA containing upstream CTG (PSO)
and compared its ill vitro translation products with those from p46 eDNA. rnterestingly, pSO eDNA
produced four protein isoforms with molecular weights of 50, 46, 33 and 29 kDa. respectively (Fig.
3.3A). Deletion of the upstream CTG in p46 cDNA resulted in the loss of pSO isoform and the
enhanced expression ofp46, p33 and p29 (Fig. 3.3A). To correlate my in \'irra translation results with
those ill vi~'O, I compared the expression panern ofhBAG-1 protein products in HeLa cells with those
from ill vitro transcription/translation ofp50 and p46 cDNAs by Western blot. Consistently, four
hBAG-l isofonns of identical size were detected both in HeLa cells and in in vilro translated
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Fig. J.J The four hBAG-I protein isoforms were generated by the leaky scanning mechanism.
The sequence contex.ts ofcrG and three putative stan codon ATGs were modified into me Kozak
sequence. respectively. pSOK. p46K. p33K and p29K correspond to pSO. p46. p33 and p29 cDNA
containing the Kozak sequence, respectively. Conditions and labels were as described in Fig.
3. (B. (A) til vitro transcriptionluanslation of wild-type and mutated hBAG-l cDNAs. (8)
Detection of hBAG-l protein in HeLa cells and in vilro-translated protein products by Western
blot. Lysate containing 10 p.g protein from HeLa cells or 2 p.! in virro translated products .....ere
subjecled 10 10% 50S-PAGE and uansferred to an ECl niuocellulose membrane. The membrane
was subsequently incubated with anti-hBAG-! mAb (CC9E8), and detected using a goat IfRP-
conjugated anti-mouse IgG antibody by the Eel method. (C) Expression of me four hBAG-l
isoforms in vivo. The vector control plasmid PCRJ.I and the plasmids containing pSOK, p«iK,
p33K and p29K eDNA were Stably transfected into C33A cells. The C33A cells expressing
different eDNA were lysed in protein lysis buffer and 10 p.g protein were anaJyzed by Western
bIoI.
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products ofp50 (Fig. 3.3A. 3.38).
3.3.2 Alternative translation initialion resulled tllro_gll tile leaky $~.aDiDgmecbaaism
Allemalive initiation of translation is usually caused by the leaking past of the preiniliation
s~anning complex past the first AUG and the initiation of translation at a downstream start codon
when the first AUG codon is not in a perfect Kozak sequence (Kozak. 1989). Since neither the CTG
at nt 63 nor the first two AUG start cedons ofhBAG·1 mRNA are in a perfect Kozak sequence (Fig.
3.2). this leaky scanning mechanism may be the cause of alternative initiation of translation of
hBAG-1 mRJ'lA. To prove my hypothesis., I optimized each of the four putative start cedons and its
surrounding sequences into the Kozak sequence (GCCACCATGG) and analyzed the protein products
from each mutated constructs both in vitro and in vivo. As expected. optimization ofCTG-eontexts
or any of the three ATG-conlext into the Kozak sequence abolished the alternative initiation from
its downstream ATGs: when CTG was optimized in Kozak sequence (PSOK). only the pSO protein
was produced, whereas when ATGI or ATG2 or ATG3 was in Kozak: sequence (p46K, p33K and
p29K, respectively). only p46, p33 or p29 proteins, respectively, were translated in vitro (Fig. 3.3A).
The identity of each in vitro translated product was funher confirmed by Western blot using anti·
hBAG-l mAb (Fig. 3.38). Consistent results were found ill vivo when pSOK, p46K, p33K or p29K
cDNA was stably transfected inlo an hBAG-1 negative cervical cell line C33A cells (Fig. 3.3C).
3.3.3 Distinct isoforms ofbBAG-t protein are dirrerentially loulized in differeDI sub~eJlular
compartments
h8AG-1 conlains a putative bipanite nuclear localization signal (NLS) located in a.a 149·165
(Zeiner and Gehring, 1995), suggesting that it may disnibute in the nucleus. This is consistent with
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my finding that mBAG-\ fimctioncd as a transcription factor (unpublished data). However, hBAG-I
also interacts with BcI-2, which is predominantly localized in the nuclear and mitochondrial
membranes (Krajewski et 01., 1993). Therefore, the subceJlular localization ofhBAG-1 in HeLa cells
was studied by immunofluorescence and protein fractionation analysis. As shown in Fig. 3.4, hBAG-
I protein was localized in born cytoplasm and nucleus. Protein fractionation assay funher indicated
that hBAG-I protein was distributed in nuclear, cytosolic and membrane fractions, whereas BcI-2
was localized in nuclear and membrane fractions but not in the cytosotic fraction (Fig. 3.5A). lamin
B was used as the nuclear fraction marker and 13-tubulin as the cytoplasmic fraction marker (Fig.
3.5A; Joh et ai., 1997). Interestingly, the four isoforms ofhBAG-l were distributed differently in
thc cells. The p50 isoform was predominantly present in the nuclear and membrane fractions and p46
was in the fractions from all three companments, whereas p33 and p29 were found mostly in the
cytosolic fraction (Fig. 3.5A). To further confirm these results, mutated hBAG-l cDNAs expressing
only p50, p46, p33 or p29, were stably ttansfected into lhe hBAG-I-negativecervical carcinoma cell
line C33A. Protein fractionation elearly demonstrated that the distinct isoforms ofhBAG-1 were
distributed differently in the cells (Fig. 3.SB).
3.4 DISCUSSION
Using a mouse BAG-l cDNA probe, I have successfully isolated lhe human homolog ofmBAG-
I from a human cervical cell cDNA library (Chapter 2). Surprisingly, hBAG-I has 100"/0 homology
with a novel honnone receptor-binding protein, RAP46, with molecular weight of 46 kDa (Zeiner
and Gehring, 1995). Recently, hBAG-1 with a protein size of34 kDa was also isolated from a human
breast eell cDNA library by Takayama et af. (1996). Howevcr-, the three groups identified different
size of protein products for hBAG-11RAP46. More recently, a SO kDa hBAG-l protein was also
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Fig. 3.4 Subcellular localizalioo ofhBAG-l prolein. lbe subcellular Iocalizalion ofhBAG-l was
analyzed by immunonuorescence using CC9E8 mAb. Control panel shows Ihe result of
inununofluorescence analysis withoul CC9E8. DAPI stain was a control for nuclear staining. All
panels are 400 x magnification. excepl the indicaled magnificalion for !he bonom right panel.
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Control DAPI
Fig. 3.5 Distinct subcellular localization of the four IlBAG-1 protein isoforms. Protein was either
un fractionated (T) or fractionated into nuclear (N), soluble cytosolic (C) and high-speed
membrane pellet (M ) fractions by differential centrifugation. The unfractionated and fractionated
protein samples were analyzed by Western blotting with anti-hBAG-I, anti-BeI-2 and anli-~­
tubulin mAbs. and lamin 8 polyclonaJ antibodies. (A) Protein fractionation of IlBAG-I in HeLa
cells, The position of each isoform is indicated by an arrow. The positions of Be12, lamin 8 and
p-tubulin are indicated by arrowheads. (8) DifferenliaJ subcellular localization of the four
isoforms of IlBAG-l in C33A cells. Lysates of C33A expressing different isoforms of hBAG-l
protein were fractionated. into different subcellular fractions (N, C and M).
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observed by Packham el al. (1997). My results reconciled the discrepancies observed by others and
clearly demonstrated that hBAG-I .....as expressed as four isofonns of protein. pSO, p46, p33 and
p29. which .....ere produced by alternative initiation of translation. Analogously, three species of
mBAG-l with molecular .....eights of50 kDa (p5Om), 30 kDa (p3Orn) and 28 kDa (p28m) may have
been produced by alternative translation as .....ell, since there are two AUG stan cedons on mBAG-I
mRJ'JA. and the first AUG is not in perfect Kozak ~uence. Most interestingly, the expression of
mBAG-1 protein in mouse cell lines is also tissue-specific. Mouse PI9 embryonal carcinoma cells
expressed all the three products of mBAG-I. p50m, p30m and p28m, whereas no p28m was
expressed in mouse fibroblast NlH 3T3 cells (data not shown).
Alternative initiation of translation usually results from a leaky scanning mechanism. in .....hich
the prcinitiation scanning complex bypasses or "leaks" past the first AUG and initiates at a
downstream codon when the first or second AUG codon is not in a perfect Kozak sequence
(GCCAlGCCAUGG) for recognition by the scanning complex (Kozak. 1989). Since neither the
upstream CUG IlOT the first AUG of tlBAG+I mRNA is in the optimal Kozak sequence, translation
may start from the first, second or third AUG. By optimization of context ofCTG and each of the
three ATGs into the Kozak sequence, I provided both in vitro and in vivo evidence that alternative
Initiation ofhBAG·1 is caused by the leaky scanning mechanism. Although not common, use of
alternative translation initiation sites occurs in other genes such as c+myc (Spons et al., 1997), COL
(Aoki Ct al., 1993) and glutathione peroxidase (Pushpa-Rekha et ai., 1995). In addition. proteins
lranslated by alternative initiation of translation from start codon AUGs were previously shown to
have diITerentlransfonning activity (Aoki el al., 1993) or transactivation function (Spotts el al.,
1997). 11 would be of interest to srudy whether these four isofonns of hBAG-I have distinct
functions in the cells.
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Although BAG-J was originally identified as a BcI.2.binding protein. its subcellular localization
was apparenl1y different from that of BcI-l. Using immunofluorescence and protein fractionation.
I demonstr.lted that tlBAG·1 proteins were localized in all the cellular compartments, including the
nucleus, cytosol and membranes, whereas BcI-2 was only localized in the nuclear envelope and
membranes (Krajewski et aJ., 1993; Fig. 3.SA). Since hormone receptors are distributed in the
cytosol and nucleus (Sackey et aJ., 1996), tlBAG-I may interact with Bcl·2 on the membranes and
with hormone receptors in the cytosol or nucleus. Most imponanlly, I found that pSO protein was
predominantly localized in the nuclear and membrane fractions., whereas p33 and p29 proteins were
mostly present in the soluble cytosol. Consistent with this result, analysis of functional domains in
different BAG-I isoforms revealed that only pSO has an SV40·like NLS (Chapter 2.3.3; Fig. 2.7).
Differential subcellular localization ofaltematively Ira11slated proteins was also found for other
genes, such as FGF and hck (Bugler el at., 1991; Lock el at., 1991). Different sLlbcdlular
localization of BAG-I isoforms may be responsible for their distinct function in the cells (see
Chapter 7.4)
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SECTION 3
ROLE OF BAG-I IN APOPTOSIS
CHAPTER 4
HUMAN BAG-I SENSITIZES CERVICAL CELLS TO N-(4-HYDROXYPHENYL)
RETiNAMIDE-INDUCED APOPTOSIS
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4.1 INTRODUCTION
N-(4-hydroxyphenyl) retinamide (4-HPR or fenretinide) is one of the most effectivc and
promising synthetic rctinoids used for human cancer chemotherapy (Costa, 1993; Fonnellj and
Cleris, 1993; Sabichi el al., 1998: Zou et aI., 1998). It has both preventive and therapeutic effects
in experimental systems and clinical practice. In carcinogen-treated rodents, 4-HPR significantly
decreases the incidence of bladder, breast, cervical, lung, prostate and skin cancer (Moon and
Mehta. 1989; Pollard el al., 1991; Kelloff et al., 1994; Fonnelli and C1eris, 1993). In addition. 4-
HPR is effective against established carcinogen-induced mammary tumors, and prostate and ovarian
tumor cells transplanted in rats (Dowlatshahi et 01., 1989; Abou-Issa et al., 1989; Pienta e/ aI., 1993;
Fonnelli et al., 1993). Unlike other retinoids, 4-HPR exhibits low normal tissue toxicity and long-
term tolerability. in both animals and humans (Routmensz et al., 1991; Moon et al., 1992; Lotan,
1995; Abou-Issa et aI., 1997; Pienta el aI., 1997).
Recently, 4-HPR was shown to induce apoptosis in various human cancer cells, suggesting that
this function may be important for its chemopreventive and chemotherapeutic effects (Delia et of.,
1995; Lotan et al., 1995; Pellegrini el 01., 1995; Hsieh and Wu, 1997; Scheret al.• 1998; Zou el 01.,
1998; Montaldo et 01., 1999). Most retinoids function by binding to their nuclear receptors, RAR a,
13. and y and retinoud X receptor a, p, and y, whereas 4-HPR does not bind effectively in most cell
lines (for review, see Chambon, 1996). Although several studies have shown that4-HPR can induce
apoptosis through interacting with RARs (Liu et al., 1998b; Sun et 01., 1999), other reports
suggested that 4-HPR can induce apoptosis via an RAR-independent mechanism (Delia et 01., 1993;
Lotan et 01., 1995; Sheikh et ai., 1995; Clifford et al., 1999; Sun et ai., 1999 a, b). In addition, in one
study, 4-HPR could induce apoptosis in cells such as C33A containing mutated p53 without
changing the levels of Bcl-2 and Sax. indicating that induction of apoptosis by 4-HPR is
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independent of p53, BcI·2 and Bax (Oridate et 01., 1995, 1997; Zou et 01., 1998). However. in
another study, it was found tha14-HPR induced apoplosis by decreasing the BcI-2:Bax ralio (Shen
etaf., 1999). Further studies indicated that 4-HPR. ralher than other retinoids such as all-trans RA.
induces apoplosis by increasing reactive oxygen species (ROS) (Delia er at., 1997; Oridate etal.,
[997). Treatment ofcells with the antioxidant, pyrrolidine dilhiocarbamate (PDTC), inhibiLS 4-HPR·
induced apoptosis, suggesting that produclion of ROS may ~ imponar.l. However, although a
number of studies have shown that ROS are required for apoptosis (Ross et ot., 1993; Lowe et of.•
199.:1; Symonds et of.• 1994), others have shown that apoptosis could be induced under hypoxic
conditions in which ROS generation was inhibited (Schwartz and Bennett, 1995; Johnson et af.,
1996). Therefore, it is unclear what role is played by the retinoid receptors. apoptosis-regulating
genes and ROS in 4-HPR·induced apoptosis.
BAG·1 is an anti.apoptolic gene that can function independent ofBcI-2 (Chapter 5). Recently,
BAG-1 was shown to inhibit all·trans-RA-induced growth inhibition by interacting with RAR (Liu
el aI., 1998a). Therefore, I examined whether BAG-l can inhibit 4-HPR-induced apoptosis.
Surprisingly, overexprcssion of BAG-I enhanced apoptosis induced by 4-HPR. Further expetimenLS
indicated that distinct regions of BAG-I protein are necessary for its functions as a pro.apoptotic
protein in 4-HPR-induced and an anti-apoptotic protein in staurosporine.induccd apoptosis.
4.2 MATERIALS AND METHODS
4.2.1 Construction or BAG-I eDNA deletion mutations
PCR was employed to delete either N-tenninal or C-terminal sequences from BAG-l 85·2
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cDNA (Fig. 4.1). Approximately 100 ng of BAG-I cDNA plasmid were amplified by PCR using
primcrs corresponding to different BAG-I cDNA regions and a GeneAmp PeR System 2400 (Perkin
Elmer). To produce single protein products, the Kozak sequence (GCCACCATGG) was included
in-frame in each 5' primer (Yang et 01., 1998b). The conditions for PCR were as follow: 1>< PeR
buffer [10 mM Tris-HCl, pH 8.3, 50 mM KCI, 3 rnM MgCl!.O.Ql% (w/v) gelatin]. 0.5 mM dNTP.
0.2 mM of sense and antisense primers, and 2 U Taq polymerase (Promega) in 20 ~1. The PCR
program was: 94°C for 3 min for the first cycle; 94 °C for 30 sec. 60 °C for I min and 72 °C for I min
for a total of35 cycles; 72 "C for 7 min for the last cycte; and 4·C on hold. The PCR products were
SUbsequently cloned into a eukaryotic expression vector, PCRJ.I, using a TA cloning Idt (lnvitrogen).
The identity of each PCR product was confirmed by sequencing.
4.2.2 Stable traosfectioD of BAG-I eDNA
Stable transfection of PCRJ.I vector control and BAG·I cDNA into C33A ceHs was as
described in Chapter 3.2.1.
4.2.3 Cell deatb assays
4.2.3.1 loductiOD or cell deatb
To assay cell death induced by various apoptotic stimuli, exponentially growing C33A cells
deri vcd from clones overexpressing NEO or full-length or deletion mutated BAG-l were seeded at
5 >< IO~ cells/well in 12·well plates and incubated for 24 h. Then. the cells were treated with various
agents.
4.2.3.2 Cell viability assays
88
Fig. 4.1 Deletion mutations of full-length human BAG·I eDNA. To produce single prolein
products, the Kozak sequence (GCCACCATGG) was constructed in frame S' to each eDNA
sequence during insertion into a eukaryotic expression veclor. Amino acid (a.a) positions are shown
on the top. The BAG·! amino acid positions and apparent molecular weights in kDa (Fig. 4.6) are
shown on the right.
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I 100 200 300 345 aa kDa! ! ! ! !
p50K 1-345 50
p46K 72-345 46
p33K 116-345 33
p29K 139-345 29
6N4K 213-345 21
6C1K 1-320 48
6C2K 1-219 30
Cell viability was determined with the trypan blue exclusion assay after the induction ofceJl
death. In brief, equal volumes of cell suspensions and 4% trypan blue were mixed gently. The
viabilily of me cells was examined immediately by microscopy. Viable cells were unstained, whereas
dead cells stained blue. Cell viability represents the pereentage of treated cells compared with
untreated cells that excluded trypan blue dye. The statistical significance of the difference in cell
death between control NEO- and fuJI-length or deletion mutated BAG-I-overexpressing cells was
analyzed using the Student t-test.
4.2.3.3 Flow cytomelry apoptosis a.alysis b~' aaaed. V-fluorescein isol~iocyaDale (Flye)
To detennine the effect of BAG-I and 4-HPR, apoptosis was analyzed using an Annexin V-
FITe Assay kit (phanningen), according to the manufacture's instruction. In brief, approximately
101 cells were plated in each well of 6-well plates and incubated for 24 h. Cells were treated with
O. I. 5 or 10 I!M 4-HPR for I day, and both floating dead cells and attached viable cells were
harvested. 101 cells were incubated with annexin V-Flrc and 5 I!glml propiodium iodide (Pr) in
I" binding buffer (10 mM HEPES-NaOH, pH 7.4, 140 mM NaCl, 2.5 rnM CaCI~) at room
temperature in the dark for 15 min. Apoptotic cells were quantified using a Becton Dickinson
FACStar Plus flow cytometer. Data analysis was perfonned with the standard Cell Quest software
(Becton-Dickinson). In general. negative annexin V-FlrC and negative PI signals represented viable
cells; positive annexin V-FITC and negative orintennediate PI staining represented apoptotic cells;
while positive annexin V-FITC and high PI staining represented necrotic cells. APOPlOtic cells were
calculated as the percenlage ofMI (see Fig. 4.4) in tOlal ceils after subtraction afthe percentage for
untreated (0 IlM) cells.
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4.2.3.4 Caspas~3 activity
Cysteine protease caspase-3/CPP32 activity was assayed by colorimetry using an ApoAlen
CPP32 protease assay kit (Clomech).ln brief, HI' cells were plated in each well of6-well plates and
incubated for 24 h. Cells were treated with 10 ILM 4·HPR for 0, 2, 4, and 6 h, harvested and lysed
on ice for 10 min in SO ILl of ice-chilled lysis buffer. Lysates were incubated with 100 ILM DEVD-
pNA CPP32 subslTate at 37 °C for I h and the casapase.) activity was determined as the absomam:<:
al 400 nm (A.I«I) using a spectrophotometer.
4.2.4 In vitro traascriptioo/tnnslallon
1/1 vilro transcription/translation of full·length or deletion mutated BAG· I cDNA was as
described in Chapter 3.2.5.
4.2.5 "'estero blot analysis
Western blot analysis of caspase-3 activation and BAG-l expression in different stable
transl3led clones was as described in Chapter 3.2.3. The experimental conditions were as described
for easpase-3 activity assay (Chapter 4.2.3.4).
4,3 RESULTS
4.3.1 Inhibition of cell death by BAG-I
First, I examined the role of full-length human BAG-l in cell death induced by various
stimuli. Comparing cells overexpressing BAG-l versus control NEO, cell viability was significantly
and similarly enhanced by BAG· I after inducing cell death by UV irradiation. heat shock,
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staurosporine, cisplatin and doxonabicin (Fig. 4.2).
4.3.2 Enhancement of 4-HPR-IDduced cell death by BAG·.
4.3.2.1 Cell Viabilil)'
Surprisingly, BAG-l enhanced 4-HPR-induced cell death. After treatment of cells with 4-
HPR. the viability of cells overexpressing BAG-I was significantly lower than that ofNED veclor
control cells at 4-HPRconcentrations higher than 1 11M (Fig. 4.3). The same results were obtained
when other full~length BAG-I-overexpressing clones were examined (data not shown).
4.3.2.2 Apoptosls analysis by Annesin V-fITC assay
To confirm the cell death induced by 4-HPR was due to apoptosis, I analyzed apoptosis by
anncxin V·FITC staining and flow cytometty in both NED control and BAG-I-overexpressing cells.
Since PI staining in both types of cells for all concentrations of 4-HPR was either negative or
intcnnediate (data not shown). all annexin V-F1TC-positive signals represented apoptotic cells. The
percentage ofapoptotic cells was calculated as the percentage of the Mt in lotal eell population
(Fig. 4.4). The Ml background annexin V-FITC signals detected for both untreated NED control
and BAG-I-overexpressing cells were subtracted from values for the respective treated cells.
Consistent with the cell viability assay (Fig. 4.3), more cells died via apoptosis in BAG~l­
overexpressing than NED control cells. While no apoplosis was detected after the cells were treated
with I j.1M 4-HPR, 21.5% of NED control cells and 56.4% of BAG-I-overexpressing cells
underwent apoptosis after they were treated with 5 IlM 4-HPR. Treated wilh 10 IlM 4-HPR, 54.7"/0
of NED control cells died through apoptosis. whereas 75.2% of BAG-l-overexpressing cells
underwent apoplosis (Fig. 4.4).
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Fig. 4.2 Effect of full-length BAG-Ion cell death ofC33A cells treated with different apoptotic
stimuli. The treatment conditions were as follows; IN irradiation (UV); 50 mJ/cml ; heat shock
(HS): 48 gc for 10 min; stawosporine(St); 41lM for 2 days; cisplatin (Cis); 10 IlM for 2 days; and
doxorubicin (Dox): I IlM for 2 days. Cell viabilily represents the percentage of treated cells
compared with untreated cells that excluded trypan blue dye.•, p < 0.05. is the statistical
significance of the difference in cell viability between control NE0- and full-length BAG-I-
(p50K)-overexpressing cells after treatment.
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fig. 4.3 Effect of BAG-I and 4-HPR concentration on cell death. NEOcontrol cells and full-length
BAG- [-overexpressing cells were treated with 0, 0.2, 1.0, 2.0, and 5.0 11M 4-HPR for 2 days. Cell
viability represenrs the percenrage ofrreared compared wirh untreated cells that excluded trypan
blue dye.
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Fig. 4.4 Annexin V-FITC assays of the effect of full-length BAG-I and 4-HPR concentration on
apoptosis. Cells were treated with 0, 1.0.5.0, and 10.0 11M 4-HPR for I day. Values were calculated
as the pen;entage apoptotic FITC·positive (MI) of total cell populations after subtraction ohhe
percentage for untreated (0 ,....M) cells.
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4.3.2.3 Caspase actl"ity ••d .cti"allon
It has been shown that activation of effector caspases, especially caspasc.3, is one of the most
important events in apoptosis (for reviews, see Cryns et al., 1998; Nunez et al., 1998). To test
whether BAG-l caused more cell death stimulated by 4-HPR by enhancing caspase.3 activity.
caspase-3 activity was compared in BAG·I-overexpressing and NEO control cells after treating the
cells for 0-6 h with 10 }.1M 4-HPR. Maximum caspase-3 activity was detected 4 h after cell
lreattncnt. Consistent with the apoptosis assay, caspasc activity was significantly higher in BAG-I-
overexpressing compared with NEO control cells, indicating that BAG-I sensitizes cells to
apoptosis by a pathway that activate caspase-3 (Fig. 4.5A).
Since the 17 kDa caspase-3 was activated by proteolytic cleavage of 32 kDa procaspase.3
(Stennicke et al., 1998), it was examined whether the enhancement of 4·HPR-induced caspase
activity by BAG-I was due to increased procaspase-3 processing. Correlating well with caspase-3
activity, Western blot analysis showed that a higher level of 17 kDa caspase-3 in BAG-I-
overexpressing than NEO control cells (Fig. 4.58). The highest level of 17 leDa caspase-3 was
produced after treatment of both NEO and BAG·I-overexprcssing cells with 10 }.1M 4-HPR for 4
h. as observed for caspase-3 activity (Fig, 4.5A, B). These results indicated that caspase-3 activity
in 4-HPR-stimuJatcd BAG-I-overexpressing cells was enhanced and the enhancement was due to
increased cleavage ofprocaspasc-3.
4.3,3 Effects of dlslincl BAG-I proleln rUDclioDal domains on cell dealh Induced by 4-HPR
and staurosporinc
To identify the functional domains of BAG-l responsible for enhancement of4-HPR-induced
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Fig. 4.5 Time-dependent effect of full-length BAG-Ion caspase-3 activity and proteolytic activation
after treatment of cells with 4-HPR. Cells were treated with 10 ~M 4-HPR for 0, 2, 4, and 6 h.
A.Caspase·3 activity was assayed by spectrometry. 8. Caspase·3 activation. Western blot analysis
was used. The indicated 32 kDa protein represents pro.caspase-3, whereas the 17 kDa doublet
represents activated caspasc-3.
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cell death. two series ofplasmids containing nested deletions from N- orC-termini were generated
from full-length (P50K) BAG-} cDNA (Fig. 4.1). Single protein products were produced when each
cDNA eukaryotic expression plasmid was itl vitro transcribed/translated in the presence of elSj_
methionine (Fig. 4.6A). Fig. 4.6B shows the Western blot analysis of BAG· I proteins from C33A
cell clones overexpressing each full.length or deletion mutated BAG-l protein. Since the EE8C9
anti-BAG-I monoclonal antibody (Yang et af., 1998b) does not recognize 6C2, overexpression of
.6.C2 was confirmed ill vivo by Nonhem blot (data not shown).
In the presence of 4-HPR, full-length BAG-I p50K significantly decreased cell viability
compared with the NEG vector control (p < 0.05). Deletion ofN-tennini in the three other isofonns,
p46, p33 and p29. did not alter this inhibition (Fig. 4.1. 4.7). However, funher deletion of the central
BAG- I cDNA region in .6.N4K abolished the enhancement of4-HPR-induced cell death by BAG-I
(p > 0.05). Deletion ofC-tenninal 25 or 124 amino acids did not eliminate the BAG-I-induced
enhancement. Instead. cell death was greater (p < 0.01). Interestingly, in contrast to cell death due
to 4-HPR. staurosporine-induced cell death was unaffected by the 6.N4K deletion of the central
BAG-l region (Fig. 4.8). Moreover, the C-terminal deletions in .6.CIK and 6.C2K BAG-I proteins
abolished the inhibition ofceH death induced by staurosporine.
4.4 DISCUSSION
Although 4·HPR has been extensively used for the treatment of human cancers, the molecular
mechanism of its action and differential response of tissues to this drug is still unclear. Recent
studies suggested that 4-HPR inhibits tumor growth through activation ofapoptosis (Delia et al.,
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Fig. 4.6 In vi/rQ and ill vivo expression of full-length and deletion mutated BAG-I cDNA. All
cDNA expression constructs are described in Fig. 4.\. Molecular weight markers in kDa are shown
on the lefl. A. 11/ vi/yo expression of BAG-\ eDNA. BAG-I cDNA was in vitro-
transcribed/translated in the presence ofe'Sl-methionine. The e'Sl-labelied protein products were
separated by tOO;" SDS-PAGE and subsequenlly detected by lluorography. Luciferase was used as
a positive control for the reaction. B. In vivo expression. The vector control plasmid PCRJ.1 and
BAG-l cDNA expression plasmids were stably transfected into C33A cells and 10 J.lg protein were
analyzed by Western blot.
105
t:C >
N N
- w
-l:> 0\ B w -l:> ~ Bv, 0 0\ 0\ VI 0 0\
I I I :» I I I I :»
1 • Luciferase
I
p50K
p46K p50KI Ip33K p46K
p29K I
p33K
6N4K , p29K
6 I 6N4K
CIK
6 6
C2K C1K
I 6NEO C2K
Fig. 4.7 Effect or BAG-I funclional domains on cell dea!h induced by 4·HPR. Cell viability
represents the percenlage or 4-HPR-treated cells compared wilh unU'ealed cells !hal excluded trypan
blue dye."'. p < 0.05, and ...., p < 0.01, are the stalislical significance oflhe difference in cell
viability between NEQ control cells and cells overexpressing full-Ienglh and deletion mutated
BAG-I cDNA treated with 5 ~M 4-HPR rOT 2 days.
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Fig. 4.8 Effect of BAG-I functional domains on cell death induced by staurosporine. Cell viability
represents the percentage ofslaurosporine-treatcd cells compared with untrealed cells that excluded
trypan blue dye. *. p < 0.05, is the statislical significance ofthe difference in cell viability between
NEQ control C33A cells and cells overexpressing full-length and deletion mutate<! BAG~I eDNA
treated with 0.5 J.IM slaurosporine for 2 days.
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1995; Lotan et al., 1995; Pellegrini er aJ., 1995; Hsieh and Wu, 1997; Scher et aJ., 1998; lou et oj.,
1998; Montaldo er 01., 1999). Therefore, it is possible that the level ofapoptotic proteins may affect
the sensitivity of cells to 4-HPR. However, previous studies showed mat overexpression ofBcI-2,
an anti-apoptotic protein that can inhibit apoptosis induced by a variety of apoptosis stimuli (Reed,
1994; \998a), failed to protect C33A cervical carcinoma cells from apoptosis induced by 4-HPR
treatment (Oridate er oj.• 1997).
Since BAG-I was originally identified as a Bcl-2-binding protein and can inhibit apoptosis
when Bcl-2 was do\vnregulated (Takayama et a/., 1995; Yang et aJ., I999a), I examined whether
BAG-l can inhibit 4-HPR-induced apoptosis in C33A cells. SW'prisingly, although overexpression
of BAG-I inhibited apoptosis induced by a variety ofapoptotic stimuli, cell viability studies showed
that it sensitized C33A cells to apoptosis induced by 4-HPR. These results were confinned by
Annexin V-FITC flow cytometry assay, which examines early stage apoptosis using annexin v, a
calcium-dependent phospholipid-binding protein with a high affinity for me membrane
phosphatidylserine (PS). In apoptotic cells, PS is translocated from the plasma membrane ituler to
outer outer leaflet, where it can tightly bind to annexin V. Similar results were also observed using
the US7 glioblastoma cell line (data not shown). In agreement with my results. resistance to 4-HPR-
induced apoptosis was found in normal human cervical epithelial cells (Oridatc et 01., 1997), in
which. no BAG-I protein was detected (Chapter 5). Furthennore. ovetexpression ofBAG-\ and Bel-
2 was shown to enhance apoptin-induced apoptosis through a pS3-independent pathway (van
Oorschot et al., 1997). Since p53 was mutated in C33A cells (Scheffner et 01., 1991), apoptosis
induced by 4-HPR in this cell line should be p53-independenl. Therefore, BAG-) may enhance pS3·
independent apoptosis induced by Ihis effective chemotherapeutic retinoid.
Previous and present studies indicated that BAG-I can inhibit apoptosis induced by apoplotic
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stimuli other than 4~HPR such as slaurosporine through suppressing caspase-3 activil)' (Schulz el
al., 1997; data not shown). The reason for pro- and anti~apoptotic activity of BAG-I is unknown.
However, the studies reported here found that distinct regions of BAG-I were responsible for either
pro- or anti-apoptotic activity. The C-tenninal BAG- t homology domain, wruch is highly conserved
during evolution (Chapter 2.3.3) and required for interacting with other proteins such as
hsp70lltsc70 (Takayama el al., 1998), appears to be additionally important for inhibiting apoptosis
induced by both 4-HPR and suurosporine. However, the central ubiquitin homology domain, which
might be important for protein-protein interaction (Toniola el al., 1988) or protein stability (Hershco
and Ciechanover, 1992), may support an even greater apoptosis enhancing function that is induced
by 4-HPR, but not staurosporine. Therefore, it is possible that BAG-I may modulate, in a stimulus-
specific manner, apoptosis through interaction ofdilTerent proteins with its ubiquitin-Iike versus
BAG-l domains.
Although many studies suggest that 4-HPR induces apoptosis through a spe('ific signal
transduction pathway such as production ofROS (Delia el aI., L997; Dmitrovsky, 1997; Oridate el
al.• 1997; Sun et al., 1999), the pathway for 4~HPR-inducc<l apoptosis is still controversial. In this
study. 4-HPR was found 10 induce apoptosis through activating caspase.3, a proteolytic cascade
effector in many apoptosis pathways (Fig. 1.2; Nunez el al., 1998; Porter and Janicke, 1999).
Similar results were also found by others in different cell systems (Piedrafita and Pfahl, 1997;
OiPielrantonio el al., L998). Therefore, activation of caspase-3 is an important step for 4-HPR-
induced apoptosis. However, the increased 4-HPR·induced activation of caspase-3 by BAG·I was
nol due to ROS, because activation of caspase-3 after 4-HPR treatment was nOI inhibited by the
ROS inhibitor POTC (data not shown). Similar findings were also observed by others studying
hydrogen peroxide-induced apoptosis (Gotz el 01., 1999). Therefore, BAG-I enhanced 4~HPR·
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induced caspase activalion through an ROS-independenl pathway, possibly through RARs (Sun
elal., I999b).
Cervical cancer is the third most common malignancy in women worldwide and is especially
common in developing counlries (Parkin et aI., 1999). 4-HPR has been used for the trealment of
premalignam and malignant cervical neoplasia (Mitchell et al., 1995). The finding thai
overexpression of BAG-I enhanced 4-HPR-induced apoplosis may have an imponant significance
in cervical cancer chemotherapy. Firs!, since the level of BAG-I is relatively higher in human
cancer than in normal cervical cells (Chapter 4; Yang et al., 1999a), 4-HPR will probably induce
more apoptottc cell death in cancer than normal cells. This may be why 4-HPR has not only high
tumor tissue cytotoxicity through apoptosis bUI also lower normal tissue cytotoxicity, than other
drugs (Rolmensz el aI., 1991; Moon et al., 1992; Lolan, 1995; Abou-Issa et al., 1997; Pienta et aI.,
1997). Second, BAG-I may be useful to assess me efficacy of 4-HPR for individual cervical
carcinomas, because this protein was found at various levels in different cervical tumor biopsies
(Chapler 4, 5, 6). Third, it may be possible to enhance 4-HPR chemotherapy by inlrOducing a BAG-
I-expressing adenovirus vector into 4-HPR-resistanl cervical cancer cells. To test me relevance of
the ill ,'itro results presemed herein vivo, thecorrelalion of BAG-I levels with the response to 4-
HPR needs to be examined in normal and cancer tissues from palients.
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SECTION 4
ROLE OF HUMAN BAG-l AND OTHER ANTI-APOPTOTIC
PROTEINS IN TUMORIGENESIS
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CHAPTERS
OVEREXPRESSION OF ANTI·APOPTOTIC GENE BAG-I IN
HUMAN CERVICAL CANCER
S.I INTRODUCTION
Cervical cancer is the third most frequent malignancy among women in the world (Parkin ef
ul., 1999). In the past 10 years, compelling evidence confirmed the hypothesis that HPVs, especially
high risk HPVs such as HPVl6 and HPVI8, are the major conuibuting factor of this cancer.
Furthermore, il/ I,ifro and ill vivo studies strongly suggest that HPV infection is necessary but not
sufficient for causing cervical cancer. Other factors, such as honnone, cigarette smoke and
dysregulation of oncogenes and tumor suppressor genes, are also required for full malignant
transformation (Herrington, 1995; Yang et aI., I996b; Yang et al., 1997). Howevcr, the molcr:ular
mechanism of the multistep, multi factor oncogenesis of cervical cells remains unclear.
Recently, overexpression ofBd-2 was found in cervical carcinoma cell lines and premalignant
and malignant tissues (liang etal., 1995; ter Hannsel ef al., 1996; Pillai et aI., 1996), suggesting that
enhanced level ofanti-apoptosis proteins may underlie the development ofcervical cancer. However,
the expression of apoptosis-associated proteins other than Bcl-2 and p53 has not been examined in
cervical cancer. In this repon, I investigated the expression of BAG-I in cervical oncogenesis. The
results show that both BAG-I RNA and protein were o\'erexpressed in human cervical carcinoma
cell lines and tissues, indicating that BAG-I may play an imponant role in the development of
ccrvical cancer.
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5.2 MATERIALS AND !\lETHODS
5.2.1 Containment for blobazards
Level 2 biohazard containmeOl procedures recommended by the MRC ofCanada were followed
for all tissue culture and experiments using human cervical biopsies. The experiments were approved
by the Memorial University of Newfoundland Biosafety Committee.
5.2.2 Cell culture and ntablisbmcot ofBAG-I-overnpresslDg trusfe<:taat
Human endocervical cells (HEN) and ectocervical cells (HEC) were obtained after dissection
of pathologically nonnal cervical tissues derived from h.ysterechtomies performed for benign
conditions. and were maintained in serum·free media for keratinocytes (OmeO BRL, Beth.esda,
MD). All cervical carcinoma cell lines were obtained from ATCC and cultured in DMEM containing
10% FCS.
The transfection of p50K (BAO-I) and a control PCRJ.1 plasmid (NEO) imo C33A and the
establishment ora transfectant line was as described Chapter 3.2.1.
5.2.3 Cell \·iabilit~.. assays
To assay cell viability of cervical cells after treatment with a DNA damaging reagent.
staurosporine, exponentially growing cells were seeded at 5 " 10~ cells/well in 12·well plates and
incubated for 24 h. Then the cells were treated with. either 0.2,uM staurosporine for the indicated
times for the experimems comparing primary and cancer cells or 0.5 ,14M staurosporinc for the
indicated times for the experiments with slably BAG·I-lTansfected C33A cells. Cell viability was
dctcmtined with. the trypan blue exclusion assay as described in Chapler 4.2.3.2.
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5.2.4 Rr."iA and proteiD extraction from lIumaD cervical cellilaes or biopsies
Total RNA was extnlCted from cervical nonnal and carcinoma cells at 70% confluencc using
the CsCI gradient centrifugation method (Sambrook et aI., 1989). Protein was extracted from 107
celisorO.\ g biopsies by lysis in I ml ice-eold extraction buffer (50 mM Tris-HCI, pH 8.0. 150 mM
NaCI. 0.02% sodium azide, 1% NP40, 0.1% SOS, 0.5% sodium deoxycholate, 100 I!gfml of PMSF,
50 IJ.glml ofaprotinin; for 30 min and centrifugation at 12.000 g for 10 min.
5.2.5 Northero, Western aad Soutbern blot aIIalysls
Northern blot and Western blot analysis of cellular gene expression was as described in
Chapters 1.2.4 and 3.2.3. CC9E8 anti-hBAG-1 mAb was generated, as described in Chapter 3.2.1.
Anli-BcI-l and anti-fJ-actin mAbs. and anti-BcI-XL and anti-GR polyc1onal antibodies,
purchased from Santa Cruz Inc. (Santa Cruz, CA).
DNA extraction and Southern blot analysis of high molecular weight genomic DNA from
cer;tical cells was as described (Sanna et al., 1996).
5.3 RESULTS
5.3.1 O"erexpression of BAG·1 protein in cervical carcinoma tellUaes and tissues
I first examined the expression of BAG-I protein in nonnal and cervical carcinoma cell lines
using Western blot analysis to determine if BAG-I is involved in the oncogenesis of cervical cells.
While no BAG-I protein was detected in primary HEN and HEC,threc (P50. p46and p33) of the
fOUT isofoTms of BAG-I, were overexpressed in all the cervical carcinoma cell lines. The shortest
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isoform of BAG-I, p29. was only expressed in SiHa and HeLa cells, in which the highest protein
level ofp50. p46 and p33 was found (Fig. 5.1). Since synergistic effect ofBAG-i and BeI-2 in anti-
apoptosis was found (Takayama et al., 1995), I examined whether the level ofBAG-i-imeracting
protcins. BeI-2, Bel-Xl and GR. were also enhanced in cervical carcinoma cell lines. As was seen
for BAG-I. no or low expression ofBel-2. Bel-XL and GR was found in primary HEN and HEC,
whereas Bcl-2. Bel-XL and GR were overcxpressed in three (CaSki, HeLa and C33A). five (SiHa,
HeLa. C4-I. C33A and HT-3) and six (CaSki, SiHa, HeLa, C4-I, C33A and HT-3) oftbe six cervical
carcinoma cell Hnes (Fig. S.!). The expression levels of Bel-XL and GR were correlated with that
of BAG-I. However, thc expression level ofBel-2 and BAG-I did not correlate. For example. the
highest expression ofBAG-i was found in SiMa cells, whereas no BeI-2 was detected in this cell
line. On the odler hand, the lowest level of BAG-I protein was found in C33A cells. while the
highest level ofBel-2 was detected in this cell line (Fig. 5.1).
To compare my resulls forcelliines with those in vivo, I examined the expression of BAG-I
and its interacting proteins in primary normal and cervical carcinoma tissues. In general, BAG-!
protein was low or not detected in normal cervical tissues, but it was overexpressed in most of the
cervical carcinomas. Each isoform of BAG-l displayed distinct paUem in these tissues. pSO was
dctcrted in only two of eight (25%) normal cervical tissues, whereas it was overexpressed in six of
eight (75 %) cervical carcinomas; p46 was not expressed in any of the nonnaltissues, whereas it
was detected in two of eight (25 %) cervical carcinomas; p33 was not present in any of the nonnal
tissues, whereas it was ovcrexprcssed in seven of eight (88 %) cervical carcinomas; p29 was not
detcrted in any of the tissues examined (Fig. 5.2). On die other hand, in contrast to the cultured cells.
all three BAG-i-interacting proteins, Be!-2, Bel-XL and GR, were expressed on average at
comparable levels in both cervical nonnal and carcinoma tissues (Fig. 5.2).
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Fig. 5.1. Overexpression orSAG-1 and its interacting proteins in cervical carcinoma ccll lines. For
Weslem blots. 10 f.lg of proteins from nonnal HEN and HEC and cervical carcinoma cells were
separated in a I()O/O SDS-PAGE gel and ttansrerred 10 an EeL nitrocellulose membrane. Each protein
was detected by the ECL syslem using primary antibodies to BAG-I, Bcl-2, Bel-Xl andGR, and
then secondary HRP-conjugated anti·mouse IgG. l3·actin was used as an inlcmal control.
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Fig. S.2. Overcxpression of BAG·1 protein in cervical carcinoma tissues. Western blot methods and
labels were as described in Fig. s. t. Each lane numbered 1-8 represents different cervical normal or
carcinoma tissues.
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5.3.2 RNA expreuioD and intearity oftbe BAG-I gene I. «rVkal Dormal aad carcinoma cell
lines
To investigate whether the overexpression of 8AG-1 protein in various cancer cell lines is
caused by enhanced transcription. I analyzed the expression of BAG-I RNA from cervical cultured
nonnal and cancer cells by Northern blot. My results showed that the expression of BAG-I RNA
(Fig. 5.3) correlated well with mat ofBAG·J protein (Fig. 5.1), suggesting that the overexpression
of BAG-I protein is caused by increased transcription of BAG-I gene.
Since high level ofbci-2 expression in fonicular lymphoma is thought 10 be a consequence of
the t(14;18) ct\romosomal translocation of me bci-2 gene (Graninger et ai., 1987), I used Southern
bioI analysis to examine whether a genomic rearrangement might underlie the increased transcription
ofSAG-I RNA in cervical carcinoma cells. When DNA from cervical normal and carcinoma cells
was digested with £coRJ, four BAG-I DNA fragments with molecular weights of 2.0, 3.0, 8.1 and
IS.:! kb were prescnt in all the cell types (Fig. 5.4). When Ihe DNA was cleaved with Pstl. four
BAG-I DNA fragmenlswith molecular weights of 0.7, 1.8. 5.0 and 10.0 kb were found from all the
samples. Compared 10 the band pattern of HEN and HEC DNA, no loss or gain of BAG· I bands
were detected in any of the cervical carcinoma cell lines.
5.3.3 Effect of BAG-I overnpressioD on tbe resistance ofcervini carcinoma cells to apoplosis
induced by slaurosporlne
BAG-I was originally identified as an anti-apoptotic protein (Takayama et ai., 1995).
Thererorc, [ examined whether enhanced resistance to apoptosis in cervical carcinoma cells was
correlated with the overexpression of BAG-I. As expected. decreased cell viability or enhanced
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Fig. 5.3. Overexpression of BAG-l RNA in cervical carcinoma cell lines. For Nonhem blots, 20
j..tg of total RNA from normal HEN and HEC and cervical carcinoma cells were size-fractionated on
a 1.0% agarose formaldehyde gel, transferred to nitrocellulose membranes and hybridized with e2pj_
labelled BAG-l cDNA probe.ll·actin was used as an internal conl:rol.
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Fig. 5.4. Southern blot analysisofBAG·t in genomic DNA from cervical nonnal and carcinoma
cells. Ten Ilg of high molecular weight genomic DNA was digested with EcoRi or Pst!, separated
in a l% agarose gel and transferred 10 a Hybond-NX nylon membrane. BAG-I DNA was detected
by probing the blot with (HPJ-labelled full-length human BAG-I eDNA. Molecular weight markers
are shown on the left.
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resistance to apoptosis correlated well with overexpression ofBAG~1 p50. As shown in Fig. 5.5,
while all the HEN and HEC cells died after lreaDnent with 0.2 /-1M staurosporine for 24 h, the
viability ofcervical carcinoma cells (CaSki, SiHa. HeLa. C4-I, C33A and HT-3) was over 80% after
48htreatment.
To examine whether BAG~I is directly involved in the resistance of cervical carcinoma cells
to apoptosis, I stably transfected BAG-I eDNA into theC33A cervical carcinoma cell line, which
expressed low level of BAG-I (Fig. 5.1). Since C33A was relatively resistance to apoptosis induced
by 0.2,uM staurosporine, I assayed apoptosis after treaDnent of the cells with O.5,uM sUllfOsporine.
Because distinct isofonns of human BAG~I have similar function in anti.apoptosis (unpublished
data), only the result for p50 was shown in Fig. 5.6. The viability was significantly higher in the cells
overexpressing BAG·I (BAG-I) than in the cells expressing vector plasmid (NED) aftrr treatment
with 0.5 jJ M staurosporine for 6 days (p < 0.05: Fig. 5.6), indicating that overexpression of BAG-I
enhanced the resistance of cervical cells to apoptosis.
5.4 DISCUSSION
A number of studies support the concept that HPVs, a family of small double-stranded circular
DNA viruses, are the major cause of cervical cancer(zur Hausen, 1991; zur Hausen and de Villiers.
1994; zur Hausen, 19%). High risk HPVs, in panicular HPVI6 and HPVlS, have becndetected in
90% ofcervical carcinoma biopsies (Riou et al., 1990; zur Hausen, 1996). Since cooperation of the
£6 and £7 proteins of high risk HPVs is sufficient to immortalize human cervical keratinocytes and
epithelial cells, they have been considered to be oncogenic proteins important (or cervical
carcinogenesis (for review, see zur Hausen and de Villiers, 1994; MacDougall, 1994).E6 and E7
protcins were shown to hind 10 tumor suppressor proteins pS3 and Rh, respectively, and \I) inactivate
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Fig. 5.5. Resistance of human cervical carcinoma cells 10 apoptosis induced by staurosporine.
Cervical nonnal (panel A) and carcinoma (panels A and B) cells were treated wilh 0.2 pM
staurosporine for the indicated limes. The percentage of viable cells was determined by trypan blue
exclusion assays. The results represent the mean ± the standard deviation of three experiments.
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Fig. 5.6. Enhanced resiSlance to staurosporine-induced apoptosis by oven::xpression of BAG-I
eDNA in C33A cells. The vector control plasmid PCRJ.I (NED) and the plasmid containing pSOK
eDNA (BAG-I) were stably transfected into C33A cells. (A) Overexpression ofBAG-I pSO in C33A
cells. Western blot melhods and labels were as in Fig. S.l. (B) Resistance to apoptosis induced by
stauroporine in BAG·I-overexpressing C33A cells. The cells were trealed with 0.5 /-1M staurosporine
for the indicated times. Detection of apoplosis and presentation of the data were as described in Fig.
5.5.
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their rumor suppressor activity, leading to uncontrolled cell growth (Munger er 01., 1989; Wemess
et 01., 1990; McDougall, 1994; zur Hausen, 1998). Therefore, inactivation ofp53 and Rb by HPV16
E6 and E7 was considered to be one of the necessary steps toward transformation of cervical cells.
p53 is a tumor-suppressor gene that functions as a panicipant in cell cyele control, DNA
synthesis and repair, and maintenance of genomic stability (for review, see Levine, 1997). Deletions
or mutations of p53 have been detected in about 50% of human cancers (Hollstein et aI., 1991;
Levine, 1997). Recently, pH was also found to modulate apoptosis by upregulating the expression
of the pro-apoptotic gene box and downregulating the anti-apoptotic gene bcl-2 (Miyashita el 01.,
1994a, b; Miyashita et 01., 1995). Since p53 was inactivated in a variety of human cancers, it was
consistent that enhanced expression of BcI-2 was observed in these cancers (Tsujimoto and Croce,
1986; Hollstein eta!., 1991; Reed et 01., 1991; McDonnell elal., 1992; Halderet 01.,1994; Ikegalci
ct 01., 1994; Liang et 01., 1995; Sinicrope et 01., 1995). In this study, I provided the first evidence that
anti.apoptotic protcin BAG·1, a BcI.2-interacting protein, is overexpressed in human cervical
carcinoma cclliines and tissues and that overexpression is due to increased transcription ofthe BAG-
I gene. On the other hand, overexpression of BAG-I.interacting proteins, Bcl-2, BcI-XL and GR,
was found in only cervical carcinoma cell lines but not cervical carcinoma tissues. Enhanced
expression of BcI-2 in cervical cancer cell lines and tissues has also been reponed previously (ter
Hannscl el 01., 1996; Pillai el 01., 19%; ter Harmsel el 01., 1997). One Iik.ely explanation for the
discrepancy between my results and those ofothers for the expression ofBd-2 in cervical carcinoma
tissues is that all the previous studies used immunocytochemistry in which the level of BcI-2
represented the percentage of cells stained but nol the total signal intensity from all the cells as
presented in my data using Western blot analysis. However, my results suggest that BAG-t may
serve as a better molecular marker than BcI-2, BeI,Xl or GR for the oncogenesis ofcervical cells in
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\'iI"O. Because only eight nonnal and eight cancerous samples were used in this study. analysis ofa
larger number of samples will be perfonned to address this suggestion.
The exaet mechanism for the enhanced expression of BAG-l in cervieal cancers is unknown.
Since p53 was inactivated by either its mutation (C33A and HT-3) or HPV (CaSld, SiHa, HeLa and
C4-1) in cervical carcinoma cell lines (Scheffuer et al., 1991). the enhanced expression of BAG-I
may be the result of loss of transcriptional repression by pS3. Consistent with this hypothesis.
enhanced expression of BAG-I was also found in HPVl6-immonalized HEN in which pS3 was
reduced (Yang er aI., 1998a) probably through its degradation by HPV16 E6. I have eloned the
promoter region of the BAG-l gene (Chapter 8). However. the BAG-I promoter was not suppressed
by wild.type p53 (Chapter 8). Since pS3 can suppress bcl-2 transcription through the bcl-2 5'-
untranslated region (UTR) sequence (Miyashita et aI., 1994b), it remains possible that p53 may
negatively regulate BAG-I transcription via its S'·lJfR sequence.
Although the role of BAG-I in aPOPlosis has been extensively studied, it had not been
examined in cervical cells. This study provided the first evidence that overexpression of BAG-I in
cervical carcinoma cells may partially contribute to their enhanced resistance to apoptosis induced
by DNA-damaging reagenls. The enhanced resistance to induction ofapoptosis in cervical carcinoma
cells is not due 10 a reduced expression of the pro--apoptotic proteins Sax and Bak, since no
difference in Bax and Bak expression was found compared with that in HEN and HEC (unpublished
dam). Although the increase of Bel-Xl in cervical carcinoma cells was not pronounced compared
with that in normal cervical cells, enhanced expression of Bel-XL may also contribute to the enhanced
resistance of cervical carcinoma cells to apoptosis. In addition, my results suggest that BAG-I and
BcI-2 have imponanl independent compensatory effects in apoptosis, apart from the synergistic
effect found by Takayama el al. (1995). For example, overexpression of BAG-I but not Bel-2 was
134
found in SiHa cervical carcinoma cells that had enhanced resistance 10 apoptosis. On the olhcT hand,
much higher level of Bcl-2 than BAG-I was delected in C33A cervical carcinoma cells thaI also
exhibited enhanced resistance to apoPlosis.
In conclusion, my study provided the first evidence that BAG·J protein is overexpressed in
human cervical carcinoma cell lines and lissues. Reduced apoptosis in cancer cells by upregulation
of BAG-l possibly plays an important role in the developmenl ofcervical cancer.
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CHAPTER 6
ENHANCED EXPRESSION OF ANTI-APOPTOTIC PROTEINS IN HUMAN
PAPILLOMAVIRUS-IMMORTALIZED AND CIGARETTE SMOKE
CONDENSATE-TRANSFORMED HUMAN ENDOCERVICAL
CELLS: CORRELATION WlTH RESISTANCE TO
APOPTOSIS INDUCED BY DNA DAMAGE
6.1 INTRODUCTION
I previously established an ill vitro system in which primary human endocervical cells (HEN)
were immortalized by HPVI6 and subsequently transformed by treatment of immortalized cells with
cigarctte smokc condensate (eSC). This in vitro syslem mimics the multislage oncogenesis of
cervical cells ill sim (Tsutsumi el 0/., t992; Yang et 0/., 1996). To elucidate the role of expression
of gcnes regulating apoplosis in this ;n vitro multistage oncogenesis. I examined the protein
expression of genes promoting or inhibiting apoptosis in primary, HPV 16-immortalized and CSC-
transformed HEN by Weslern blot analysis. My study showed thai the protein levels of anti-
apoptolic gencs (Bel-2, Bel-XL and BAG-I). but nOI pro-apoptotic genes, were progressively
enhanced after immortalization and transformation of primary cervical cells. The enhanced prolein
levels of anti-apoptotic genes in HPVl6-imrnortalized and CSC-transformed cells were correlated
with enhanced resistance ofthesc cells to apoplosis induced by staurosporine or cisplatin.
6.2 MATERIALS AND METHODS
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6.2.1 Cell culture and Irealmeal of cells wilh slaurosporiae or dsplatia.
HEN and HPVI6-immortalized HEN-16and HEN-I 6-2 were established and propagated in
culture. as described previously (Sun et al.• 1992; Tsutsumi et aI., 1992). CSC-transformed cells,
HEN-16T and HEN-16-2T. were established from HEN-16 and HEN-16-2. respectively. by
treatment of immortalized cells with CSC (Yang et af.• 1996b). All the cells were mainlained in
serum-free media forkeratinocytes (GrBCO BRL. Bethesda. MD). The growth rates ofall cell types
were similar in this culture condition (Yang et al.. I996b). To assay the resistance ofdifferent cells
to DNA damage. exponentially growing cells were treated with 0.2 I-I-M staurosporine or 5 I-I-M
cisplatin for 12.24 and 48 h. Cell viability was detennined with trypan blue exclusion assays. as
described in Chapter 4.2.3.2.
6.2.2 DNA fragmenlado. aaalysis
Cervical cells were incubated with 0.2 I-I-M staurosporine or 5 I-I-M cisplatin for 48 h and then
5 '" 10l cells were lysed in 20 1-1-1 lysis buffer. After incubation with 300 J,lglml RNase A at 37°C
for I h. 10 III proteinase K(20 Ilgllll) were added and the mixture was incubated at 50°C for 14 h.
The DNA was resolved byelcctrophoresis in a 1.5%agarose gel and visualized by ethidium bromide
staining.
6.2.3 Western blot aaalysis
Western blot analysis ofceHuJar proteins was as described in Chapter3.2.3. Mouse anti-p53
and anti-actin mAbs were purchased from OAKO (Glostrup. Denmark) and Sigma (Oakville,
Canada). respectively. Rabbit polyclonal antibodies for BcI-X l • Bax and BAG-I and mouse mAbs
for Bak and BcI-2 were obtained from Santa Cruz Biotech. (Santa Cruz. CA). To identify the
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specificity ofbands bound by each antibody, peptide competitors of specific antibodies were added
to the hybridization assays in 1O-fold excess. The bands eliminated by addition ofcompetitor peptide
(data not shown) were regarded as genuine bands.
6.2.4 Reverse transcription-PeR (RT-PCR) ...Iysis
To assay the expression of bel·x mRNA, RT·PCR wasperfonned, as described (Yang et al.,
1997). The PCR primers used for the amplification of bel-XI. and bcl-Xs were: sense,S'·
TTGGACAATGGACTGGTTGA-3'; and antisense, S'-GTAGAGTGGATGGTCAGTG-3'. The
peR program was: 94°C for 3 min for the first cycle; 35 cycles of94 °c for I min, 56 °c for 2 min
and 72 °c for 2 min; and 72 °c for 7 min for the last cycle.
6.3 RESULTS
6.3.1 Levels of anti.apoptotic proteins were enbanced in HPVlti-immortalized and CSC·
transformed buman endocervical cells
The levels ofapoptosis-promoting proteins, pS3, Bak, Bax and Bel-Xs, were examined by
Westem blot analysis. The expression ofpS3 protein was high in HEN and decreased in HPV16·
immonalized cells, HEN-16 and HEN· I6--2. [15 leve[ increased more than 3-fold or was little affected
in HEN-16·2T or HEN·16T, respectively, compared with thaI in their immonalized counterparts
(Fig.6.1; Table 6.1). However, there was no significant difference for the high expression ofBak and
Sax proteins among all five cell types examined (Fig. 6.1, Table 6.1). Since the expression ofBcI·Xs
protein could not bcdetected by Western blot analysis in any cell type (data not shown). I employed
RT·PCR to test ifmRNA was expressed in the cells. While the 591 bp RT-PCR product of bel-Xs
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Fig. 6.1. Expression of p53. Bak and Bax apoptosis.promoting proteins in nonnal, HPV.
immonaHzed and eSC-transformed human endocervicaJ cells. Wcstern blot analysis is shown using
actin as an internal control.
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was detected for all the cell types, the level was low relative to bel-XL and no major difference was
observed in the level of its expression among the five cell typeS (Fig. 6.28).
The expression ofanti-apoptotic proteins, BcI-2, Bel-XL and BAG-I, increased progressively
from HEN to HPVl6-immortalized cells (HEN-16 and HEN-16-2) and then to CSC-transformed
cells (HEN-16T and HEN-16-2T) (Fig. 6.2A; Table 6.1). While the level of Bc1-2 was very low in
HEN. it increased relative to HEN about 6- and IO-fold in HEN-16 and HEN-I 6-2 and 16- and 27-
fold in HEN-16T and HEN-I6-2T, respectively. A similarpanem was observed for the expression
of BAG-l protein. Compared with the expression ofBcI-2 and BAG-I proteins. the increases in BcI-
XL level were less pronounced. The two BcI-XLproteins (28 kDa and 30 kDa) were high in HEN.
They increased about2-fold in HPVI6-immortalized cells and were further increased to about 2- to
4-fold in CSC-transformed cells relative to HEN (Fig. 6.2A; Table 6.1).
6.3.2 Resistance to APOplosls Induced by Siaurosporine or Cisplalia Was Correlaled witb Ibe
Enbanced Protein Levels of Anli-Apoplolk Genes
To examine whether there was a correlation of the expression ofapoptosis-inhibiting genes
with resistance 10 apoptosis, I assayed the induction ofapoptosis by two DNA-damaging reagents,
staurosporine and cisplatin, in primary, HPVl6-immortalized and CSC·transformed HEN. The
resistance to apoplosis increased greatly after immonalization of primary HEN. Similarly, the
resistance to apoptosis was enhanced in HEN-16T and HEN-16-2T, compared with that in their
immortalized counterpans, HEN-16 and HEN-I6-2. respectively. After 48 h treatment of cells with
0.2 J..lM staurosporine, only 5% of HEN were viable. whereas 48% and 4O%ofHEN-16 and HEN-
16-2. respectively, and 74% and 50% ofHEN-16T and HEN-16-2T, respectively, were viable, as
determined by trypan blue exclusion assays (Fig. 6.3). Consistent results were seen when all the
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Fig. 6. 2. Expression ofBel-2. Bel-XL and BAG-l apoptosis-inhibiting proteins in nonnal, HPYl6-
immonalized and CSC-transformed human endocervical cells. A. Western blot analysis of BeI-2,
Bel-XL and BAG-I. B. RT-PCR analysis of Bel-XL and Bel-Xs. Conditions for Western bIoI were
as in Fig.6.1.
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endocervical cells were treated wim S J.1M cisplatin. For HEN, 59"/0 were viable, whereas 70% and
68% ofHEN-16 and HEN·16-2, respectively, and 81% and 71% ofHEN-16T and HEN-16-2T,
respectively, were viable after the cells were treated with cisplalin for 48 h (Fig. 6.3). A similar
panem was obtained when apoplosis was tested by DNA fragmentation analysis. confirming mat me
cell death was apoptotic (Fig. 6.4).
6.4 DISCUSSION
Recent clinical studies show a strong correlation between apoplosis and progression of
premalignant cervical lesions (Isacson er ai., 1996; Shoji et al.• 1996). Cellular genes regulating
apoptosis. such as bcl-2, but not HPVs, were considered to be important in this correlation (Shoji
er ai.. 1996; Pillai et al., 1997). However, the exact role of me apoptosis-associated genes in this
oncogenic progression is poorly unde~tood.The purpose of this study was to determine whemer the
expression of the proteins of apoptosis-associated genes varied during multistage oncogenesis of
human cervical cells. I found Ihat the expression ofanti-apoptotic proteins. Bel-2, Bel-XL and BAG-
\. increased both in HPVI 6-immortalized and CSC-transformed cells, indicating that their genes
may be involved in the mutistage oncogenesis ofcervical cells. In contrast, the apoptosis--promoting
proteins. p5J. Bak and Bax. varied little during multistage oncogenesis.
p53 was also found to play an important role in apoptosis. Loss ofpSJ function was reported
to result in resistance to apoptosis induced by DNA-damaging reagents in various human cells (Zhao
et al., 1994). On the other hand, overexpression ofp53 was shown to induce apoplosis in certain cell
types (Yonish-Rouaeh et al., 1991; Oren, 1994; Yonish-Rouach er ai., 1996). In cervical carcinoma
cells, pS3 is usually degraded by a ubiquilin-mediated proteolysis through interaction with E6
protein of HPVs (Schermer el al., 1994; Wemess er al., 1990). Consistently, in my study, decreased
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Fig. 6.3. Resistance ofhuman endocervical cells to apoptosis induced by staurosporine or cispiatin.
Endocervical cells were treated with 2 ~M staurosporine or 5 j,lM cisplatin for different period of
time. The percentage of the viable cells was determined by rrypan blue exclusion assays. The results
represent the mean ± the standard deviation of three experiments.
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Fig. 6.4. Comparison ofstaurosporine~or cisplatin-induced DNA fiagmenlalion in normal, HPV 16-
immonalized and CSC-transfonned human endocervical cells. Cells were [feated with 0.2 IJM
staurosporine or 5 f.lM cisplalin for 48 h. The low molecular weight DNA fonned after DNA
fragmentation was subsequently extracted and examined on an ethidium bromide agarosc gel.
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expression ofp53 protein was delected in HPV 16-immonalized cells (Fig. 6.1). Further, the reduced
p53 level was in agreement with enhanced resistance to apoptosis induced by staurosporine or
cisplatin. In contrast, due to enhanced expression ofpH mRNA in these cells (Yang el al., 1997),
the expression of p53 protein increased after transformation ofHPV l6-immonalized cells by CSC.
However, the resistance 10 apoptosis increased in CSC-transfonned cells compared with their
immortalized counterparts, indicating thaI the sensitivity to apoptosis in cervical cells also involves
a p53-independent mechanism and thaI other genes regulating apoplosis may be imponant in this
process. Inactivation ofp53 by HPV E6 has been shown to enhance, reduce or have no effect on
apoplosis induced by DNA-damaging reagents (Fan et 01., 1995; Labrecque et 01., 1995; Tsang el
al.. 1995; Wahl et 01., 1996; Xu et 01., 1995). Therefore, the exact role ofp53 in apoptosis of human
cervical cells awaits full elucidation.
Bax and Bak are BcI-2 family members that promote apoptosis by helerodimerizing with
Bcl-2 (see Chapter 104.1.1). ba..y was also shown 10 be downstream ofp53 and transactivated by p53
(Miyashita el 01., 1994; Miyashita and Reed, 1995). Like p53, ba.T can function as a tumor
suppressor gene by inducing apoptosis in tumor cells (Yin et 01.• 1997). Although reduced
expression of Bak or bax was detected in primary colorectal adenocarcinomas and breast cancers
(Bargou el al., 1995; Krajewska el al., 1996), no changes were found in CSC·tnmsformcd human
cervical cells. No changes in the expression of Sax or Sak proleins were also found in cervical
carcinoma cells (see Chapter 5). This suggests that dysregulated expression of Bax or Bak may not
be common in human cervical cancer.
Relative 10 nonnal keralinocytes, overexpression of BcI-2 was found in human cervical
carcinoma ccll lines (Liang et 01., 1995). However, the role ofbcl-2 in multistage oncogenesis of
human cells has rarely been studied. Bc1·2 was found 10 be involved in an early event in vivo in
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colorec!al !Umorigenesis (Sinicrope et al., 1995). In this study, [ found thai the expression ofBeI-2
was progressively enhanced from primary HEN to HPVl6·immonalized HEN and to esc·
transfonned immortalized cells, suggesting that activation of the bcl-2 gene was involved in early
and late events in cervical oncogenesis. lnterestingly, enhanced expression of Bcl-2 was closely
correlated with an increased resistance to apoptosis induced by DNA-damaging reagents in both
immortalized and transfonned cells (Fig. 6.2-6.4). This indicated that overexpression of Bc1·2 may
play an important role in both apoptosis and multistage oncogenesis of human cervical cells, at least
in our ill vitro system. Previously, bcl-2 mRNA expression was shown to be suppressed by p53
through a p53-dependent negative response element (Miyashita et al., 1994a., b). Therefore, an
in\·erse correlation between the expression ofbd-2 and pH was found in breast cancer cells (Halder
er al., (994). Since an inverse correlation in the relative expression ofp53 and BcI·2 was found after
immortalization but not after lransformation of human cervical cells, ovetexpression of Bc1·2 in
human cervical cancers may be through p53-dependent and p53-independent pathways, as suggested
previously (Liang et al., 1995). Funher, since p53 and BcI·2 have opposing effects on apoptosis, the
relative levels ofp53 and 8cl-2 may be more important in apoptosis. For example, although HEN-
16-1T had the highest expression of8cl-2, it also had relatively higher level ofp53. Possibly as a
result. the resistance of HEN- I6-2T to apoptosis induced by staurosporine and cisplatin after 48 hr
treatment were similar to that for HEN-16 and HEN-16-2. Therefore, the sensitivity of cells to
apoptosis induced by DNA-damaged reagents may be determined by the relative protein level of
apoptosis-assodated genes.
Two splice variants ofbcl·X mRNA. BeI.XL and bcl."s. have different functions: BeI.XL is
the longer form ofbcl-X mRNA and has an anti-apoptotic effect, whereas bcl."s is the shoTter bcl-X
mRNA and promotes apoptosis by inhibiting BcI-2 function (Boise et al., 1993). Overexpression of
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Bel-Xl mRNAs and proteins was reported in many human cancers (see Chapter 1.4.1.2). However,
there is no report on the expression of bc/-X in human cervical cells. In this study, I found lhat Bel-
Xl was the predominant fonn of bc/-X expressed in human cervical cells and it was expressed
relatively higher in both HPVl6-immortalized and CSC-lr.lnSfonned cell lines lhan in nonnal
cervical t.:clls. in contrast, the expression of BcI·Xs protein was undetectable in all cells and a
relatively low level of its transcript was detected only by RT-PCR. This study suggested that
enhanced expression ofBcI-Xl may be correlated with lhe resistance to apoptosis of human cervical
cells and oncogenesis.
Although BAG-I was overexpressed in various human cancers, its role in muhistage
carcinogcnsis has not been examined. In this study, 1 found progressively increased expression of
BAG-I protein after immortalization of primary HEN by HPVI6 and transformation by CSC. The
synergistic enhancement of BAG-l and Bel-2 was closely correlated with the resistance ofcells to
apoptosis induced by staurosporine or cisplatin. These results suggest that BAG-I plays an important
role in both the early stage and late stage ofoncogenesis of human cervical cells.
Taken together, my results provided the first evidence that anti-apoptotic gene proteins, Bcl-
") Bel-Xl and BAG-I, were progressively increased during mutistage oncogenesis of human
cervit.:al t.:clls. The enhanced expression of these genes in HPVl6·immortalized and CSC-
transformed cells closely correlated with their resistance to apoptosis induced by DNA-damaging
slaurosporine or cisplatin, indicating that reduced cell death by apoptosis due to progressive increase
of anti-apoptotit.: proteins may play an important rote in the multistage oncogenesis of human
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CHAPTER 7
DIFFERENTIAL EXPRESSION Of ANTI·APOPTOTICGENE BAG-liN HUMAN
BREAST NORMAL AND CANCER CELL LINES AND TISSUES
7.1 INTRODUCTION
Recently, enhanced expression of BAG-I in breast cancer tissues was found by Zapata et ai,
(1998). However, only one breast normal and three carcinoma tissues were used for Western blot in
their study. [n addition, I have recenlly shown thai BAG·1 is expressed as four protein isofonns, p50,
p36. p33 and p29. through alternalive translation initiation (Yang et al., 1998b). However, the role
ofdifTerent BAG-I isoforms in lUmorigenesis has not been elucidated. In this study, I showed that
BAG-I isofonns can be differentially expressed in eelliines in vitro compared with tissues ill vivo.
Further, I provided evidence rnat BAG-l isoforms. p46 and p33, were overexpressed in both breast
carcinoma cell lines and tissues and may pray an imponant role. independent ofBcI·2 and BcI.XL>
in breast carcinogenesis.
7.2 l\.IATERlALS AND METHODS
7.2.1 Cell culcure aDd breasc biopsin
Three nonnal human mammary gland cell lines (HS574, HS578 and HS787) and nine human
breast carcinoma cell lines (BT-20, BT-474, HS578T, MCF-7, SK-BR-3. t\tIDA·MB·157, MDA·MB·
231. MDA·MB-436 and MDA-MB-468) were used in this study. All the cell lines were obtained
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from ATCC. Except forSK-BR-3 which was cultured in McCoy's Sa medium, all thecelliincswcre
maintained in DMEM containing 10"10 heat-inactivated FCS.
The breast nonnal and carcinoma tissues were obtained from the General Hospital. me Health
Science Center (St. John's, Canada) and NCIC Manitoba Breast Cancer Tumor Bank (Winnipeg.
Canada). Tissue samples were excised fresh from operalive specimens. Each specimen was eimer
cut into I mm segments or sliced into 50 Ilm thick pieces and stored at _700 C before protein
extraction. Sections were histologically classified with respect to the presence of breast nonnal and
invasive carcinoma tissues. Care ~as taken to exclude all nonnal tissue from invasive tumor samples
using histological examination.
7.2.2 Rc"1A and protein extractions from buman breast cell lines or biopsies
Extraction of RNA and protein from human breast cell lines or biopsies was as described in
ChapterS.2.4.
7.2.3 Norrhero and Western Blot Analysis
Northern and Western blot analysis of cellular RNA and protein was as described in Sections
2.2,4 and 3.2.3.
The statistical significance of the difference of protein expression between normal and tumor
tissues was analyzed by the Siudent t-test.
7.3. RESULTS
7.3.1 O,'erexpresslon of BAG-I RNA In buman brustcaocer ullllnes
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To investigate the role of BAG-l in oncogenesis of human breast cells, I examined the
expression of BAG-I RNA in three cell rypes (HS574. HS578 and HS787) derived from normal
breast epithelium and in nine breast cancer cell lines (BT-20. BT-474. HS787T, MCF-7, SK-BR-3,
MDA-MB 157, l\.1DA-MB23I, MDA·MB436 and MDA-MB468) by Northern blouing (Fig. 7.1).
Whereas the expression of BAG-I RNA was low in all the three normal breast cell lines. it was
significantly higher (increased 3.75 to 7.76--fold) in seven of the nine breast cancer cell types. Only
two breast carcinoma cell lines, HS578T and MDA-MB157, expressed relatively low level of BAG-I
RNA (O.7o-fold and 1.78-fold, respectively, relative to BAG-l RNA level in nonnal breast cell lines,
Table 7.1).
7.3.2 O,'erexpressloD orroar BAG-I prolelD lsoforms 10 breasl cancer cell lines: correlation
wltb the BAG-I-lnteractlD& proteins, Bel-I and Bel-XL
Consistent with BAG-I RNA expression, the expression of the four BAG-I protein isofonns,
p50. p46. p33 and p29 (Yang el aJ.. 1998b), was low in the three nonnal breast cell lines. BAG-!
protein expression was higher relative to nonnal cell lines in seven of the nine breast carcinoma cell
lines. Only H$578T and MDA-MB-157 expressed relatively low level ofBAG-' protein (O.65-fold
and a.7S-fold, respectively, relative to the BAG-I protein level in normal breast cell lines, Fig. 7.2;
Table 7.1). Since BAG-I binds and synergizes with &1-2 to suppress apoptosis (Takayama el ai.,
1995). 'examined whether the expression of BAG- I-interacting anti-apoptotic proteins. Bel·2 and
Bel-XL' was also higher in breast cancer cell lines than in nonnal cells. Interestingly, Bel-2 protein
level was higher in six of the nine breast cancer cell lines and the level ofdoublet Bel-XL was higher
in five of the nine cancer cell lines (Fig. 7.2). The expression level of BAG-I, Bc1-2 and Bel-XL is
summarized in Table 7.1. Overall, BAG-! protein was overexpressed in carcinoma cell lines and its
IS'
Fig. 7.1 Overexpression of BAG-I RNA in human breast carcinoma cell lines. For Northern bioI,
:W )Jg of IotaI RNA from human breast nonnal and carcinoma cells were size-fractionated on a 1.0"/0
agarosc formaldehyde gel. transferred 10 nitrocellulose membranes and hybridized with [J~Pl_labelled
BAG-I eDNA probe.lJ-actin was used as an internal control.
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Fig. 7.2 Expression of BAG-I , BcI-2 and Bel-XL proteins in breast normal and carcinoma cell lines.
For Western blot, lysate containing 10 f.Ig protein from normal and cancer cells was subjected to
10% SDS~PAGE and transferred to an EeL nitrocellulose membrane. The membrane was
subsequently incubated with anti-human BAG-I mAb (CC9E8), anti~BcI·2 mAb or anti.BeI-Xl
polyclonal antibody and signals were detected using a goat HRP-eonjugated anti-mouse IgG
antibody by lhe ECL method. j3-actin was used as an internal control. The four BAG~I isofonns are
indicated on the right.
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level was statistically (p < 0.05) correlated with those of Bc1-2 and Bel-XL in breast normal and
carcinoma cell lines.
7.3.3 O"erexpression ofOAG-1 protein in breast urdaoma tissues
To test the relevance of BAG-I protein overexpression in breast carcinoma cell lines to the in
I'ivo condition, I examined the expression of BAG- ( protein in 24 normal and 4S invasive carcinoma
breast tissues. The expression level of each isoform ofBAG-I protein was quantified by normalizing
the level of each band in Western blots with that of the j}-actin control. Fig. 7.3 shows an example
of the Western blots and Fig. 7.4 shows the distribution of protein level among individual samples.
In general. both the mean level and percentage of sample positivity of p46 and p33 were markedly
higher in breast carcinoma than normal tissues (Fig. 7.3. 7.4; Table 7.2). The mean level and
percentage of p46-positive samples are 0.0"/0 and 4.2%, respectively. in normal tissues, whereas they
arc 0.12% and 80.0%, respectively, in carcinoma tissues. Similarly, the mean level and percentage
ofp33.positivc samples are 0.01 % and 4.2%. respectively. in norma.ltissues, whereas they arc 0.19%
and 62.2%. respectively. in earcinoma tissues. Statistical analysis also shows that the expression of
p46 and p33 in normal and breast cancer tissues is significantly different (p < 0.001; Table 7.2).
Although the level ofp50 in breast carcinomas was statistically higher than that in normal mammary
tissues. its mean level or percemage of BAG-I-positive tissues was the same or almost the same
(normal versus tumor tissue: mean, 0.99 versus 1.18, p < 0.05; % positive. 100% versus 100%; Fig.
7.4; Table 7.2). p29 was detected only in one breast carcinoma tissue (Fig. 7.3). While p33 was the
predominant isoform of BAG-I protein in breast normal and malignant cell lines (Fig. 7.2), pSO was
the predominant isofonn in breast nonnal and most carcinoma tissues (Fig. 7.3).
In contrast to my experiment using breast cell lines. BcI-2 and BcI,XL were not overexpressed
\6\
Fig.7.3 Expression of BAG-I, BcI-2 and Bel-Xl proteins in breast normal and carcinoma tissues.
Western blot analysis and labels were as described for Fig. 7.2.
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Fig. 7.4 Normalized expression level of BAG-I pSO, p46 and p33 proteins in breast nonnal and
carcinoma tissues. The level oreach protein in Western blot was determined with a densitometer. The
relative levels of pSO, p46 and p33 were indicated for each tissue sample by the ratio of proteins to
p-actin.
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p'O
p46
p3J
Bel·2
Bcl-X
Tllble 7.2 SUllinlary oflhe exprcssion ofOAG·I, Bel·2 lUlll lJel.X1 in brcust
nonnal :1110 carcinoma tissues'
Normal,N=24 Tumor, N"'4S
Mean±S.D. IOf. positive Mean:l:S.D. Of. positive
0.99± 0.85 100.0 J.l8±0.S7 100.0
0.00=*:0.00 4.2 0.12=*:0.12 80.0
0.01 =*:om 4.2 0.19±0.21 62.2
1.12:1:0.97 91.7 0.11 :/:0.23 28.9
0.10:/:0.12 100.0 0.07 ± 0.Q7 93.3
Statislical
sif;~~~l~:~)c~
·,p"0.018
", p<O.OOI
··,1'<0.001
··,p<O.OOI
No, P "0.20S
"The level of each protein in the Western bIoI was quantified by densitometry ~md nonnalizcd using the p-aclin conlrol. The mean
=*: the slandard dcviation of all nomlal or lumor samples was cKprcsscd in arbill'llry units; % positive represents Ihe percentage of
samples with det«tablc BAG-I.
"No, ., and •• n..j)rcscntno, low (I' < O.OS) and high (p < 0.001) statistically significant difference by Studcnll·test comparison of
the level of each protein in norma] and lunlOf samples.
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in breast cancer tissues (Fig. 7.], 7.5). No difference was observed in the level of Bel-Xl between
breast nonnal and cancer tissues (Table 7.2). Moreover, the mean level of BcI-2 was lO-fold lower
in breast cancer than nonnal tissues.
7.4 DISCUSSION
Allhough breast cancer is the second leading cause ofcancer·associated death for women (pisani
et a/., 1999), the molecular mechanism for the carcinogenesis has not been fully understood.
Recently, a number of observations have suggested that dysregulation of apoptosis plays an
important role in the pathogenesis of human cancers (for reviews, see Williams, 1991; Orrenius,
1995; Thompson, 1995). While the expression of the apoptosis-associated genes,p53, bcl-2 and bax,
has been extensively studied in breast cancer, conflicting results have been reported in the literature
(Haldar et al.; Bargou el af., 1995; Bargou et al., 1996; Steck et af., 1996). BcI·2 was found to be
overexpressed in some breast carcinoma cell lines (Haldar et af., 1994), but not changed or even
lower in some other breast cancer cell lines or tissues (Bargou et al., 1995; Bargou et al., 1996; Leek
el at., 1994). Rcduced expression ofpro-apoptotic gene, bar:, was observed in breast cancer cell lines
and tissues and the expression ofmRNA for the anti-apoptotic genes, bcl·2 and bcl.Xl , was similar
in breast nonnal and cancer tissues (Bargou et al., 1995; Bargou et al., (996). Heterogeneous
expression of Bax was also detected in primary breast tumors (Krajewski et af., 1995). To fully
understand the role ofapoptosis in the pathogenesis of breast cancer, it is necessary to examine the
expression of genes other than p53, bax and bcl-2 that are involved in apoptosis.
In this study, I examined the expression of BAG-I, an anti-apoplOtic protein, and its interacting
proteins in breast nonnal and carcinoma celliincs and tissues using Western blot analysis. I provided
convincing evidence that the expression of BAG-I protein was increased in breast carcinoma versus
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Fig. 7.5 Normalized expression level of BcI-2 and Bel-Xl in brcast normal and cancer tissues. The
level of each protein in Western blot was determined with a densitometer. The normalized levels of
Bcl-2 and Bel-Xl are indicated for each tissue sample by the ratio of proteins to 13-actin.
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nonnal cell lines and tissues. Although immunohistochemistry is not quantitative or able to
distinguish isoforms, similar trends were observed when comparing BAG-I staining in breast
carcinoma with normal tissues using this method (unpublished data). My Western blot analysis of
the four BAG-I isofonns showed that there was a significant difference in normal versus cancer cells
ill ~'itro compared with tissues in vivo. While all the BAG-I protein isofonns were overexpressed in
breast carcinoma cell lines (Fig. 7.1). only p46 and p33 were higher in breast carcinoma tissues (Fig.
7.2). Since the levels of BAG-I RNA and protein were closely correlated in breast cell lines,
enhanced expression of BAG-I protein isofonns in these carcinoma ceil lines is likely due to
increased production of BAG-I RNA. However, all BAG-I isofonns are translated from a single
mRNA transcript (Yang et a/., 1998b). Therefore. higher level ofp46 and p33 but not pSO in breast
carcinoma tissues may be caused by relatively increased usagc of the second and third initiation
codons during translation of BAG-I in breast cancer tissues. Similarly, a significant difference was
also found for Bcl-2 and Bd-Xl in breast cell lines and tissues. One possible cause for the differential
expression of BAG-I, Bc1-2 and Bel-XL in breast normal and carcinoma cell lines versus breast
normal and primary carcinoma tissues is the changes occurring in cell growth requirements or cell
selection during initial or after prolonged culture of normal or tumor cells in vitro. In addition,
changes for gene expression during the menstrual cycle in tissues (Sabourin et 01., 1994) but not cell
lines may be another cause for the difference. Limited sample size could also contribute to the
difference. Funher experiments using a greater number of breast cel1lines and tissues arc needed
to confirm the above possibilities.
Finding higher expression ofp46 and p33 bU! not pSO in breast cancer tissues is of interest. My
previous study indicated that different BAG-I isofonns may have distinct subcellular localization
(Yang el al., 1998b), suggesting that they may have distinct function in the cells. Interestingly, pSO,
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but not p46 or p33, was recently found to enhance AR-mediated transactivating activity (Froesch et
a/., 1998). Therefore, the four BAG-I isofonns may have different roles in transcription regulation.
apoptosis and tumorigenesis. Recently, enhanced expression of BAG-I p33 in three breast primary
tumors was observed by Zapata et a/. (1998). Since other BAG-I isoforms. p50. p46 and p29, were
not examined in their study, the differential expression of BAG-I isofonns in breast carcinoma was
not clear. The molecular mechanism for the overexpression of p46 and p33 in breast carcinoma
tissues is still unknown. Further experiments need to be performed to elucidate the role of BAG-I
isofonns in carcinogenesis ofbrcast cells by transfecting different BAG-I isofonns into human breast
carcinoma cells and examining the tumorigenicity ofBAG-I-overexpressing cells in nude mice.
A synergistic effect of BAG-I and Bcl-2 on anti-apoptosis has been shown previously by
Takayama et al. (1995). However, the expression level of BAG-I and &1-2 was only correlated in
breast cell lines but not tissues. While the expression level of BAG- ( increased in invasive breast
carcinoma tissues, that of BcI-2 decreased. Similar results were obtained by Zapata et al. (1998)
using immunohistochemical assay for BAG-I and Bcl-2. In addition, although a strong correlation
between Bel-2 immunostaining and ER positivity in invasive carcinoma of the breast was reported
previously (Teixeira et a/.• 1995), no such correlation was found between BAG-I level and ER
positivity (data not shown).ln addition, BAG-I did not correlate with conventional prognostic factors
such as age, histology, stage. but its overexpression is associated with a shoner disease-free and
overall survival (Tang et a/., 1999). Further. no correlation between BAG-I and Bel-XL was found.
Therefore, BAG-I may serve as a molecular marker, independent of BcI-2, Bel-XL and ER, for
breast oncogenesis ill vivo.
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SECTIONS
TRANSCRJPTION REGULATION OF THE HUMAN BAG-l GENE
CHAPTER 8
CLONING AND CHARACTERJZATlON OF THE HUMAi'W BAG-I GENE
PROMOTER: UPKEGULATION BY TUMOR-DERJVED pS3 MUTANTS
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8.1 INTRODUCTION
To study the mole(:ular mechanism for the transcriptional regulation of the human BAG-I
gene, I have cloned its 5' flanking region from genomic DNA. Computer analysis and functional
assays in different tumor cell lines were used to identify, localize and characterize the BAG-I
promoter. More importantly, I provided the first evidence that tumor-dcrived gain-of.function pS3
mutants can upregulate the BAG-! gene promoter activity.
8.2 MATERJAlS AND METHODS
8.2.1 Cellcultu.-e
Human cell lines, HeLa (cervical carcinoma), C33A (cervical carcinoma), MCF·7 (breast
carcinoma) and U87 (glioblastoma), were obtained from the American Tissue Culture Collection and
cultured at 3rc in 5% CO~ in DMEM supplement with 10% rcs.
8.2.2 Cloning and computer analysis o( the buman BAG-I promoln '-eaion
Cloning of the BAG· I promoter DNA was perfonned using a GenomeWalker kit (Clontech),
according to the manufacture's instructions with minor modifications. In brief, t\.1;0 rounds ofPCR
were performed using five GenomeWalker "libraries", which are composed of undoned. adaptor.
ligated human genomic DNA fragments from DNA digested with EcoRV, &aI, Dral, Pvtlll and
Ssp!. The primary round of peR used the outer adaptor primer (API: 5'-
GTAATACGACTCACTATAGGGC-3') provided in the kit and an outer, BAG-I.speci fic primer
(BGP!: S'-CTGAGCCAGGCCCGCACTTGTTGACC.3'). The PCR conditions are as follows: 2
sec at 94°C and 3 min at 70°C for 7 cycles; 2 sec at 94°C and 3 min at 65°C for 32 cycles; and
65°C for an additional 4 min. The primary PeR reaction mixture was then diluted I :50 and used as
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a template for a secondary PCR using a nested adaptor primer (AP2: 5'-
ACTATAGGGCACGCGTGGT-3') and a nested BAG-I-specific primer (BGP2: 5'·
GGAAGCTGAGCGCGGCGTCTCAC..o\AC-3' ). The major PCR products were subsequently
ligated into PCRJ.I vector (Invitrogen) and sequenced.
Homology searches were performed using BLAST (Basic Local Alignment Search Tool)
from the National Centre for Biotechnology lnfonnation (NCBI) at http://www.ncbi.nlrn.nih.gov.
A search for CpG islands was perfonned using GRAlL (Gene Recognition and Assembly Internet
Link) at htlp:/lcompbio.oml.gov/Grail.l.3. PUlative transcription factor binding elements in the
BAG-I promoter were analysed using the TESS (Transcription Element Search Software) program
at: hllp:/lagave.humgen.upenn.edu/tess.index.htrnl.
8.2.3 Conslruclion or luciferase reporter lene cooslrucls
All constructs of the BAG-I promoter for luciferase assays were generated by peR and
ligaled into the XllollHi"dUl sites of the promoterless pGL3-Basic (promega) vector. The identity
of each construct was confinned by sequencing. The pGL3-Control (pGL3-C) postive control
plasmid was obtained from Promega.
8.2.4 Tnnsrectioo,luclrerase assa}'s aad NOrlbera bioI .a.lysis
All transfcclions were done in triplicate in 12-well plates. About to' cells/well were seeded
14 h prior 10 transfection. Plasmids were transfected into cells using LipofectAMlNE reagent
(GIBCQ-BRt). The cells were incubated in lransfection mix for 5 h, and then harvested after 40 h
in culture. Luciferase assays were performed using luciferasc assay reagent (promega) and
Monolight 2010 Lwninometer (Analytical Lwninescence Laboralory).I3-galactosidase reporter
plasmid was cotransfected with luciferase reporter vector. Luciferase activity was nonnalized by 13-
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gaJactosiase activity. Each experiment was repeated at least three times. Purification of RNA from
transfected cells and Northern blot analysis were as described previously (Yang et al., 1997).
8.3 RESULTS
8.3.1 Cloning and sequence a.alysis oUlle buma. BAG-l promoter
To clone the 5' flanking region of the BAG-I gene, human genomic DNA was digested by
EcoRV and Ssp!, and the fragments were amplified by nested PCR. Two 866 bp (BGEV) and 485
bp (BGSP) PCR products were generated from the DNA digested with EcoRV and SspI,
respectively. DNA sequence analysis showed that BGSP is contained within the 485 bp 3' end of
BGEV (Fig. 8.IA). A BLAST search for homology of BGEV DNA with sequences in the database
showed that 37 bp al the most 5' end of the BAG-I cDNA sequences reported in the literature are
identical to the 3' end 37 bp ofBGEV DNA (Fig. 8.IA). Since no other homology was found, this
indicates that r have been the first to clone the 5' flanking region of the human BAG·I gene. Fig.
8.18 shows the 893 bp sequence of me BAG-I gene upstream of the first rranslation start codon
(CTG) in the BAG-l gene. No TATA box was present. However, a CCAAT box and five 3'end-
proximal GC boxes were found. Further, I identified several GC-rich regions containing four Sp1
binding sites from 51 to (40 bp upstream of me first translation stan codon CTG, three of which
encompass three GC boxes (Fig. 8.1 B). These features were also found in the promoter regions of
other genes and required for basal and conditional expression (Ji er al.. 1996). DNA sequence
analysis using GRAlL predicted a 272 bp CpG island located from nt 47210 -200. The CpG island
has an average GC content of60"/0 and a CpG score of0.89. Sequence analysis using TRAN$FAC
identified 15 putative binding sites for transcription factors, including zeste, Spl, WTI, Ets,
transfonning growth factor (TGF}-l! receptor, NF-I, AP-I, GATA·l, GCN4 and YYI.
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Fig.8.1. Nucleotide sequence of human BAG·I gene S'·flanking regions, putative transcription
factor binding sites and CpG island. (A) Diagrammatic representation. The first nucleotide of the
translation initiation site CTG (+1) is indicated by an arrow. The position of a CpO island is shown
as a black rectangle. The locations ofthe two PeR products, BGEV and BGSP, are shown as striped
boxes. The transcription factor binding sites are indicated. (8) Nucleotide sequence. The numbers
ofnucleotides upstream ofme first nucleotide C (+1) of translational start codon (CTG) are shown
on the left of the sequence. Sequence motifs for transcription factor binding are underlined and
designated.
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ACTATAGGGC ACGCGTGGTC GACGGCCCGG CTGGTATCAA GCTGAGTCCT
GATGTGGACT GGGGATGACA GATGGMGM GGGTYAAGGG ATCAGGCAGG
n1
ATGAGGTGGG AAGGGTGTAT GGGCCTAAGG CTGGGTGAGG TGAGAGGATC
MGGCGAGAG CGAGTGGACG GGCAATGGGC ATCAAMCGG GTTGGGTGCT
GGCAGGGCAA GGCAGTGACG GGGTTAGGGG TTCCCTGGTT TGTGGCGTTA
~ GGGTAACAGG GATGMGGGG AGAAGGT~GAGAGGGQOI.. laD-I
ACGACGTGTA AGGGGCCCAG GACCCGAAAT GMGTGGAAG AATATGGGCC
CGGGGCTGGG GGTGGGCGAG GTCGGGTGTG TCAGAGGTCC TGAGCCTACT
----.;r- ----;;r- Ail
TATGCATGAT CAMTGCCCA CCGTGCCAAT GCAGTCAGTC AGGCTGGGCG
"'-1 CCti¥""l.oaGCGGAGCCTT GGGTTTCGCT T'TCCCGAAGA GTCGGTTCAT CTTGAGCAGC
CGCGAAGAAA CCCAAACACT AGAGCM.1I.AC CAGAAACGGA AGCAGAGTCA
CTCCCGCCTC GACITCCGGC CCCTCCGTCG CAAGCGCAAT ATGCCTCCTG
t'GI'-llU: n.-l
GCGTTTCCCG AITCTTTTTC CGGATTTTCA GCCGGGTCTT CCGGAGATGG
AGAGCAAAAG GACTTGGTGC TCTCGGAGAG AGCCTGCAGG GGGCGGGGTG
iiiCiOi
TTGGTAGAAG GAGTGGGAGG GGTTTTACTG TAGCAAGGCG GGGCCTCAGT
ft'1 GIl: bo.
TGAGTGGGTG GGGCCTGGAG GCMCTAACG CGGCATAGGG CGAGGGCGGG
"I Ci: bOa GC a- .,.1~CGGCAGGC C~CTGGGAAGTA GTC~ GTTGTGAGAC
"'1 "'1GCCGCGCTCA GCTTCCATCG CT~C AACAAGTGCG GGCCTG
z.ate GC boa +1
8.3.2 BAG~I promoter activity iD differeDllumor cellli.es
To test the promoler activity of the BAG~I upslrearn sequences in vivo. the BGEV fragmenl
was subcloned into a promoterless luciferase reporter vector. pGL3-basic (pGL3~B). in sense and
anti-sense orientations. Then, the plasmids were lnUlsiently colnUlsfecled with Ihe ~galactosidase
control vector into HeLa cervical carcinoma cells. Luciferase activity was 16~fold higher than thai
for the pGL3-B vector when BGEV was in the sense orientation (BGP~Luc) and was markedly lower
than that for BGP-luc when BGEV was in antisense orientation (BGP-AS; Fig. 8.2). As a positive
control. pGU-Control (pGL3-C). which contains the SV40 promoter/enhancer, exhibited high
luciferase activily. Since BAG-I RNA was expressed at various levels (Takayamaet af., 1998; Yang
et a/.. 1998). (tesled the cell spedlicity of the BAG~1 promoter in four different eanceredllincs.
The luciferase activity from BGP~Luc was also high in another cervical caTCinoma cell line. C33A.
and a breast cancer cell line, MCF-7. bUllower in a glioblaslOrna cell line. US7 (Fig. 8.3).
8.3.3 Location oflhe BAG-I promOler region
To identify the functional region containing the BAG-l promOler. a series of 5' deletion
mutation constructs were produced using PCR with BGEV DNA as template (Fig. 8.4). The PeR
products were subsequently cloned inlo the pGLJ-B vector. Luciferase plasmids containing full-
length or mutated BAG-I upstream DNA were transiently cotransfected with I}-galactosidase
expression plasmid into HeLa cells. The plasmid containing the BAG-! 5' flanking sequence from
-868 to -28 (-868/~28~Luc) had moderately high luciferase activity. Deletion ofnucleotides from-
868 to -702, containing a VYt sile, led to a 50% increase ofluciferase activity. The highest promoter
activity was obscrved in the -353/-28-Luc conslrUct. Deletion of nucleotides from -353 10 ~240.
contain1ng a TGF-I} response element (TGF-I}RE). an Ets-t motif and half the CpG island,
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Fig. 8.2. Constitutive activity of the BAG-I promoter. HeLa cells were transiently transfected with
lucifcrase plasmid constructs containing the BAG-I S'-flanking region in the sense (BOP-luc) or
antisense (BOP-AS) orientation. The vector plasmid pOL3-Basic (pOL3-B) and the pGL3-Control
plasmid (POD-C) were used as negative and positive controls, respectively. Following transfection,
the cells were cultured for an additional 40 h and then lysed in luciferase lysis butTer. RLU indicates
relative lucifemse units. The values represent the mean of the I}-galactosidase.normalized lucifcrase
activity ofthrce independent transfections and error bars represent the standard deviation.
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Fig. 8.3. BAG-I promoter activity in different human cancer cell lines. Experimenlal conditions
and error bars are as described in the Fig. 8.2 legend. Luciferase activity is presented as the fold
increase ofluciferase activity from BGP-Luc relative to that from the pGL3-B vector control.
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Fig. 8.4. Deletion analysis of the 5'-flanking region of the BAG·I gene. The diagram on the left
represents the lucifcrase (LUC) constructs made by a series of deletions extending from 28 bp
upstream (-28) of the BAG-I open reading frame. Values for each construct transfected into HeLa
cells represent the percentage ± the standard deviation, relative to the construct ·3S3f·28·Luc, which
gave the highest (100%) activity. Conditions were as described for Fig;. 8.2.
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dramatically decreased the luciferase activity (5.4-fold). Deleting nucleotides from -122 to -54,
containing three Sp I sites. three GC boxes and a WTI site. abolished lucifemse activity, leaving only
control level activity for the plasmid containing the BAG-I promoter 5' proximal 54 nucleotides (.
54/-18-Luc). Taken together. the data show that the nt ·353 to ·54 region contains the maximum
activity of the BAG-I promoter.
8.3.4 Transa~th"atlonoftbe BAG-I promoter b)' tumor-derlved p53 mutanls
Previous repons demonstrated that mutations ofpH playa role in over 50010 of human
cancers (Hollstein et af.• 1991) and BAG-I was overexpressed in variety of human cancers (Zapata
el al.. 1998; Takayama et al., 1998; Yang et af.• 1998). Mutant p53 derived from human cancer can
cxhibit gain--of-function and transactivate several genes associated with cell growth or tumorigenicity
such as c-myc (frazier et of.• (998). Therefore. overexpression of BAG-I in human ~an~er cells may
be due 10 the transactivation of its promoter by mutant p53. To test this hypothesis. I first
cotransfected an expression vector for mutant p53-143A with the BGP-Luc BAG-I promoter
rcponcr plasmid into HeLa human cervical carcinoma c~lls. When increasing amounts ofp53-143A
were cotransfected. progressive second order increases in luciferase activity from BGP-Luc were
secn (Fig. 8.5). This is consistent with the requirement of the oligomerization domain of mutant p53
for some but not all promoters that are transactivated (Lanyi et af.• 1998). The luciferase activity
expressed from BGP-Luc was increased IO·fold by I ,...g of pH-143A. whereas the luciferase
aclivity of a control vector plasmid. pGLJ-B. was unaffected by I ,...g ofp53-143A (Fig. 8.5). This
result indicated that the BAG·I promoter was specifically transactivated by mutant p53.
Furthennore. I showed by Nonhem blot that the increase of BAG·I promoter activity caused by p5J-
143A was associated with a 2.5-fold increase in the level of BAG-I RNA (fig. 8.6). Consistent with
an earlicr report that c-myc transcription was transaetivated by mutant p53 (Frazier et al.• 1998). an
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Fig. 8.S. Transactivallon of BAG-I promoter by tumor-derived mUlanl p53-143A. BGP-luc was
cotransfected with the indicated amounts ofp53-143A in CMVexpression vector. Conditions and
labels arc as described for Fig. 8.2 and 8.3. pGL3-B was used as a negative control. Luciferase
activity is presented as the fold increase ofJ3-galactosidase-nonnalized lucifcrase activity from HeLa
cells cotransfected with BGP·luc andp53-143A. compared with BGP·Luc and equal amoun!s of
CMV vector control.
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Fig. 8.6. Effect of mutant p53-l43A on BAG-I RNA transcription. CMV vectororp5J-143A CMV
expression plasmid was lransiently ITansfecled into HeLa cells. RNA was extracted from the cells
incubated 40 h after transfection. Twenty 1J8 of RNA were sized-fraclionaled on a 1.0% agarose
fonnaldehyde gel, transferred to nitrocellulose membrane and sequentially hybridized with e:Pj-
labeled human BAG-I and e-myc eDNA probes. l3-aetin was used as an intemal control.
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increase in the level ofc-myc RNA was found whenp53.143A was transfected into HeLa cells (Fig.
8.6). In addition. cotransfection of various levels of wild-type p53 eDNA expression vector into
HeLa cells had no effect on BOP-luc activity when nonnalized relative to the IJ-galactosidase
intcrnal control activity (daLa not shown).
To examine whether the effectofp53·143A on the BAG·I promoter is common among other
gain-of-fWlCtion pS3 mutants, J repeated the above experiment using I j.tg of differentp53 mutants
derived from different human tumors (Hinds el al., 1990; Frazier el aI., 1998; Ryan and Vousden,
1998). Consistent with thep53.l43A results, 4- to 8-fold induction ofBAG-! promoter activity was
found (Fig. 8.7). As a negative control, no induction was observed when lite parental CMV
expression vector was cotransfected with BGP-Luc into HeLa cells.
8.4 DISCUSSION
As a first step toward understanding the molecular mechanism of BAG·J upregulation in
human cancer, I cloned the promoter region of the human BAG·I gene. Analysis of this 5' flanking
region identified a number of putative transcription factor binding sites including consensus
sequences for YVI. GATA-l, Spl. AP·1, TGF-Il receptor, Ets-I and WTI. interestingly, several
similar features were found in the promoter region of BAG-l and those of the genes, bcl·2 and bcl-
XL' of its interacting proteins. As for bel-2 and bel-XL' the BAG-I promoter has no TATA box, but
several putative Spl-binding motifs were found in GC·rich regions in all three promoters. Spl-
binding motifs were shown to be essential for the function of the SV40 promoter in vivo (Negrini
el af.. 1987; Grillot el al.• 1997). Consistently, deletion ofthe three Spl.binding sequences at the 3'
end of the BAG-I promoter abolished its activity (fig. 8.1 and 8.4). Further, several other
Iranscriplion factor binding sites (GATA-1. Ets and WTI) that were previously found in the
promoter region ofbcl·2 and bcl·X were also identified in the promoter region of BAG-I (Negrini
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Fig. 8.7. Transactivalion of BAG·1promoterbyp53 mutants derived from different rumors. BGP-luc
was cotransfected with citherCMY vector or the indicated human mUIantp53 expression vectors into
He La cells. Cell extracts were then assayed for luciferase activity. Data represent the fold increase
ofluciferasc activity for thep53 mutanls relative to the CMV control. Conditions were as in Fig. 8.5.
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et al.. 1987; Grillot et al., 1997; Fig. 8.1). Both WTl and EIS proteins were shown to negatively
regulate the bcl-l promoter (Chen and Boxer, 1995; Heckman et al., 1997). Therefore, the three
anti-apoptotic genes, BAG-I, bcl-2 and bel-X, may be regulated by the same rranscription factors.
Computer analysis of the sequence of the BAG-I promoter identified a 272 bp CpG island
located from nt -472 to -200, indicating that BAG-I expression may be regulated by
rncthylationldemethylation. DNA methylationldemethylation is important for gene regulation and
may play an important role in tumor progression. Activation ofoncogenes by demethylation and
inactivation of tumor suppressor genes by methylation has been suggested to be a significant event
for different genes in all steps that lead to human cancer (Laird and Jacnisch, 1996; Baylin et al.,
1998). Since no rearrangement of the BAG-} gene was found in human cancer cells (unpublished
data). dcmcthylation of the BAG·l promoter could contribute to the enhanced expression of BAG-I
RNA in these cells. In addition, although BAG-I RNA level was low in C33A cervical carcinoma
cells (Yang et aI., 1998), promoter activity of the BAG-I gene was high in this cell line (Fig. 8.3).
The laller result indicates that all transcription factors necessary for initiating the transcription of
BAG-I RNA are present in C33A cells. Therefore, methylation of the endogenous BAG-l promoter
could be one of the reasons for the low transcription of BAG·I RNA in C33A cells. It will be
interesting to test these possibilities by examining the effect on luciferase activity of in vitro
methylation of the BAG-I promoter in the luciferase vector before its transfection into HeLa or
C33A cells and i/l vivo demethylation by 5.azacytidine of the endogenous BAG-I promoter DNA
in nonnal human, HeLa or C33A cells.
It was reported that wild-type p53 can suppress the promoter activity ofa number ofcdlular
genes including c:fos, hsp70, Rb and OPI (Ginsberg el al., 1991; Shiio el al., 1992; AgotT el al.,
1993; Gopalkrishnan et al., 1998). Since bel-2 transcription can also be downregulated by wild-type
p53 (Miyashita el 01., 1994 a, b; Miyashita and Reed, 1995), enhanced expression of BcI-2 in cancer
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cells was at least panially due to the loss ofp53·mediated bcl-2 suppression. Therefore, enhanced
expression of BAG-I in tumor cell lines (Takayama et aI., 1998; Yang et aI., 1998) may have
rcsulted from loss of suppression by wild-type p53. Although my results showed that BAG-I
promoter activity relative to protein level was reduced by wild-type p53, no change in its activity
was found when it was nonnalized using 13·galactosidase as an internal control. The same
observation was made for the c-fos promoter by others (Ryan and Voosden, 1998). Therefore, the
suppression of gene promoters by p53 may have been eaused by apoptosis, as suggested by Ryan
and Vousden (1998). Alternatively, p53 may indirectly repress the promoter activity of some genes
by modulating the binding of other transcription factors to the promoter. For example, p53 can
suppress HIV-I LTR activity by preventing Sp I from binding to its binding siles in the LTR
(Bargonetti el al.• 1997). Generally. wild·type p53 has been shown 10 inhibit viral or cellular
promoters that do not have known p53-binding sites. while trarlsaclivating promoters, such as those
of WAFI and ba:c. which eonlain p53-binding sites. Considering all the data, Ihe significance of
wild-type p53 in transcription repression remains poorly understood.
Previous studies demonstrated that mutant p53 can confer a gain.-of-function. for example
inducing transformation, binding to Hsc70 or transaeti"ation of a variety of cellular genes. including
hsp70.MDR-I. PCNA. andc-myc (Hinds et aI., 1990; Chin el al.. 1992; Deb et aI., 1992; Tsutsumi-
Ishii ef af.• 1995 ; Frazier el al., 1998). Since BAG·I is an Hsp70-interacting protein (Takayama el
al.. 1997). this raised the possibility that BAG-I, like hsp70, may also be activated by mutant p53.
In this report. I provided convincing evidence that gain of function p53 mutants. p53-143A, pH-
175P,p53-248W,p53-273H, andpH.28lG (Dittmer et al.• 1992), can transactivate the activity from
a reponer gene driven from the BAG-I promoter and transcription of BAG· I RNA. Although the
molecular mechanism for the rransactivation ofcellular genes by gain-of-function mutant p53 is
uncertain, p53 mutants often modulate the transcription of genes such as BAG-I that lack putative
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p53-binding siles (Lanyi et al., 1998) through an indirect mechanism. For hsp70, mutated p53
indireclly transactivated its promoter through a heat shock element (Tsutsumi-Ishii et al.. 1995). Spl
has been suggested 10 mediate the transactivalion of me HIV-I LTR by mutanl pS3 (Subler et aJ.,
1994). Further experiments need 10 be performed 10 clarify how mutant pS3 transactivates the BAG-
I promoter. However. my resuhs do indicate thai the enhanced expression of BAG-I in human
cancer cells may be due 10 the transactivalion of the BAG-l promoter by pS3 mutants. Furthermore,
recent studies indicate Ihat mutant pS3 can enhance the resistance ofcells to apoptosis induced by
anticancer drugs through a pS3.independent mechanism (Li et al.• 1998; Blandino el al., 1999).
Co,iitined wilh my results. this suggests that mutant pS3 can cause drug resistance by increasing the
level of anli-apoptotic protein BAG-I through transactivating BAG-! transcription. Therefore,
understanding the transcriptional regulation of me BAG-I promoter would be helpful to explain the
molecular mechanism of not only BAG-! overexpression in human cancers. but possibly also how
p53 gain-of-function mutants can lead 10 some hwnan cancers and their resistance to chemotherapy.
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SECTION VI CHAPTER 9
FUTURE DIRECTION
This thesis has described in detail the molecularclorung and characterization ofhuman BAG-
I. This study has provided information on how BAG-I is involved in human cancers. However. to
fully understand the molecular mechanism of BAG-I function, several experiments could be done
in the future:
I) The finding that BAG· I is expressed as four protein isofonns is very important. Funher.
I and others in the laboratory found that the BAG-I pSO isofonn had not only a distinct subcellular
localization. but also a different role in modulating vitamin 0 receptors. as compared with the other
isofonns (Witcher and Yang, unpublished data). Therefore. it would be interesting to examine
whether distinci BAG- I isofonns also have different roles in other cellular process such as
metastasis.
2) BAG-I has previously been shown to bean anti-apoptotic protein. Moreover. in this study.
BAG- I was demonstrated to cnhance 4-HPR-induced apoplosis in cervical cells. Funher
experiments examining the role of BAG-I-eellular prolein interactions in apoptosis will help to
explain this phenomenon.
3) Although BAG-I has been shown to be overexpressed in various human cancers, there is
no experimenlal data that show it is directly involved in tumorigenesis. Using soft-agar and nude
mice assays, I have found that BAG-I increased cell proliferation but nOI nude mouse
lumorigenecity ofC33A cells (unpublished data). It will be interesting to examine how BAG-I is
involved in multistage carcinogenesis via increasing cell proliferation. Comparing the cellular gene
expression in BAG- I-overexpressing versus control cells. using eDNA microarray (Clontech). may
finally solve the mystery.
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4) In this sludy. tumor-derived pS3 mutants were shown to transactivate the BAG·I
promoter. However. the DNA sequence that mediates this transcription activation has not been
identified. Deletion and mutation analysis of BAG-I promoter should finally identify the response
elements for pS3 mutants.
S) Although wild-type pS3 was not found to have any effect on the BAG-I promoter. it has
been shown that pS3 suppresses bcl-2 transcription by negatively regulate the S'·tJTR of the bcl-2
gene (Miyashita et al., I994b). Therefore, me elTect of wild-type pS3 on BAG-\ transcription can
be examined using exclusively the S'·tJTR of the BAG-I gene.
6) Several putative transcription factor binding sequences, such as the WTt binding sile.
which were shown to mediate the suppression of bd-2 promoter by WTI (Hewitt et at., 1995). were
identified in the BAG·I promoter. Further examining the roles of these sequcllCcs in the regulation
of BAG-I transcription will be helpful in elucidating the molecular mechanism of BAG·\
overexpression in human cancers.
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